<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12185290</article-id><article-id pub-id-type="pmcid-ver">PMC12185290.1</article-id><article-id pub-id-type="pmcaid">12185290</article-id><article-id pub-id-type="pmcaiid">12185290</article-id><article-id pub-id-type="pmid">40557144</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1595276</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Multiple sclerosis: etiology in the context of neurovascular unit and immune system involvement and advancements with <italic toggle="yes">in vitro</italic> blood&#8211;brain barrier models</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>El-Taibany</surname><given-names initials="AA">Aya A.</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2976721/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heydarian</surname><given-names initials="P">Parichehr</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Porada</surname><given-names initials="DA">Daniel A.</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seeds</surname><given-names initials="MC">Michael C.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2249571/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Atala</surname><given-names initials="A">Anthony</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1369821/overview"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine</institution>, <addr-line>Winston-Salem, NC</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Valentina Tomassini, University of Studies G. d&#8217;Annunzio Chieti and Pescara, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Margaret A Jordan, James Cook University, Australia</p><p>Tianmeng Chen, University of Pittsburgh, United States</p></fn><corresp id="fn001">*Correspondence: Aya A. El-Taibany, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:aeltaiba@wakehealth.edu">aeltaiba@wakehealth.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480569</issue-id><elocation-id>1595276</elocation-id><history><date date-type="received"><day>17</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>24</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-25 09:25:53.217"><day>25</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 El-Taibany, Heydarian, Porada, Seeds and Atala</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>El-Taibany, Heydarian, Porada, Seeds and Atala</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-16-1595276.pdf"/><abstract><p>Multiple sclerosis affects a significant portion of the world&#8217;s adult population and is the most common nontraumatic neuroimmunology disorder. Although the specific etiology of multiple sclerosis remains unknown, it has been associated with autoimmune components. While current treatment options relieve some symptoms in MS patients, most are immunosuppressive and only delay the progression of the disease without conferring definitive curative measures. Hence, a thorough understanding of disease pathobiology, the contribution of the neurovascular unit (NVU), and biological body-on-a-chip systems that replicate the blood&#8211;brain barrier may open new horizons for the discovery of potential therapeutics for MS.</p></abstract><kwd-group><kwd>multiple sclerosis</kwd><kwd>autoimme disease</kwd><kwd>neuroinf lammation</kwd><kwd>blood brain barrier</kwd><kwd>neurovascular unit</kwd><kwd><italic toggle="yes">in-vitro</italic> model</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. WFIRM&#8217;s mission driven research is supported by various funding sources to include state and sponsored funding.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="4"/><equation-count count="0"/><ref-count count="456"/><page-count count="24"/><word-count count="10940"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Multiple Sclerosis and Neuroimmunology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Multiple sclerosis is a chronic inflammatory demyelinating disorder of the CNS that affects adults aged 20&#8211;40 years and disproportionately affects the female population at a ratio of nearly 3:1 (<xref rid="B1" ref-type="bibr">1</xref>). One study reported that approximately 1.7 million people were diagnosed with MS globally in 2019, resulting in 22,438 deaths (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>Many risk factors have been implicated both in the development of MS and in modulating the clinical severity of the disease. Most MS patients show evidence of previous Epstein&#8211;Barr virus (EBV) infection, which is reflected by increased IgG antibody titers to EBV nuclear antigens (EBNAs) (<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>), and the same association has been reported in meta-analysis studies (<xref rid="B6" ref-type="bibr">6</xref>&#8211;<xref rid="B8" ref-type="bibr">8</xref>). It has been proposed that EBV increases the risk of multiple sclerosis via molecular mimicry (<xref rid="B9" ref-type="bibr">9</xref>) and that EBNA-1-specific T cells are cross-reactive with myelin antigens (<xref rid="B10" ref-type="bibr">10</xref>). Another study linked an increased risk of MS to increased BBB permeability due to acute primary EBV infection (<xref rid="B11" ref-type="bibr">11</xref>). Furthermore, one study reported that B cells infiltrating the CNS were infected with EBV (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>), but the same finding was not confirmed in other studies (<xref rid="B14" ref-type="bibr">14</xref>). One review concluded that CNS infection with EBV has not been effectively proven (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Vitamin D has a well-established immunoregulatory function involving major histocompatibility complex (MHC) genes involved in antigen presentation that may impact MS (<xref rid="B16" ref-type="bibr">16</xref>&#8211;<xref rid="B18" ref-type="bibr">18</xref>). Additionally, the presence of vascular comorbidities worsens the progression of MS (<xref rid="B19" ref-type="bibr">19</xref>). Smoking has been identified as a risk factor for increased susceptibility to MS due to the release of carbon monoxide and nitric oxide (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>).</p><p>Other environmental factors that affect MS and may lead to exacerbations are high altitude, which has been implicated as a risk factor for MS due to changes in oxygen levels, cerebral vasoreactivity, and changes in the immune system (<xref rid="B22" ref-type="bibr">22</xref>). Latitude can affect the disease course of MS leading to earlier onset and higher prevalence. People living in high latitudes are more prone to develop MS. The prevalence is estimated to be a 10-fold increase between the equator and 60&#176; north and south (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>).</p></sec><sec id="s2"><title>Genetic susceptibility</title><p>Genetic susceptibility to MS has been described through family and twin-concordance studies where researchers reported a 25% recurrence risk in monozygotic twins and a 2&#8211;5% risk rate in dizygotic twins and first-degree relatives (<xref rid="B25" ref-type="bibr">25</xref>). Additionally, genome-wide association studies and the International MS Genetics Consortium have discovered 230 genetic susceptibility loci for MS (<xref rid="B26" ref-type="bibr">26</xref>). Most of these loci are linked to the immune system, and the strongest genetic association is linked to major histocompatibility complex II (MHC II) molecules, which are responsible for antigen presentation to T cells and their activation. Approximately 32 associations belong to the major histocompatibility complex (MHC). One highly associated link was HLA-DRB1*15, which confers a threefold increase in MS risk (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>).</p><p>A more recent GWAS study integrated with single cell accessibility data revealed the association of signals with B cell and monocyte/microglial cell-types (<xref rid="B29" ref-type="bibr">29</xref>).Transcriptional analysis studies are crucial to understanding the relation between genetic variants and gene expression. Transcriptional analysis helps decipher the pathogenic mechanisms in MS and identify potential therapeutic targets (<xref rid="B30" ref-type="bibr">30</xref>). Beyond GWAS and transcriptional analysis, genetic predispositions to MS have been revealed by variety of methods and thoroughly reviewed in other articles (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>).</p><p>Notably, some of these immune system gene variants have a potential link to disrupted NVU components that increase the complexity of disease etiology (<xref rid="B33" ref-type="bibr">33</xref>). This evidence implies that the integrity and function of the BBB warrant further investigation for its potential to ameliorate MS.</p></sec><sec id="s3"><title>Clinical manifestations</title><p>MS manifests in four different clinical forms. Approximately 80% of patients present with relapsing&#8211;remitting MS (RRMS), where they experience flare-ups of the disease that coincide with the formation of new contrast-enhancing lesions in the brain and spinal cord followed by periods of remission where symptoms improve or disappear. Optic neuritis and brainstem and spinal cord syndromes are the most common manifestations, with cortical presentations being less common. After each relapse episode, there is a residual cumulative neurological deficit. After many relapses, remission tends to be incomplete. Approximately 50% of RRMS patients will develop secondary progressive MS (SPMS), in which the disease process becomes slowly progressive with or without periods of remission. However, 10&#8211;15% of patients will develop primary progressive MS (PPMS), in which the disease progressively worsens from the start with no remission. PPMS affects the spinal cord more with fewer lesions in the brain and commonly presents with progressive spastic paraparesis. The evidence of active lesions is much less common in PPRM than in SPMS. The progressive nature of the disease is reflected by the presence of the brain and spinal cord atrophy. An exceedingly rare form is progressive relapsing MS (PRMS), where the disease progresses from the start, and the patient can additionally suffer from periods of worsening symptoms (<xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>).</p><p>These forms lack distinctive differential pathologies but represent a spectrum of disease progression starting from active infiltration and inflammation accompanied by demyelination to progressive irreversible damage to neurons and a decrease in the neurological reserve (<xref rid="B35" ref-type="bibr">35</xref>).</p></sec><sec id="s4"><title>Neuropathology</title><p>The hallmarks of MS disease in the CNS are the formation of focal lesions of demyelination, the death of oligodendrocytes, astrogliosis, and the activation of microglia with infiltration of immune cells (<xref rid="B39" ref-type="bibr">39</xref>). These lesions are mostly found in the perivascular space and are localized mainly in the white matter, although they have been found to a lesser extent in the gray matter, deep brain stem nuclei and the spinal cord (<xref rid="B40" ref-type="bibr">40</xref>&#8211;<xref rid="B42" ref-type="bibr">42</xref>). These MS lesions show variable degrees of remyelination (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). The lesions can be categorized into active lesions, chronic active lesions, and chronic inactive lesions (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). The inactivity of the lesion is determined histologically by the absence of microglia and macrophages and the absence of myelin degradation. Active lesions are more highly expressed in acute relapsing patients, whereas chronic lesions are mostly found in patients with the progressive form of the disease (<xref rid="B46" ref-type="bibr">46</xref>). Focal white matter lesions may be less abundant or equal in PPMS than in SPMS (<xref rid="B46" ref-type="bibr">46</xref>&#8211;<xref rid="B49" ref-type="bibr">49</xref>). Both adaptive and innate immune system cells are found within lesions, but their composition varies with disease stage and activity.</p><p>Lesions in primary progressive MS show less immune cell infiltration than those in secondary progressive MS do (<xref rid="B50" ref-type="bibr">50</xref>), whereas active lesions show the most infiltration. In chronic progressive disease, the immune cell infiltrate is mostly composed of MHC class I-restricted CD8<sup>+</sup> and, to a lesser degree, MHC class II-restricted CD4<sup>+</sup> T cells (<xref rid="B51" ref-type="bibr">51</xref>&#8211;<xref rid="B53" ref-type="bibr">53</xref>), whereas the CD4+ T-cell population comprises the bulk of cells found in the active lesions.</p><p>CD20<sup>+</sup> B cells can also be detected, especially in active lesions, with more plasma cells present in chronic progressive lesions (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B66" ref-type="bibr">66</xref>). The presence of oligoclonal immunoglobulin bands in the CSF of approximately 85% of MS patients supports the role of B cells in the pathogenesis of the disease (<xref rid="B73" ref-type="bibr">73</xref>).</p><p>Innate immune system cells, including activated microglia and macrophages, have been observed at CNS lesion sites in both acute and progressive MS but are present to a greater extent in the active disease state. Another form of aggregated immune cells is found in the Virchow Robin spaces of the periventricular veins and meninges, which, in severe cases, form tertiary lymphoid follicles (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). These follicles have been reported to be associated with SPMS and rapidly progressive PPMS but not slowly progressive PPMS (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>).</p><p>Cortical demyelination and neurodegeneration have been reported in MS patients, especially those with SPMS and PPMS (<xref rid="B80" ref-type="bibr">80</xref>). These lesions have been observed in autopsy samples from early disease stages and increase in frequency and size in progressive stages (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B81" ref-type="bibr">81</xref>). These cortical lesions are associated with diffuse periventricular white matter abnormalities, which have not yet been well characterized but are likely associated with diffuse inflammation and secondary degeneration due to neuronal loss in the cortex (<xref rid="B80" ref-type="bibr">80</xref>). These lesions can also be detected in deep gray matter nuclei and spinal cord gray matter (<xref rid="B82" ref-type="bibr">82</xref>&#8211;<xref rid="B84" ref-type="bibr">84</xref>). Additionally, macroscopically normal white matter can show evidence of demyelination (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B85" ref-type="bibr">85</xref>), and MS severity is related to the severity of cortical demyelination (<xref rid="B86" ref-type="bibr">86</xref>). Cortical demyelination can be associated with meningeal inflammation, but meningeal inflammation by itself does not appear to be a prerequisite for cortical demyelination to occur (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>).</p><p>The diffusion of soluble neurotoxic factors may activate microglia and cause demyelination in the cortex or direct damage to myelin (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Some of these factors, including ceramide and semaphoring, have been previously characterized in MS patients (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B89" ref-type="bibr">89</xref>). In demyelinated cortical lesions, microglia are activated, which can be induced by soluble factors from B cells found in the meningeal cell infiltrate (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>).</p><p>The pathological hallmark of MS white matter lesions can be readily detected via conventional magnetic resonance imaging (MRI) (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>). However, the severity of these lesions has not been linked to neurological deficits or disability in MS patients. This is attributed in part to the presence of macroscopically undetected chronic injury in normal white matter, which can be detected by the magnetic resonance (MR) magnetization transfer ratio and diffusion tensor imaging (<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B94" ref-type="bibr">94</xref>). The definitive pathology of these lesion areas has not yet been fully elucidated but has been shown to include axonal injury, secondary demyelination, increased blood&#8211;brain barrier permeability, and microglial activation (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>). These normal-appearing white matter (NAWM) abnormalities have been linked to the presence of active focal lesions and demyelination that results from axonal loss, known as secondary Wallerian degeneration (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>).</p><p>NAWM changes have also been demonstrated to be associated with meningeal inflammation and are independent of focal lesion presence (<xref rid="B99" ref-type="bibr">99</xref>). Furthermore, metabolic disturbances in myelin phospholipids have been reported in areas of the NAWM (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B101" ref-type="bibr">101</xref>). These observations raise the possibility that MS could be a primary neurodegenerative disease that elicits immunological interactions in the CNS. It has been hypothesized that focal lesions in MS patients are only the &#8220;tip of the iceberg&#8221; of a more diffuse injury occurring in the CNS (<xref rid="B102" ref-type="bibr">102</xref>). Thus, elucidating the pathology of NAWM lesions and their associated BBB damage would provide insights into the pathogenesis of MS and aid in the development of therapeutics that target the disease process, as it might represent events prior to lesion formation (<xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B104" ref-type="bibr">104</xref>).</p></sec><sec id="s5"><title>Blood&#8211;brain barrier pathology</title><p>The evolution of MS lesions in the CNS includes myelin autoreactive encephalitogenic CD4+ T cells breaching the blood&#8211;brain barrier (BBB) and gaining access to the CNS parenchyma to initiate the lesion.</p><p>The function of the BBB is to maintain CNS homeostasis by regulating the passage of molecules into the CNS and providing efflux of metabolic waste and harmful materials from the brain. The BBB is formed mainly by brain microvascular endothelial cells (BMECs) surrounded by pericytes and astrocyte-end feet and regulated by CNS parenchymal cells such as microglia, neurons, and oligodendrocytes in a structure known as the neurovascular unit (NVU) (<xref rid="B105" ref-type="bibr">105</xref>). BMECs acquire their barrier properties through the formation of interendothelial sealing tight junctions (TJs) and adherent junctions (AJs) formed by specialized junctional complexes and accessory proteins (<xref rid="B106" ref-type="bibr">106</xref>&#8211;<xref rid="B109" ref-type="bibr">109</xref>).</p><p>BMECs also possess a highly specialized membrane transport system (<xref rid="B110" ref-type="bibr">110</xref>), decreased pinocytic activity, and lack the transendothelial fenestrations observed in other capillary systems (<xref rid="B105" ref-type="bibr">105</xref>). As a result, BBB transendothelial electric resistance (TEER) ranges from 1,000 to 1,500 &#8486;/cm2 (<xref rid="B111" ref-type="bibr">111</xref>). Two major tight junction proteins expressed by BMECs are occludins (<xref rid="B112" ref-type="bibr">112</xref>) and claudins (<xref rid="B113" ref-type="bibr">113</xref>). The integrity of the BBB was shown to be maintained after occludin expression was knocked down, but the integrity of the BBB was lost after claudin expression was knocked down (<xref rid="B114" ref-type="bibr">114</xref>&#8211;<xref rid="B116" ref-type="bibr">116</xref>). Accordingly, there is increasing scientific awareness of the role of claudin-5 in the integrity of the BBB and its involvement in many neurological disorders (<xref rid="B117" ref-type="bibr">117</xref>). Consequently, this protein has been investigated for its therapeutic potential in many of these disorders, and its manipulation has been investigated as a vehicle for drug delivery into the CNS (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>). In addition to the main junctional complex proteins, accessory junctional proteins, such as the cytoplasmic zonula occludins proteins ZO-1, ZO-2, and ZO-3 (<xref rid="B120" ref-type="bibr">120</xref>), are membrane-associated guanylate kinases that interact with other intracellular molecules, including cingulin (<xref rid="B121" ref-type="bibr">121</xref>), the 7H6 antigen (<xref rid="B122" ref-type="bibr">122</xref>), and other cytoskeletal proteins. Additional proteins coexist with junctional proteins, including junctional adhesion molecules (JAMS) (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>) and platelet/endothelial cell adhesion molecule-1 (PECAM-1) or CD31 (<xref rid="B125" ref-type="bibr">125</xref>). PECAM-1 is involved in transendothelial transmigration, and PECAM-1-deficient mice exhibit increased BBB permeability (<xref rid="B126" ref-type="bibr">126</xref>).</p><p>Histopathological studies revealed abnormalities in the BBB in active as well as inactive lesions in multiple sclerosis (<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>). More recently, BBB abnormalities have been reported in NAWM (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B129" ref-type="bibr">129</xref>). This finding suggests that such barrier disruption occurs even before obvious lesion formation and immune cell infiltration are evident, which makes the mechanisms of BBB disruption in diseases such as MS particularly important to study, as they might provide novel insights into the process of disease development. Whether BBB dysfunction is a consequence or cause of increased immune cell infiltration in the CNS is still debated, with evidence supporting both hypotheses (<xref rid="B130" ref-type="bibr">130</xref>&#8211;<xref rid="B132" ref-type="bibr">132</xref>).</p><p>The transmigration of immune cells through the BBB occurs through a highly regulated series of sequential events. Initially, activated leukocytes are captured by endothelial cells via interactions between selectins and their receptors on the surface of the inflamed brain endothelium. Binding to selectins leads to slowing of immune cells (crawling) followed by the activation of leukocytes by chemokines through G-protein signaling and induces their firm adhesion to BMECs through the binding of endothelial cell adhesion molecules to their receptors on the surface of activated T cells (<xref rid="B133" ref-type="bibr">133</xref>). One of the most prominent inflammatory changes in the BMECs in MS is the upregulation of the selectin family of endothelial adhesion molecules; cell adhesion molecules such as ICAM-1, VCAM-1, MCAM, and ALCAM; chemokines on the luminal surface of brain endothelial cells; and the upregulation of class II MHC molecules (<xref rid="B134" ref-type="bibr">134</xref>), which contribute to the migration of immune cells into the brain.</p><p>Selectins are transmembrane glycoproteins. E-selectin and P-selectin are expressed on the surface of activated brain endothelial cells and are responsible for the initial adhesion of leukocytes to endothelial cells. L-selectin is expressed on leukocytes and is involved in directing leukocytes to inflammatory sites and binding leukocytes to other immune cells to recruit them. P-selectin glycoprotein ligand (PSGL-1) is the receptor for these three selectins and can also bind to CD44 (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B135" ref-type="bibr">135</xref>&#8211;<xref rid="B137" ref-type="bibr">137</xref>).</p><p>The intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) bind to their respective ligands, &#945;L&#946;2 [lymphocyte function-associated antigen 1 (LFA-1)], and &#945;4&#946;1 [very late antigen 4 (VLA-4)] integrins, which are upregulated in encephalitogenic CD4+ T cells. It has been proposed that &#945;4&#946;1-integrin binding to VCAM-1 helps in the transmigration process in spinal cord microvessels, whereas LFA-1 binding to ICAM-1/2 regulates Th17 adhesion to the endothelial barrier in the brain ( (<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>). Melanoma cell adhesion molecule (MCAM) (<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>) is another adhesion molecule involved in T-cell transmigration, and its expression is a marker for GM-CSF, IL-22, and IL-17A/IFN-&#947;, which coproduce Th17 cells. Recently, &#945;v&#946;3 integrin was shown to control Th17 transmigration, and depletion of the &#946;3 subunit improved symptoms in an EAE model (<xref rid="B142" ref-type="bibr">142</xref>). In addition to this cellular upregulation, soluble forms of these adhesion molecules can be detected in patient sera and CSF, and their levels are associated with the severity of disease activity (<xref rid="B143" ref-type="bibr">143</xref>&#8211;<xref rid="B145" ref-type="bibr">145</xref>).</p><p>The factors that influence the pathway used by different immune cell subsets are still under investigation, although it has been demonstrated that the remodeling of certain junctional proteins influences transmigration routes, favoring either paracellular diapedesis (<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>) or the transcellular route (<xref rid="B148" ref-type="bibr">148</xref>, <xref rid="B149" ref-type="bibr">149</xref>), and that experimental interference via one route increases the utilization of the other commensurately. These findings indicate that BBB proteins are very important in determining the route of transmigration.</p><p>The activation of brain microvascular endothelial cells and disruption of the BBB in MS result either from the direct effects of cytokines secreted by activated myelin-specific T cells or indirectly from the effects of these cytokines on neurovascular unit (NVC) astrocytes and pericytes (<xref rid="B129" ref-type="bibr">129</xref>). Leaks in the BBB lead to increased infiltration of immune cells and their soluble immunomodulators; for instance, fibrinogen leakage across the BBB can be detected early in the disease process and signifies disruption of the BBB (<xref rid="B150" ref-type="bibr">150</xref>, <xref rid="B151" ref-type="bibr">151</xref>).</p><p>Exposure to cytokines leads to many alterations in junctional complexes. Alterations in BBB TJs and AJs in MS have previously been described in many studies. These changes could result from various mechanisms, such as downregulation of expression, destruction of junctional proteins, their internalization, or changes in their binding affinities. As an example of these alterations, occludin expression decreases with exposure to IFN-&#948; alone or paired with TNF-&#945; (<xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B153" ref-type="bibr">153</xref>), but TNF-&#945; alone does not decrease occludin expression (<xref rid="B154" ref-type="bibr">154</xref>). TNF-&#945; has also been shown to cause VE-cadherin phosphorylation (<xref rid="B155" ref-type="bibr">155</xref>) and induce the internalization of junctional proteins by upregulating NF-K&#946;, which in turn induces the transcription of myosin light chain kinase (MLCK), which is responsible for this delocalization (<xref rid="B156" ref-type="bibr">156</xref>). IFN-&#948; can also affect ZO-1 through downregulating its expression and changing its subcellular localization (<xref rid="B157" ref-type="bibr">157</xref>, <xref rid="B158" ref-type="bibr">158</xref>), as well as inducing endocytosis of occludin and claudin-1 (<xref rid="B159" ref-type="bibr">159</xref>). The downregulation of occludin and ZO-1 expression has also been reported in BMECs treated with IL-17 and IL-22 (<xref rid="B160" ref-type="bibr">160</xref>, <xref rid="B161" ref-type="bibr">161</xref>). ZO-1, occludin, claudin-5, and junctional adhesion molecules can be cleaved by increased expression of MMP-9 (<xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>) induced by IL-1&#946; (<xref rid="B164" ref-type="bibr">164</xref>). Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement (<xref rid="B165" ref-type="bibr">165</xref>). Other factors in addition to cytokines can lead to BBB disruption, such as oxidants, which cause ZO-1 and occludin breakdown, and VEGF, which induces the phosphorylation of tight junctions (<xref rid="B166" ref-type="bibr">166</xref>). These effects were demonstrated by studies in which MS patient sera were used to treat brain endothelial cells <italic toggle="yes">in vitro</italic> to identify soluble mediators that disrupt BBB integrity and learn how to counteract their effects (<xref rid="B167" ref-type="bibr">167</xref>, <xref rid="B168" ref-type="bibr">168</xref>).</p><p>This BBB pathology extends to astrocytes, which exhibit astrogliosis, an inability to upregulate AQP4, and astrocytic end-feet retraction from the glia limitans (<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>). The basement membrane (BM) also shows irregularity and deposition of its degraded components, mostly because of the secretion of MMPs and other enzymes by immune cells that cleave the BM, especially those associated with active lesions (<xref rid="B171" ref-type="bibr">171</xref>, <xref rid="B172" ref-type="bibr">172</xref>). Some studies have concluded that the volume of Virchow Robin spaces (VRSs) is greater in MS patients than in controls, as shown via MRI; this increase in VRSs is associated with white matter and gray matter lesions, and VRSs accumulate immune cells that participate in the neurodegenerative process in MS, as previously mentioned (<xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B174" ref-type="bibr">174</xref>).</p><p>All of the described changes lead to increased BBB permeability, reflected by leakage of gadolinium contrast material during MRI examination, and consequently lead to increased solute permeability and infiltration of immune cells into the CNS (<xref rid="B175" ref-type="bibr">175</xref>).</p><p>Chemokines play an effector role in guiding immune cell adherence and infiltration across the BBB. They are secreted by many cells, such as microglia, astrocytes, and immune cells. Cytokines might also be potent contributors to chemokine production. Many chemokines are upregulated on the surface of brain endothelial cells during MS, and research is ongoing to identify key chemokines in MS that could be potential targets for treatment. For example, CCL19, CCL21 and their receptor CCR7 are upregulated Th1 in inflamed BMECs. The knockdown or inhibition of these cytokines leads to decreased myelin-specific T-cell adhesion to BMECs (<xref rid="B176" ref-type="bibr">176</xref>). Similarly, CXCL13 is increased in the CSF of MS patients compared with normal controls, and its level is correlated with increased immune cell infiltration. The interaction of chemokines with their receptors changes the low-affinity selectin-mediated interaction of leukocytes with the brain endothelium to a more potent integrin-mediated interaction (<xref rid="B177" ref-type="bibr">177</xref>). Chemokines bind to transmembrane G protein-coupled receptors on leukocyte surfaces and mediate the upregulation of integrins through G protein signaling (<xref rid="B178" ref-type="bibr">178</xref>). Presenting further detail about these chemokines is beyond the scope of this article but can be found in detail in other reviews (<xref rid="B179" ref-type="bibr">179</xref>).</p></sec><sec id="s6"><title>Immunopathogenesis</title><sec id="s6_1"><title>T cells</title><p>CD4<sup>+</sup> T cells are the main initiators of MS lesions in the CNS on the basis of histopathological examination, disease modeling from <italic toggle="yes">in vivo</italic> experimental autoimmune encephalomyelitis (EAE) animal models, and the association of MS with variants in MHC class II genes and regulatory molecules involved in their interactions (<xref rid="B54" ref-type="bibr">54</xref>). CD4<sup>+</sup> cells are either Th1 or Th17 CD4<sup>+</sup> T- cells. Th1 cells secrete TNF-&#945; and IFN-&#947;, and their differentiation is dependent on T-cell transcription factor (TBET) (<xref rid="B58" ref-type="bibr">58</xref>&#8211;<xref rid="B61" ref-type="bibr">61</xref>). Th17 T cells mainly secrete IL-17, and their differentiation is driven by IL-23 (<xref rid="B62" ref-type="bibr">62</xref>&#8211;<xref rid="B65" ref-type="bibr">65</xref>). Both Th1 and Th17 cytokines are highly elevated in the patient&#8217;s plasma before active disease and decrease with remission (<xref rid="B180" ref-type="bibr">180</xref>). It has been proposed that activated myelin-specific Th1 cells lead to spinal cord inflammation, whereas Th17 cells induce inflammation in the brainstem, cerebellum, and cerebrum (<xref rid="B181" ref-type="bibr">181</xref>, <xref rid="B182" ref-type="bibr">182</xref>).</p><p>CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells in MS lesions show evidence of clonal expansion, targeting myelin autoantigens. This clonal expansion implies that they are activated by specific antigens, although despite decades of research, these antigens remain unidentified (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). Some studies have suggested that these antigen-specific T cells could serve as brain-resident T cells against neurotropic viruses that are activated by specific cytokines released from sources or events that are not specific to their antigens (<xref rid="B57" ref-type="bibr">57</xref>).</p><p>The activation of myelin-specific T cells in the peripheral circulation by molecular mimicry, where T cells are activated by viral or bacterial antigens that share homologous sequences with CNS antigens, has been a long-standing theory for peripheral activation of the immune system in MS (<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B184" ref-type="bibr">184</xref>). Recent evidence suggests that the gut and lymphoid tissue contribute to the activation of these cells (<xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B186" ref-type="bibr">186</xref>). Both activated myelin autoreactive T cells and those reactive to antigens other than neural antigens can cross the BBB. However, only those specific to myelin are able to induce lesions in the CNS because of their reactivation by antigen-presenting cells inside the CNS (<xref rid="B187" ref-type="bibr">187</xref>, <xref rid="B188" ref-type="bibr">188</xref>). There is no definite evidence for any difference in the frequency of myelin-specific T cells between MS patients and normal controls (<xref rid="B189" ref-type="bibr">189</xref>&#8211;<xref rid="B192" ref-type="bibr">192</xref>). Some studies have demonstrated functional differences in the increased secretion of IFN-&#945;, IL-17, and GM-CSF by myelin-reactive T cells between MS patients and healthy controls (<xref rid="B193" ref-type="bibr">193</xref>). Additional functional differences include the suppressive ability of regulatory T cells in RRMS patients compared with controls and the resistance of effector T cells in MS patients to regulatory T-cell suppression (<xref rid="B194" ref-type="bibr">194</xref>, <xref rid="B195" ref-type="bibr">195</xref>). It has also been suggested that peripheral activation of myelin-reactive T cells yields an autoproliferative ability that bypasses the need to be activated and maintains the capacity to produce IFN-&#945; (<xref rid="B196" ref-type="bibr">196</xref>, <xref rid="B197" ref-type="bibr">197</xref>). Another study hypothesized that myelin-specific T cells have what is called &#8216;T-cell degeneracy&#8217;, which means that they can be activated by many ligands even if they do not share homology with the original stimulus (<xref rid="B198" ref-type="bibr">198</xref>).</p><p>After crossing the BBB, inflammatory T cells cross the basement membrane (BM) via the binding of &#945;6&#946;1 integrin on the leukocyte surface to laminin &#945;4 in the BM (<xref rid="B199" ref-type="bibr">199</xref>). Finally, immune cells reach the perivascular space, where they recognize their specific autoantigens via antigen-presenting cells and become reactivated to augment the immune response (<xref rid="B200" ref-type="bibr">200</xref>, <xref rid="B201" ref-type="bibr">201</xref>). Ultimately, the entry of these activated immune cells into the CNS parenchyma requires passing through the glia limitans, which are enriched with laminin &#945;1 and &#945;2 (<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B202" ref-type="bibr">202</xref>&#8211;<xref rid="B204" ref-type="bibr">204</xref>). Passage is achieved by the effect of secreted MMPs, whose level is correlated with disease activity. MMPs also target &#946;-dystroglycan, a receptor that anchors astrocytic end feet to the parenchymal basement membrane, the disruption of which activates astrocytes and increases their chemokine secretion (<xref rid="B183" ref-type="bibr">183</xref>).</p></sec><sec id="s6_2"><title>Other immune cells</title><p>B cells are also indirectly involved in the pathogenesis of MS lesions through their antigen-presentation capabilities (<xref rid="B67" ref-type="bibr">67</xref>) and are directly involved through their suggested role in producing factors that trigger demyelination and neurodegeneration (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>). The role of CD20<sup>+</sup> B cells in MS has been highlighted by the success of rituximab (a therapeutic antibody against CD20), which decreases patient disease progression (<xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B72" ref-type="bibr">72</xref>). The extent of increase in B cells correlates with the clinical severity of MS in patients (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B205" ref-type="bibr">205</xref>). Myelin-specific antibodies may contribute to lesional demyelination, likely by binding to target antigens and activating the complement system. Additionally, increased oligoclonal bands in patients with clinically isolated syndrome (CIS) are highly predictive of an increased risk of conversion to MS (<xref rid="B206" ref-type="bibr">206</xref>).</p><p>Innate immune cells as macrophages and microglia interact with adaptive immune T and B cells and can induce direct damage to myelin and neuronal axons. This damaging effect has been proposed to be mediated by the production of reactive oxygen and nitrogen species (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>). The microglia and macrophages phagocytose myelin debris from the lesion, and the presence of degradation products correlates with the activity of the lesion in terms of demyelination and neurodegeneration.</p></sec></sec><sec id="s7"><title>The inside-outside theory</title><p>Failure to cure or arrest disease progression in RRMS patients treated with current immunosuppressive and immunomodulatory drugs and failure to identify specific autoantigens against which autoreactive T cells are especially prevalent in MS despite decades of research poses many questions regarding the nature of MS disease (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B207" ref-type="bibr">207</xref>). An existing hypothesis is that MS originates from a disease process inside the CNS itself that leads to the activation of resident immune cells, the microglia, which in turn could lead to BBB disruption and peripheral immune system activation. In this context, immune cell infiltration is recognized as a secondary response to a primary event inside the brain rather than immune system activation outside the CNS. The presence of some areas in MS brains that show loss of oligodendrocytes with minimal immune cell infiltration is suggested to represent an early prephagocytic phase. This could favor the interpretation of the disease having an intrinsic origin within the CNS (<xref rid="B103" ref-type="bibr">103</xref>, <xref rid="B208" ref-type="bibr">208</xref>, <xref rid="B209" ref-type="bibr">209</xref>).</p><p>The inside-out theory of the CNS implies the presence of a draining lymphatic system with reciprocal access to the brain, which contradicts the old concept that the CNS is an immune-privileged organ (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B210" ref-type="bibr">210</xref>&#8211;<xref rid="B213" ref-type="bibr">213</xref>). Connection of the CNS with the cervical lymph nodes has been demonstrated, through which CNS antigens can be processed and presented to peripheral immune system cells through CNS antigen-presenting cells. Moreover, the CSF represents a draining system for CNS antigens. Brain microvascular endothelial cells have been implicated in antigen presentation to immune cells (<xref rid="B214" ref-type="bibr">214</xref>). One study demonstrated the ability of BMECs to support and promote the proliferation of CD8+ T cells through T-cell receptor and co-stimulation, and another suggested that myelin/MHC II complexes on the inflamed brain endothelium are recognized by myelin-reactive T cells and aid their transmigration (<xref rid="B215" ref-type="bibr">215</xref>, <xref rid="B216" ref-type="bibr">216</xref>). Despite this, the presence of primary oligodendrocyte pathology is not supported by genome-wide association studies that found no MS variants related to neuro-glial units, but loci of genetic susceptibility were detected in the MHC locus and immune cell loci. Furthermore, secondary immune cell infiltration of the CNS is not achieved in genetic animal models of primary oligodendrocyte death, which results in the activation of microglia, suggesting that a primary defect in oligodendrocytes cannot induce an autoimmune reaction (<xref rid="B217" ref-type="bibr">217</xref>). Furthermore, immune cell infiltration is not a common feature of primary neurodegenerative disorders (<xref rid="B218" ref-type="bibr">218</xref>). Transient CNS infections may damage oligodendrocytes and cause the release of myelin epitopes with subsequent activation of myelin-reactive T cells, but in the Theiler&#8217;s murine encephalitis model of MS (Theiler&#8217;s Murine Encephalitis Virus-Induced Demyelinating Disease (TMEV-IDD)), immune-induced damage depends on the persistence of the virus and its clearance leads to disease subsidence (<xref rid="B219" ref-type="bibr">219</xref>).</p><p>The search for the true etiology of MS pathological events seeks to fill gaps in the existing body of knowledge, including the failure of current pharmacotherapeutics to halt the progress of MS disease in RRMS (<xref rid="B130" ref-type="bibr">130</xref>), the presence of diffusely abnormal white matter changes, axon death and demyelination with minimal immune cell infiltration, and the presence of the same pathology in pre-phagocytic lesions, together with the accumulating evidence of BBB disruption before lesion formation and in areas of NAWM (<xref rid="B220" ref-type="bibr">220</xref>, <xref rid="B221" ref-type="bibr">221</xref>). In studies examining changes in the level of myelin in MS, myelin abnormalities were detected in the inner myelin sheath, which does not support the idea that myelin injury is immune- or antibody-mediated. Genome-wide association studies revealed a strong link between the MHC cluster and immune cell polymorphisms in patients with the RRMS variant of MS owing to its greater prevalence. For these patients, the immune system reaction to a primary event in the brain could be overwhelming and primarily reflect an increased immunogenetic predisposition to the unknown CNS disease process releasing autoantigens. This, in turn, could explain the wide spectrum of disease variants, which may reflect different degrees of the immune system response to the primary degenerative event in the brain.</p><p>Microglia are the resident CNS immune cells and account for 12&#8211;16% of the total human parenchymal CNS cells (<xref rid="B222" ref-type="bibr">222</xref>). They originate from erythro-myeloid progenitors of yolk sac (mesodermal) origin; they are self-renewing and are not replaced by blood-derived monocytes (<xref rid="B223" ref-type="bibr">223</xref>&#8211;<xref rid="B225" ref-type="bibr">225</xref>). Microglia proliferate and increase in number when activated, and this activation has been discovered in many neurodegenerative disorders, including MS, Parkinson&#8217;s disease, Alzheimer&#8217;s disease, and amyotrophic lateral sclerosis (<xref rid="B226" ref-type="bibr">226</xref>). In contrast, the choroid plexus and meningeal and perivascular macrophages are collectively known as border-associated macrophages (BAMs). These cells are nonparenchymal and reside at the interface of the CNS and blood&#8211;brain barrier (<xref rid="B227" ref-type="bibr">227</xref>, <xref rid="B228" ref-type="bibr">228</xref>).</p><p>Under normal physiological conditions, microglia have important functions in CNS development (<xref rid="B229" ref-type="bibr">229</xref>), including synaptic pruning, remodeling, myelination (<xref rid="B200" ref-type="bibr">200</xref>, <xref rid="B230" ref-type="bibr">230</xref>, <xref rid="B231" ref-type="bibr">231</xref>) and the modulation of synaptic plasticity (<xref rid="B200" ref-type="bibr">200</xref>). In addition, microglia contribute to surveillance of the CNS microenvironment via the expression of pattern recognition receptors, such as Toll-like receptors (TLRs), the lipid and phosphatidylserine receptor TREM2, complement receptor 3, and the C-type lectin receptor DC-SIGN87. In response to any change in the CNS microenvironment, microglia can proliferate, change their morphology, present antigens, phagocytize macromolecular agonists, and secrete cytokines and chemokines (<xref rid="B232" ref-type="bibr">232</xref>). Microglia are traditionally classified as M1 proinflammatory microglia or M2 anti-inflammatory microglia. Recently, there has been increasing evidence for different subtypes of microglia with different regulatory functions and characteristics that form a vast phenotypic spectrum (<xref rid="B233" ref-type="bibr">233</xref>, <xref rid="B234" ref-type="bibr">234</xref>).</p><p>In MS, activated microglia can be found in active lesions as well as in normal white matter (<xref rid="B209" ref-type="bibr">209</xref>, <xref rid="B235" ref-type="bibr">235</xref>, <xref rid="B236" ref-type="bibr">236</xref>). Microglia are also found in areas without inflammatory infiltration, and these areas are preactive lesions (<xref rid="B235" ref-type="bibr">235</xref>). Furthermore, microglial activation was shown to precede immune cell infiltration from the peripheral circulation in MS mouse models of Theiler&#8217;s murine encephalomyelitis, virus-induced demyelinating disease, and experimental autoimmune encephalomyelitis (EAE). In EAE mice, microglia first take up myelin antigens and present them to T cells through MHC II and costimulatory molecules (<xref rid="B237" ref-type="bibr">237</xref>), and the infiltration of inflammatory cells coincides with microglial activation (<xref rid="B238" ref-type="bibr">238</xref>).</p><p>During MS, activated microglia secrete nitric oxide (NO) and reactive oxygen species (ROS) that damage myelin and oligodendrocyte progenitor cells (<xref rid="B239" ref-type="bibr">239</xref>). Activated microglia also produce proinflammatory cytokines (TNF-&#945;, IFN-&#948;, and IL-1&#946;) and chemokines (MCP-1), which damage the BBB and downregulate VE-cadherin, occludin, and claudin-5 proteins in the BBB (<xref rid="B240" ref-type="bibr">240</xref>). Microglia secrete MMPs that contribute to the breakdown of the blood&#8211;brain-barrier basement membrane in multiple sclerosis (<xref rid="B241" ref-type="bibr">241</xref>, <xref rid="B242" ref-type="bibr">242</xref>). One of the more interesting pathways through which microglia are activated during brain injury is the production of danger-associated molecular patterns (DAMPs), which activate microglia and initiate neuroinflammation (<xref rid="B243" ref-type="bibr">243</xref>&#8211;<xref rid="B245" ref-type="bibr">245</xref>). In MS brains and EAE brains, activated microglia and T cells are usually closely associated, especially at sites of demyelination (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B246" ref-type="bibr">246</xref>), and their presence is correlated with axonal damage (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B247" ref-type="bibr">247</xref>). Microglia aid in recruiting T cells into brain tissue (<xref rid="B248" ref-type="bibr">248</xref>, <xref rid="B249" ref-type="bibr">249</xref>) and act as antigen-presenting cells by upregulating the expression of class I and II MHC molecules and coexpressing costimulatory molecules (<xref rid="B250" ref-type="bibr">250</xref>).</p><p>Conversely, microglia can also act protectively in MS and help remyelinate CNS cells through the secretion of neuroprotective molecules and anti-inflammatory cytokines (<xref rid="B251" ref-type="bibr">251</xref>), assist in oligodendrocyte proliferation, and phagocytize myelin debris (<xref rid="B252" ref-type="bibr">252</xref>). For example, previous studies in CX3CR1 knockout mice revealed reduced myelin debris clearance and remyelination due to the absence of phagocytic function of microglia (<xref rid="B253" ref-type="bibr">253</xref>). Microglia can increase the production of neuroprotective substances such as brain-derived neurotrophic factor and neurotrophin when exposed to MBP-primed Th2 cells (<xref rid="B254" ref-type="bibr">254</xref>).</p><p>The potential of some drugs to modulate the activation of microglia and hence their damaging effects in experimental models of MS or on the BBB suggests that microglia are a central contributor to inflammation in MS brains. This makes microglia an attractive therapeutic target for MS; this opportunity may be especially applicable in the progressive form of the disease for which no therapeutics are currently available. Glatiramer acetate, a drug approved for treating relapsing MS, has a demonstrated neuroprotective effect, which is thought to be mediated by activated M2 microglia (<xref rid="B255" ref-type="bibr">255</xref>). Other drugs that have been shown to be effective at modulating the severity of EAE in an animal model of MS through effects on microglia or macrophages include forskolin (<xref rid="B233" ref-type="bibr">233</xref>), bryostatin-1 (<xref rid="B256" ref-type="bibr">256</xref>), and ethyl pyruvate (<xref rid="B257" ref-type="bibr">257</xref>). The inhibition of microglia by minocycline reduces their deleterious effects on the BBB, supports the differentiation of oligodendrocyte precursors into immature oligodendrocytes and facilitates remyelination (<xref rid="B258" ref-type="bibr">258</xref>&#8211;<xref rid="B261" ref-type="bibr">261</xref>). Additionally, dipyridamole reduces microglial activation and cytokine secretion (<xref rid="B262" ref-type="bibr">262</xref>). Microglia can also be skewed toward an M2 anti-inflammatory phenotype by targeting AMP-activated protein kinase (AMPK) (<xref rid="B263" ref-type="bibr">263</xref>). <italic toggle="yes">In vitro</italic> models incorporating microglia have become advantageous for testing therapeutic targets that engage with microglia to develop MS therapeutics.</p></sec><sec id="s8"><title>Treatments</title><p>An evolving demand to investigate other potential therapeutics for MS that target different arms of the disease process, such as BBB dysfunction and microglial activation as more central processes orchestrating inflammation, is imposed by the failure of current therapeutics to treat the disease or prevent progression of the associated disability, as well as the lack of available drugs to treat the chronic progressive form of MS.</p><p>
<italic toggle="yes">In vivo</italic> and <italic toggle="yes">in vitro</italic> modeling systems are important in the processes of drug discovery and translation of research outcomes to the clinic. It is therefore important to look critically into the model systems available and their ability to mimic complex inflammatory processes and the diversity of cells and pathways involved. It is also important to consider how well models account for human genetic makeup differences.</p><p>New treatments for multiple sclerosis have been investigated intensely for more than 30 years (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). The first drug to be approved for the treatment of RRMS was injectable INF-&#946;, an anti-inflammatory cytokine, in 1993 (<xref rid="B264" ref-type="bibr">264</xref>&#8211;<xref rid="B266" ref-type="bibr">266</xref>), followed by the approval of another injectable anti-inflammatory drug, glatiramer acetate. Clinical trials have demonstrated the success of these compounds in altering MS disease progression and severity in patients as disease-modifying therapies (DMTs). This was followed by the FDA approval of the first humanized monoclonal antibody, natalizumab, which targets the &#945;-4 integrin component of very late antigen-4 (VLA-4) on the surface of leukocytes and thus prevents their adhesion to VCAM-1 on the surface of endothelial cells (<xref rid="B267" ref-type="bibr">267</xref>). The first oral drug to be approved was fingolimod, an analog of sphingosine 1-phosphate (S1P) that acts as an S1P antagonist to block the flow of T cells from secondary lymph organs into the peripheral circulation (<xref rid="B268" ref-type="bibr">268</xref>, <xref rid="B269" ref-type="bibr">269</xref>). For pediatric MS, fingolimod is the only approved oral DMT drug (<xref rid="B270" ref-type="bibr">270</xref>). Each of these drugs has been approved for RRMS but not for progressive MS. Siponimod, a selective S1P1 and S1P5 modulator, is approved for treating patients with relapsing forms of MS, including RRMS and active SPMS (<xref rid="B271" ref-type="bibr">271</xref>). Ozanimod and ponesimod are other S1P modulators that are approved for RRMS (<xref rid="B270" ref-type="bibr">270</xref>, <xref rid="B272" ref-type="bibr">272</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Current therapeutics available for multiple sclerosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Drug</th><th valign="bottom" align="center" rowspan="1" colspan="1">Mechanism of action</th><th valign="bottom" align="center" rowspan="1" colspan="1">Adverse effect</th><th valign="bottom" align="center" rowspan="1" colspan="1">Approved&#160;for</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="right" rowspan="1" colspan="1">Interferon &#223;</td><td valign="top" align="left" rowspan="1" colspan="1">Immunomodulation</td><td valign="top" align="left" rowspan="1" colspan="1">Common: injection site reaction, headache, flu-like symptoms<break/>serious: depression, hepatotoxicity, thrombocytopenia, leukopenia, thrombotic microangiopathy, seizure</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B428" ref-type="bibr">428</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Glatiramer acetate</td><td valign="top" align="left" rowspan="1" colspan="1">Immunomodulation</td><td valign="top" align="left" rowspan="1" colspan="1">Common: immediate postinjection reaction presenting with anxiety, chest tightness</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B429" ref-type="bibr">429</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Teriflunomide</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits dihydroorotate dehydrogenase leading to reduce de novo pyrimidine synthesis preventing lymphocyte proliferation</td><td valign="top" align="left" rowspan="1" colspan="1">Common: Headache, GI upset, hair thinning<break/>Serious: hepatotoxicity, peripheral neuropathy, elevated blood pressure</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B274" ref-type="bibr">274</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">fumarates</td><td valign="top" align="left" rowspan="1" colspan="1">Activates nuclear factor like 2</td><td valign="top" align="left" rowspan="1" colspan="1">Common: GI upset, flushing<break/>Serious: hepatotoxicity, lymphopenia, infections</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B430" ref-type="bibr">430</xref>)<break/>(<xref rid="B431" ref-type="bibr">431</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">fingolimod</td><td valign="top" align="left" rowspan="1" colspan="1">Sphingosine-1-phosphate receptor modulator/reduction in lymphocyte trafficking to brain</td><td valign="top" align="left" rowspan="1" colspan="1">Common: headache, infection<break/>Serious: bradycardia and cardiac arrhythmia, hepatotoxicity, seizure, hypertension, macular edema, skin cancer</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS, pediatric MS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">269</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Siponimod</td><td valign="top" align="left" rowspan="1" colspan="1">Sphingosine-1-phosphate receptor modulator/reduction in lymphocyte trafficking to brain</td><td valign="top" align="left" rowspan="1" colspan="1">Common: headache, infection,<break/>Serious: hepatotoxicity in CYP2C9*3/*3 genotype, bradycardia and brady arrhythmia, macular edema, Hypertension, VZV reactivation, disease activity rebound after stopping</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B300" ref-type="bibr">300</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">ozanimod</td><td valign="top" align="left" rowspan="1" colspan="1">Sphingosine-1-phosphate receptor modulator/reduction in lymphocyte trafficking to brain</td><td valign="top" align="left" rowspan="1" colspan="1">Common: headache, upper respiratory infection<break/>Serious: sleep apnea</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B432" ref-type="bibr">432</xref>)<break/>(<xref rid="B428" ref-type="bibr">428</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">ponesimod</td><td valign="top" align="left" rowspan="1" colspan="1">Sphingosine-1-phosphate receptor modulator/reduction in lymphocyte trafficking to brain</td><td valign="top" align="left" rowspan="1" colspan="1">Common: headache, infection,<break/>Serious: bradycardia and bradyarrhythmia, seizure, macular edema, hypertension, VZV reactivation, disease activity rebound after stopping</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B272" ref-type="bibr">272</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Cladribine</td><td valign="top" align="left" rowspan="1" colspan="1">Impairs DNA synthesis/cytotoxic on B &amp; T cells</td><td valign="top" align="left" rowspan="1" colspan="1">Common: headache, upper respiratory infection, fatigue<break/>Serious: fetal risk, risk of malignancy, risk of VZV reactivation</td><td valign="top" align="left" rowspan="1" colspan="1">RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B433" ref-type="bibr">433</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Natalizumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#913;4&#223;1 integrin inhibition</td><td valign="top" align="left" rowspan="1" colspan="1">Common: headache, infusion related reactions, joint pain, fatigue<break/>Serious: PML, encephalitis, liver failure, rebound syndrome</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B267" ref-type="bibr">267</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">ocrelizumab</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-CD20 cytolytic mab</td><td valign="top" align="left" rowspan="1" colspan="1">Common: infusion-related reaction, mild infection<break/>Serious: reactivation of HBV, severe reaction, severe infection, malignancy</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS, PPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B294" ref-type="bibr">294</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">ofatumumab</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-CD20 cytolytic mab</td><td valign="top" align="left" rowspan="1" colspan="1">Common: post injection reaction, mild infection<break/>Serious: recurrent or severe infection, HBV reactivation</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B295" ref-type="bibr">295</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">ublituximab</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-CD20 cytolytic mab</td><td valign="top" align="left" rowspan="1" colspan="1">Common: infusion-related reaction, infection<break/>Serious: reactivation of HBV</td><td valign="top" align="left" rowspan="1" colspan="1">CIS, RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B296" ref-type="bibr">296</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Alemtuzumab</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-CD52 cytolytic monoclonal antibody</td><td valign="top" align="left" rowspan="1" colspan="1">Common: infusion reaction, headache<break/>Serious: risk of autoimmune disease, strokes</td><td valign="top" align="left" rowspan="1" colspan="1">RRMS, active SPMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B281" ref-type="bibr">281</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">mitoxantrone</td><td valign="top" align="left" rowspan="1" colspan="1">antineoplastic anthracenedione that intercalates into DNA, causing damage, and it inhibits topoisomerase II</td><td valign="top" align="left" rowspan="1" colspan="1">Serious: cardiac toxicity, bone marrow suppression, risk of malignancy</td><td valign="top" align="left" rowspan="1" colspan="1">SPMS, RRMS, worsening RRMS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B284" ref-type="bibr">284</xref>)<break/>(<xref rid="B289" ref-type="bibr">289</xref>)</td></tr></tbody></table></table-wrap><p>Other drugs have been used for the treatment of RRMS, such as the oral drug teriflunomide, which inhibits the proliferation of B and T-cell blasts (<xref rid="B273" ref-type="bibr">273</xref>&#8211;<xref rid="B275" ref-type="bibr">275</xref>), and oral dimethyl fumarate, which exerts its immunomodulatory function through shifting T-helper (Th) cells from proinflammatory Th1 to anti-inflammatory Th2 cells (<xref rid="B276" ref-type="bibr">276</xref>). Additionally, oral Cladribine is an active purine nucleoside analog prodrug that accumulates in lymphocytes due to the low activity of the 5&#8217;-nucleotidase required for their inactivation, causing the death of these cells (<xref rid="B277" ref-type="bibr">277</xref>, <xref rid="B278" ref-type="bibr">278</xref>). Additionally, alemtuzumab is another humanized monoclonal antibody therapeutic, which is anti-CD52, a receptor expressed on lymphocytes (<xref rid="B279" ref-type="bibr">279</xref>&#8211;<xref rid="B281" ref-type="bibr">281</xref>).</p><p>The efficacy of these drugs was evaluated in clinical trials by assessing the reduction in disability via an expanded disability status scale (EDSS) and measuring the reduction in the number of relapses via the annualized relapse rate (aRR). These parameters were assessed in combination with other parameters, including the appearance of lesions on MRI and brain atrophy. The EDSS reflects the relative disability of MS patients on the basis of neurological examination of symptoms and signs of eight functional systems: vision; brain stem function; pyramidal and extrapyramidal systems; and cerebellar, cerebral, sensory, bowel, and bladder functions (<xref rid="B282" ref-type="bibr">282</xref>). All drugs approved for MS achieved a significant reduction in the aRR and in disability worsening when the EDSS score was equal to or greater than one third, with statistical clinical significance. Natalizumab stands out as yielding the greatest reduction in the aRR, reaching almost 70% (<xref rid="B267" ref-type="bibr">267</xref>).</p><p>Interestingly, despite the number of drugs approved for RRMS, there are currently very few drugs for primary progressive MS. However, some drugs have been tested for SPMS, including lamotrigine, dronabinol and dirucotide, but they do not demonstrate significant effectiveness (<xref rid="B283" ref-type="bibr">283</xref>&#8211;<xref rid="B286" ref-type="bibr">286</xref>). In a randomized trial of injectable drugs to treat SPMS and PPMS, the results were not positive (<xref rid="B284" ref-type="bibr">284</xref>, <xref rid="B287" ref-type="bibr">287</xref>, <xref rid="B288" ref-type="bibr">288</xref>). It was only later, after testing mitoxantrone, an anticancer drug, for the treatment of SPMS and PPMS that IFN-&#946; and mitoxantrone were approved for the treatment of SPMS, not PPMS, and only in patients with worsening disease and evidence of inflammation, leaving PPMS with limited treatment options (<xref rid="B284" ref-type="bibr">284</xref>, <xref rid="B289" ref-type="bibr">289</xref>, <xref rid="B290" ref-type="bibr">290</xref>). Trials for fingolimod in PPMS (<xref rid="B291" ref-type="bibr">291</xref>) and natalizumab in SPMS (<xref rid="B292" ref-type="bibr">292</xref>) also failed to produce positive results.</p><p>With the accrual of evidence suggesting the role of B cells in the pathogenesis of MS, monoclonal antibodies such as rituximab and ocrelizumab, which target CD20 on the surface of B cells, have emerged as therapeutic candidates (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B293" ref-type="bibr">293</xref>, <xref rid="B294" ref-type="bibr">294</xref>). In a phase III clinical trial of ocrelizumab for the treatment of RRMS, compared with subcutaneous IFN-&#946;, the drug resulted in a 45% reduction in aRR and in the progression of disability (<xref rid="B294" ref-type="bibr">294</xref>). Surprisingly, phase III trials for the same drug in the PPMS have shown positive results, and ocrelizumab was recently approved by the FDA as the first drug for the treatment of PPMS (<xref rid="B72" ref-type="bibr">72</xref>). In 2020, ofatumumab, a fully human IgG1 kappa anti-CD20 monoclonal antibody, RRMS AND SPMS, was approved for the treatment of CIS (<xref rid="B295" ref-type="bibr">295</xref>). In 2022, Ublituximab, a chimeric anti-CD20 monoclonal antibody, was approved for RRMS and SPMS (<xref rid="B296" ref-type="bibr">296</xref>).</p><p>Despite the significant efficacy of drugs approved for RRMS, most RRMS patients still progress to SPMS, which reflects an ongoing disease process. These drugs confer symptomatic treatment of the disease and slow progressive disability but are not a cure. Furthermore, some of these drugs have serious side effects, including fulminant hepatitis reported with IFN-&#946;; opportunistic CNS infection known as natalizumab-associated progressive multifocal leukoencephalopathy (PML) (<xref rid="B297" ref-type="bibr">297</xref>, <xref rid="B298" ref-type="bibr">298</xref>); bradycardia or conduction defects detected with fingolimod (<xref rid="B268" ref-type="bibr">268</xref>, <xref rid="B269" ref-type="bibr">269</xref>); and increased disease activity after the withdrawal of natalizumab, fingolimod and other drugs (<xref rid="B299" ref-type="bibr">299</xref>). These side effects and the persistent potential to convert to progressive disease highlight that these DMTs are immunosuppressive and immunomodulating agents that act only on the peripheral inflammatory component of the disease. These drugs are immunosuppressive, which could explain why they lack efficacy in progressive forms of MS where there is less immune cell infiltration into the CNS and where disease progression is led by innate immune mechanisms of the CNS mediated by microglia and macrophages (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B300" ref-type="bibr">300</xref>).</p><p>There remains a need to explore and delineate pathobiological pathways that could be targeted by therapeutics to stop the progression of MS, which might include efforts to increase myelination or change the polarization of microglia. As previously mentioned, microglia appear to be important mediators of the chronic progressive disease process in PPMS and SPMS, with research revealing that they exert their effects on the surrounding CNS parenchymal cells and the BBB. The presence of activated microglia in the NAWM of MS patients, which are believed to be prelesional areas, further makes microglia extremely attractive targets for treating MS.</p></sec><sec id="s9"><title>
<italic toggle="yes">In vivo</italic> disease models</title><p>Different animal models have been used to investigate MS <italic toggle="yes">in vivo</italic> (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>), especially the experimental autoimmune encephalomyelitis (EAE) model (<xref rid="B301" ref-type="bibr">301</xref>, <xref rid="B302" ref-type="bibr">302</xref>), which includes inflammation of the CNS triggered by infiltration of autoreactive T cells and monocytes, causing demyelination (<xref rid="B303" ref-type="bibr">303</xref>). The EAE model can be induced in vertebrates&#8212;mostly rodents (mice, rats, and guinea pigs)&#8212;either by active immunization with a CNS antigen or by adoptive (passive) transfer of activated T cells to naive animals (<xref rid="B304" ref-type="bibr">304</xref>&#8211;<xref rid="B306" ref-type="bibr">306</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>
<italic toggle="yes">In vivo</italic> preclinical models of multiple sclerosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Model</th><th valign="top" align="center" rowspan="1" colspan="1">Mechanism of induction</th><th valign="top" align="center" rowspan="1" colspan="1">Importance</th><th valign="top" align="center" rowspan="1" colspan="1">Limitation</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="right" rowspan="1" colspan="1">Experimental autoimmune encephalitis</td><td valign="top" align="left" rowspan="1" colspan="1">Active immunization with antigens derived from basic myelin protein OR passive immunization with transfer of activated T cells</td><td valign="top" align="left" rowspan="1" colspan="1">Understanding basic mechanisms of inflammation in Multiple Sclerosis</td><td valign="top" align="left" rowspan="1" colspan="1">-Dominance of CD4+ T Cells over CD8+ T Cells<break/>-Mostly involves spinal cord rather than the brain</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B317" ref-type="bibr">317</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Theiler&#8217;s Murine Encephalopathy virus</td><td valign="top" align="left" rowspan="1" colspan="1">Encephalomyelitis</td><td valign="top" align="left" rowspan="1" colspan="1">Presenting chronic progressive demyelination phase with plaque formation and axonal injury<break/>Understanding mechanisms of viral clearance<break/>Understanding the role of each lymphocytic population in disease progression</td><td valign="top" align="left" rowspan="1" colspan="1">Only induces encephalomyelitis in susceptible strains of mice</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B317" ref-type="bibr">317</xref>, <xref rid="B434" ref-type="bibr">434</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Mouse Hepatitis Virus</td><td valign="top" align="left" rowspan="1" colspan="1">Encephalomyelitis</td><td valign="top" align="left" rowspan="1" colspan="1">Presenting chronic demyelination phase with plaque formation and axonal injury</td><td valign="top" align="left" rowspan="1" colspan="1">Complex disease pathogenesis beyond dissection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B434" ref-type="bibr">434</xref>, <xref rid="B435" ref-type="bibr">435</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Semliki Forest Virus</td><td valign="top" align="left" rowspan="1" colspan="1">Encephalomyelitis</td><td valign="top" align="left" rowspan="1" colspan="1">Presenting chronic demyelination phase</td><td valign="top" align="left" rowspan="1" colspan="1">Complex disease pathogenesis beyond dissection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B435" ref-type="bibr">435</xref>, <xref rid="B436" ref-type="bibr">436</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Ethidium Bromide induced</td><td valign="top" align="left" rowspan="1" colspan="1">Interferes with DNA transcription in glial cells</td><td valign="top" align="left" rowspan="1" colspan="1">Presenting focal model of demyelination and remyelination<break/>Degeneration of oligodendrocytes and astrocytes</td><td valign="top" align="left" rowspan="1" colspan="1">Does not stimulate all the inflammatory processes involved</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B436" ref-type="bibr">436</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Lysolecitin-induced</td><td valign="top" align="left" rowspan="1" colspan="1">Integrating into cell membrane which causes increased permeability and lipid disruption thus causing damage in lipid membrane-rich myelin sheath</td><td valign="top" align="left" rowspan="1" colspan="1">Presenting focal model of demyelination and remyelination</td><td valign="top" align="left" rowspan="1" colspan="1">Does not stimulate all the inflammatory processes involved</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B436" ref-type="bibr">436</xref>, <xref rid="B437" ref-type="bibr">437</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Lipopolysacharide</td><td valign="top" align="left" rowspan="1" colspan="1">Evoking inflammatory reaction</td><td valign="top" align="left" rowspan="1" colspan="1">Demyelination expanding beyond point of injection</td><td valign="top" align="left" rowspan="1" colspan="1">Does not stimulate all the inflammatory processes involved</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B437" ref-type="bibr">437</xref>, <xref rid="B438" ref-type="bibr">438</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Cuprizone (oxalix acid bis)</td><td valign="top" align="left" rowspan="1" colspan="1">Oligodendrocyte apoptosis (probably through disfunction of mitochondrial enzymes), innate immunity</td><td valign="top" align="left" rowspan="1" colspan="1">Presenting demyelination followed by spontaneous remyelination, and ongoing axonal injury even in myelinated fibers</td><td valign="top" align="left" rowspan="1" colspan="1">B cells and T cells do not play a crucial rule<break/>Rapid and extensive remyelination and not presenting the remyelination failure seen in MS</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B438" ref-type="bibr">438</xref>, <xref rid="B439" ref-type="bibr">439</xref>)</td></tr></tbody></table></table-wrap><p>During active immunization with a CNS antigen, signs of the disease appear within 10&#8211;17 days, whereas it takes 5&#8211;7 days in adoptive transfer (<xref rid="B307" ref-type="bibr">307</xref>). Adaptive immunization can be incomplete in that disease induction is dependent only on transferred CD4+ T cells and lacks the contributions of CD8+ T cells and B cells. The basic myelin proteins used for the sensitization of immune cells in active EAE models include myelin basic protein (MBP) (<xref rid="B308" ref-type="bibr">308</xref>, <xref rid="B309" ref-type="bibr">309</xref>), myelin oligodendrocyte glycoprotein (MOG) 26959137, and proteolipid protein (PLP) (<xref rid="B310" ref-type="bibr">310</xref>); more recently, small antigenic peptides of these proteins, such as MBP<sub>1-37</sub>, MBP<sub>1-11</sub>, MBP<sub>1-9</sub>, MOG<sub>55-75</sub>, and PLP<sub>139-151, have been used</sub> (<xref rid="B310" ref-type="bibr">310</xref>, <xref rid="B311" ref-type="bibr">311</xref>). Different animal strains have different potentials for developing autoreactive T cells upon immunization and hence different clinical and pathological presentations of the disease. The animals&#8217; response is also affected by the type and dose of the antigen used as well as the animal&#8217;s age and sex (<xref rid="B312" ref-type="bibr">312</xref>, <xref rid="B313" ref-type="bibr">313</xref>). Nevertheless, all actively immunized animals share an initial first finding of perivascular infiltration into white matter. Furthermore, most pathological changes associated with EAE are noted in the spinal cord and optic nerve but not in the brain (<xref rid="B314" ref-type="bibr">314</xref>&#8211;<xref rid="B316" ref-type="bibr">316</xref>).</p><p>The active induction of EAE recapitulates many aspects of MS, including the development of inflammation with immunoglobulin deposition, demyelination, and axonal damage, including gliosis and remyelination. In contrast, other features, including primary neurodegeneration, the involvement of CD8+ T cells, and cortical lesions, are not accurately modeled (<xref rid="B317" ref-type="bibr">317</xref>&#8211;<xref rid="B319" ref-type="bibr">319</xref>). As mentioned previously, some lesions in MS patients lack the prominent immune response features of demyelination and microglial activation. This category of lesion does not appear in EAE models, in which lesions are primarily immune mediated.</p><p>Many aspects of progressive MS are still not reflected in animal models, which contribute to the deficient development of therapeutics for progressive MS despite decades of MS research. The incidence of inflammatory demyelination in EAE patients decreases after the removal of the sensitizing brain antigen from the periphery (<xref rid="B320" ref-type="bibr">320</xref>, <xref rid="B321" ref-type="bibr">321</xref>). Conversely, disease severity in progressive MS increases with time, which implies that a persistent stimulus must exist throughout the course of the disease, whether it is endogenous or exogenous to the CNS. Thus, EAE cannot recapitulate the progressive nature of the disease. One of the models mimicking secondary progressive MS involves repeated injections of the MOG <sub>35-55</sub> peptide, which causes long-term expression of the disease phenotype (<xref rid="B322" ref-type="bibr">322</xref>).</p><p>Owing to the potential viral etiology of MS, virus-induced <italic toggle="yes">in vivo</italic> models have been developed, including experimental demyelinating disease induced by Theiler&#8217;s murine encephalomyelitis virus (TMEV) (<xref rid="B323" ref-type="bibr">323</xref>, <xref rid="B324" ref-type="bibr">324</xref>) and mouse hepatitis virus (MHV) (<xref rid="B325" ref-type="bibr">325</xref>). These are superior models to EAE with respect to the progressive accumulation of disability during demyelination and the longer incubation period before the appearance of symptoms, but there is a higher mortality rate in these animals in addition to the hazards associated with working with some of these viruses (<xref rid="B326" ref-type="bibr">326</xref>, <xref rid="B327" ref-type="bibr">327</xref>).</p><p>Toxin-induced models for studying demyelination also exist, in which demyelination is induced by cytotoxic agents and does not result from immune attack (<xref rid="B328" ref-type="bibr">328</xref>). These models are useful for studying demyelination and remyelination mechanisms as well as potential remyelinating therapeutics (<xref rid="B329" ref-type="bibr">329</xref>). Examples of these focally used agents include lysolecithin (<xref rid="B330" ref-type="bibr">330</xref>), ethidium bromide (EtBr) (<xref rid="B329" ref-type="bibr">329</xref>, <xref rid="B331" ref-type="bibr">331</xref>), and cuprizone. Lesions induced by these toxins differ from each other with respect to the process by which myelin is degraded as well as the degree of astrocyte loss (<xref rid="B329" ref-type="bibr">329</xref>).</p><p>Although naturally occurring animal models of EAE do not exist, researchers have discovered spontaneous autoimmune encephalomyelitis in transgenic mice expressing T-cell receptors specific to myelin antigen peptides (<xref rid="B332" ref-type="bibr">332</xref>&#8211;<xref rid="B334" ref-type="bibr">334</xref>). Humanized EAE mouse models have been developed in trials to overcome species-related differences in the molecular mechanisms of MS, especially the antigen presentation process, cell adhesion, and role of chemokines in disease pathogenesis (<xref rid="B335" ref-type="bibr">335</xref>, <xref rid="B336" ref-type="bibr">336</xref>).</p><p>EAE has served as an experimental tool for the development of MS therapeutics, such as glatiramer acetate, mitoxantrone, and natalizumab (<xref rid="B337" ref-type="bibr">337</xref>, <xref rid="B338" ref-type="bibr">338</xref>), and has been used to investigate the efficacy and safety of many other treatments, including methylprednisolone (<xref rid="B339" ref-type="bibr">339</xref>) for MS relapses and IFN-&#946;, which cause disease exacerbation after treatment discontinuation (<xref rid="B340" ref-type="bibr">340</xref>). There are nevertheless also drugs that decrease disease activity in animal models but either fail to show any therapeutic efficacy in clinical trials or generate adverse effects. Examples of these drugs include monoclonal anti-tumor necrosis factor antibody cA2, which increases MRI activity in patients but does not improve symptoms (<xref rid="B341" ref-type="bibr">341</xref>); anti-CD28 Mab TGN-1412, which causes cytokine storms (<xref rid="B342" ref-type="bibr">342</xref>) and multiple organ failure; linomide, which causes cardiotoxicity (<xref rid="B341" ref-type="bibr">341</xref>) and oral tolerance (<xref rid="B343" ref-type="bibr">343</xref>); and sulfasalazine (<xref rid="B344" ref-type="bibr">344</xref>), which has no therapeutic effect. The translational failure of these therapeutics may be attributed in part to the differing genetic makeup between humans and rodents. In conclusion, there is no perfect <italic toggle="yes">in vivo</italic> animal model for MS, and the selection of a model should be based on the primary aim of the research and pathological mechanisms being investigated (<xref rid="B345" ref-type="bibr">345</xref>, <xref rid="B346" ref-type="bibr">346</xref>).</p></sec><sec id="s10"><title>
<italic toggle="yes">In vitro</italic> models</title><p>With the advent of the era of translational medicine and the rapid advancement of <italic toggle="yes">in vitro</italic> models, researchers are increasingly directed toward <italic toggle="yes">in vitro</italic> models for neurodegenerative disease and CNS disorders. <italic toggle="yes">In vitro</italic> models have strong potential to overcome some of the limitations mentioned in the <italic toggle="yes">in vivo</italic> models of MS, such as the differences between the human and rodent genomes and the resulting differences in molecular mechanisms. These limitations, at least in part, contributed to the failure of the translation of many therapeutics from animal models to clinical trials and the lack of a definitive cure for the disease process. In addition, one of the most important hurdles is the lack of models for progressive disease, as well as treatments. One of the main advantages of these <italic toggle="yes">in vitro</italic> models is the ability to scale them to enable high-throughput screening of drug targets and extensive studies of molecular mechanisms to reveal more therapeutic hits. In these models, interactions between different CNS cells and immune cells can be studied closely in a simple setting and manipulated with a high degree of precision.</p><p>With increasing awareness of the involvement of blood&#8211;brain barrier dysfunction in many neurological and psychological disorders, efforts have been made to model the BBB <italic toggle="yes">in vitro</italic> to offer a simplified, reproducible biological platform to study these disorders and translate findings into clinical practice.</p><p>BBB dysfunction has been reported in a variety of neurodegenerative disorders in addition to the previously discussed MS, including Alzheimer&#8217;s disease (AD) (<xref rid="B347" ref-type="bibr">347</xref>&#8211;<xref rid="B350" ref-type="bibr">350</xref>), amyotrophic lateral sclerosis (ALS) (<xref rid="B351" ref-type="bibr">351</xref>), Parkinson&#8217;s disease (PD) (<xref rid="B352" ref-type="bibr">352</xref>), and Huntington&#8217;s disease (HD) (<xref rid="B353" ref-type="bibr">353</xref>). Furthermore, BBB breakdown in epilepsy is thought to adversely affect the CNS microenvironment and neuronal physiology (<xref rid="B354" ref-type="bibr">354</xref>). Cognitive and neurological decline during aging is also attributed in part to BBB dysfunction (<xref rid="B355" ref-type="bibr">355</xref>, <xref rid="B356" ref-type="bibr">356</xref>). Furthermore, posttraumatic epilepsy and neural degeneration, which are cognitive and psychological disorders that occur after traumatic brain injury, are related to BBB dysfunction (<xref rid="B357" ref-type="bibr">357</xref>&#8211;<xref rid="B359" ref-type="bibr">359</xref>). BBB dysfunction has even been implicated in neuropsychological disorders such as schizophrenia and autism. (<xref rid="B360" ref-type="bibr">360</xref>).</p><p>Different models have been developed to investigate BBB dysfunction in brain disorders, screen drugs for their ability to cross the BBB (<xref rid="B361" ref-type="bibr">361</xref>), and study neuroimmunological interactions at the BBB interface (<xref rid="B362" ref-type="bibr">362</xref>). These BBB models differ in the source and the type of brain microvascular endothelial cells used (<xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>). During the last few years, the design of <italic toggle="yes">in vitro</italic> BBB models has progressed from using 2D monolayers or transwell models to more sophisticated designs that include shear stress induced by fluid flow in microfluidic devices or 3D organoid (<xref rid="T4" ref-type="table">
<bold>Table&#160;4</bold>
</xref>). The developments also included using more than one cell type in a co-culture rather than just using BMVECs alone. Coculture BBB models can provide endothelial cells with the necessary signals from other cells in the NVU when combined with astrocytes, pericytes, and neurons, which contributes meaningfully to barrier properties (<xref rid="B363" ref-type="bibr">363</xref>, <xref rid="B364" ref-type="bibr">364</xref>). These barrier properties are not intrinsic to brain endothelial cells but rather depend on the microenvironment of the NVU (<xref rid="B365" ref-type="bibr">365</xref>, <xref rid="B366" ref-type="bibr">366</xref>) Each of the cell types or the designs has its own advantages and disadvantages to be considered while picking up a model to answer a specific research question.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>Cell source for <italic toggle="yes">in-vitro</italic> BBB models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Cell source</th><th valign="top" align="center" rowspan="1" colspan="1">Advantages</th><th valign="top" align="center" rowspan="1" colspan="1">Disadvantages</th><th valign="top" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><th valign="top" colspan="4" align="left" rowspan="1">Species</th></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Non-Human<break/>Pigs<break/>Cows<break/>Rats<break/>Mice</td><td valign="top" align="left" rowspan="1" colspan="1">Relatively Inexpensive<break/>Easy to get from animal tissues</td><td valign="top" align="left" rowspan="1" colspan="1">Different genetic profile than humans<break/>
<break/>Complicate translation of results to humans</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B440" ref-type="bibr">440</xref>)<break/>(<xref rid="B441" ref-type="bibr">441</xref>)<break/>(<xref rid="B375" ref-type="bibr">375</xref>)<break/>
<break/>(<xref rid="B442" ref-type="bibr">442</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Human</td><td valign="top" align="left" rowspan="1" colspan="1">Human Genetic profile and functional molecules<break/>Facilitate translation to humans<break/>Can express disease phenotype of the disease</td><td valign="top" align="left" rowspan="1" colspan="1">Difficult to get from human biopsies<break/>Limited sources<break/>Expensive</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B443" ref-type="bibr">443</xref>, <xref rid="B444" ref-type="bibr">444</xref>)</td></tr><tr><th valign="top" colspan="4" align="left" rowspan="1">Cell type</th></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Primary</td><td valign="top" align="left" rowspan="1" colspan="1">Express BBB properties<break/>Express important BBB markers and functional molecules</td><td valign="top" align="left" rowspan="1" colspan="1">Limited Availability<break/>Limited capacity to proliferate<break/>Relatively low TEER value</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B445" ref-type="bibr">445</xref>, <xref rid="B446" ref-type="bibr">446</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Immortalized</td><td valign="top" align="left" rowspan="1" colspan="1">High yield and easy to expand<break/>Sustained source</td><td valign="top" align="left" rowspan="1" colspan="1">Depend on oncogenic factors to proliferate<break/>Low TEER values<break/>Do not express all BBB markers</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B447" ref-type="bibr">447</xref>, <xref rid="B448" ref-type="bibr">448</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">IPSC-derived</td><td valign="top" align="left" rowspan="1" colspan="1">High TEER value<break/>Keep genetic profile of donor cells<break/>Possibility of modeling disease of donors<break/>Do not depend on oncogenic factors to proliferate<break/>Sustained source</td><td valign="top" align="left" rowspan="1" colspan="1">Lengthy multistep protocols to differentiate</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B449" ref-type="bibr">449</xref>&#8211;<xref rid="B451" ref-type="bibr">451</xref>)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table&#160;4</label><caption><p>Designs for <italic toggle="yes">in-vitro</italic> BBB models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Model</th><th valign="top" align="center" rowspan="1" colspan="1">Set up</th><th valign="top" align="center" rowspan="1" colspan="1">Advantages</th><th valign="top" align="center" rowspan="1" colspan="1">Disadvantages</th><th valign="top" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" align="right" rowspan="1" colspan="1">Transwell<break/>monoculture</td><td valign="top" align="left" rowspan="1" colspan="1">Brain microvascular endothelial cells cultures on upper surface of porous membrane of transwell insert</td><td valign="top" align="left" rowspan="1" colspan="1">Relatively Inexpensive<break/>Simple set up<break/>
<break/>Possibility of measuring TEER values<break/>
<break/>Possibility of sampling from abluminal surface</td><td valign="top" align="left" rowspan="1" colspan="1">Do not have other cells of the neurovascular unit<break/>
<break/>Endothelial cells not subjected to sheer stress<break/>
<break/>No media flow</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B452" ref-type="bibr">452</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Transwell coculture</td><td valign="top" align="left" rowspan="1" colspan="1">Brain microvascular endothelial cells cultures on the upper surface of transmembrane insert<break/>
<break/>Other cells such as astrocytes, pericytes and neurons are cultures on the lower (abluminal) surface of the insert or on the bottom of the well</td><td valign="top" align="left" rowspan="1" colspan="1">Moderately expensive<break/>
<break/>Relatively easy set up<break/>
<break/>Allow for the contribution of other cells to the barrier properties<break/>
<break/>Simple set up<break/>
<break/>Possibility of measuring TEER values<break/>
<break/>Possibility of sampling from the abluminal surface</td><td valign="top" align="left" rowspan="1" colspan="1">Endothelial cells not subjected to sheer stress<break/>
<break/>No media flow<break/>
<break/>Cells are not in direct contact with each other</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B443" ref-type="bibr">443</xref>, <xref rid="B453" ref-type="bibr">453</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Dynamic</td><td valign="top" align="left" rowspan="1" colspan="1">Media flow in capillary tubes (hollow fibers) lined with Brain microvascular endothelial cells<break/>
<break/>Media flow controlled by using peristaltic or syringe pumps</td><td valign="top" align="left" rowspan="1" colspan="1">Generate shear stress on endothelial cells<break/>
<break/>Improve the BBB properties<break/>
<break/>Achieves higher TEER values<break/>
<break/>Allow for co-culture of cells surrounding hollow fibers</td><td valign="top" align="left" rowspan="1" colspan="1">Expensive<break/>
<break/>No direct communication between cocultured cells<break/>
<break/>Can not optically examine the cells<break/>Time consuming<break/>
<break/>Special skills required</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B426" ref-type="bibr">426</xref>, <xref rid="B454" ref-type="bibr">454</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">Microfluidic</td><td valign="top" align="left" rowspan="1" colspan="1">Chips synthesized with channels of small diameters mimicking microvascular channels<break/>
<break/>Media flow controlled by using peristaltic or syringe pumps</td><td valign="top" align="left" rowspan="1" colspan="1">Increased TEER value<break/>
<break/>Shear stress improves BBB properties<break/>
<break/>Allow for visualization of cells by microscopy</td><td valign="top" align="left" rowspan="1" colspan="1">Expensive<break/>
<break/>Time consuming<break/>
<break/>Special skills required</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B455" ref-type="bibr">455</xref>, <xref rid="B456" ref-type="bibr">456</xref>)</td></tr><tr><td valign="top" align="right" rowspan="1" colspan="1">3D self-assembled organoids</td><td valign="top" align="left" rowspan="1" colspan="1">Brain microvascular endothelial cells cocultured with other cells of neurovascular unit are allowed to form spheroids in ultra-low attachment plates<break/>
<break/>Different extracellular matrices could be incorporated in the model</td><td valign="top" align="left" rowspan="1" colspan="1">Direct contact between all cells of neurovascular units<break/>Scalable<break/>
<break/>Allow high throughput screening<break/>
<break/>Could be incorporated in microfluidic chips to experience shear stress</td><td valign="top" align="left" rowspan="1" colspan="1">Expensive<break/>
<break/>Special skills required<break/>TEER values cannot be measured (permeability is assessed using tracer molecules of different molecular weight</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B400" ref-type="bibr">400</xref>, <xref rid="B402" ref-type="bibr">402</xref>)</td></tr></tbody></table></table-wrap><p>
<italic toggle="yes">In vitro</italic> BBB models were initially developed with brain endothelial cells cultured on transwell inserts. These systems allow the measurement of transendothelial electrical resistance (TEER) values across the monolayer and direct measurement of permeability by sampling from luminal (blood facing) and abluminal (brain-facing) compartments (<xref rid="B367" ref-type="bibr">367</xref>&#8211;<xref rid="B370" ref-type="bibr">370</xref>). Transwell systems using cocultures of brain endothelial cells, astrocytes (<xref rid="B371" ref-type="bibr">371</xref>&#8211;<xref rid="B375" ref-type="bibr">375</xref>) and pericytes (<xref rid="B376" ref-type="bibr">376</xref>&#8211;<xref rid="B378" ref-type="bibr">378</xref>), either in contact or noncontact settings, presented increased TEER values, which was reflected by decreased permeability to tracer molecules such as lucifer yellow, sodium fluorescein, sucrose, and dextrans. Move to table</p><p>The transwell <italic toggle="yes">in vitro</italic> BBB model has been used to study immune system interactions at the BBB interface. In these models, endothelial cells can be stimulated by pathogenic factors such as LPS (<xref rid="B379" ref-type="bibr">379</xref>&#8211;<xref rid="B382" ref-type="bibr">382</xref>) or by proinflammatory cytokines such as TNF-&#945;, IL-6, IL-1&#946;, and IFN-&#948; (<xref rid="B382" ref-type="bibr">382</xref>&#8211;<xref rid="B384" ref-type="bibr">384</xref>). These systems have been extensively used to study the regulation of the transmigration of monocytes, neutrophils, and lymphocytes across the BBB (<xref rid="B385" ref-type="bibr">385</xref>&#8211;<xref rid="B387" ref-type="bibr">387</xref>) and to investigate the effects of adhesion molecules on leukocyte transmigration (<xref rid="B148" ref-type="bibr">148</xref>, <xref rid="B385" ref-type="bibr">385</xref>, <xref rid="B388" ref-type="bibr">388</xref>&#8211;<xref rid="B392" ref-type="bibr">392</xref>).</p><p>Transwell coculture models have also been used to study the involvement of the BBB in MS. Some studies have used 2D brain endothelial cell cultures to study the ability of patient-derived sera to modulate BBB properties, especially tight junction protein and adhesion molecule expression. Using a transwell BBB model, Shimizu et&#160;al. reported that serum from MS patients disrupts BBB function by decreasing claudin-5 expression and decreasing the TEER value, which reflects increased BBB permeability. VCAM1 expression increased in response to exposure to sera and IgG from different types of MS patients. Disruption can be prevented by the addition of MMP inhibitors. (<xref rid="B167" ref-type="bibr">167</xref>). Similarly, Minagar et&#160;al. demonstrated that sera from patients with exacerbated MS could decrease the expression of occludin and VE-cadherin in endothelial cells (<xref rid="B168" ref-type="bibr">168</xref>). Sheikh et&#160;al. demonstrated that sera from MS patients could alter the metabolic function of the brain endothelium by decreasing glycolytic activity, the oxygen consumption rate and the expression of endothelial glucose transporter 1 (GLUT-1) (<xref rid="B393" ref-type="bibr">393</xref>).</p><p>Additionally, other studies used <italic toggle="yes">in vitro</italic> transwell BBB models to study the capacity of immune cells isolated from the peripheral blood of MS patients to cross the BBB. Prat et&#160;al. showed that, compared with healthy control lymphocytes, MS patient lymphocytes exhibited enhanced migration across the <italic toggle="yes">in vitro</italic> transwell BBB and that transmigration could be reduced via the use of an anti-monocyte chemoattractant protein 1 monoclonal antibody (<xref rid="B394" ref-type="bibr">394</xref>). In another study, the authors showed that CD4<sup>+</sup> T cells from MS patients presented increased expression of P-selectin glycoprotein ligand-1 (PSGL-1). Compared with PSGL-1-negative T cells, CD4<sup>+</sup> T cells positive for PSGL-1 showed an increased capacity to transmigrate across the BBB (<xref rid="B395" ref-type="bibr">395</xref>). Despite the popularity, relative simplicity, and low cost of transwell BBB models, they may not reflect the complex interactions and contact between different cellular and acellular elements of the NVU and may lack the physiological shear stress that helps maintain several BBB properties (<xref rid="B396" ref-type="bibr">396</xref>).</p><p>3D BBB models have been developed to overcome this contact issue via coculture of primary brain endothelial cells, astrocytes and pericytes under low-adherence conditions, allowing the formation of BBB multicellular organoids, which exhibit BBB properties (<xref rid="B397" ref-type="bibr">397</xref>, <xref rid="B398" ref-type="bibr">398</xref>). These organoids have the advantages of direct contact between cells, are reproducible, and can be cost-effective relative to animal models. BBB organoids could be used to study drug transport across the BBB, investigate neurological disease mechanisms, and develop therapeutics (<xref rid="B397" ref-type="bibr">397</xref>). 3D BBB models have been used to study general inflammatory conditions by exposing organoids to exogenous inflammatory cytokines to mimic neuroinflammatory conditions. The use of 3D BBB models to study MS-specific features has not been widely applied (<xref rid="B399" ref-type="bibr">399</xref>).</p><p>The absence of neurons and glial cells is a limitation of most BBB organoids, as they are critical contributors to BBB development and are necessary to study neurovascular coupling in neurological disorders in conjunction with the BBB. Nzou et&#160;al. reported the development of a human neurovascular unit organoid model that contains all six constituent human cell types found within the brain cortex: brain microvascular endothelial cells; pericytes; astrocytes; microglia; oligodendrocytes; and neurons, with endothelial cells enclosing the brain parenchymal cells (<xref rid="B400" ref-type="bibr">400</xref>). This 3D <italic toggle="yes">in vitro</italic> system contains all major cell types found in the adult human brain cortex and provides a platform to understand the fundamental principles at play with the BBB and its function and to understand the effects of substances that cross the BBB. This sophisticated human brain model system has been used to study hypoxia, inflammation, and the delivery of therapeutic agents across the BBB (<xref rid="B401" ref-type="bibr">401</xref>&#8211;<xref rid="B404" ref-type="bibr">404</xref>).</p><p>The development and incorporation of iPSC-derived brain endothelial cells (iBECs) in BBB coculture models resulted in a BBB with high TEER values (<xref rid="B405" ref-type="bibr">405</xref>, <xref rid="B406" ref-type="bibr">406</xref>). These models have been widely used to study disease pathophysiology (<xref rid="B407" ref-type="bibr">407</xref>&#8211;<xref rid="B409" ref-type="bibr">409</xref>) and drug screening (<xref rid="B410" ref-type="bibr">410</xref>, <xref rid="B411" ref-type="bibr">411</xref>). HiPSCs have been used to model many brain disorders, including Parkinson&#8217;s disease (PD) (<xref rid="B412" ref-type="bibr">412</xref>) and Alzheimer&#8217;s disease (AD) (<xref rid="B413" ref-type="bibr">413</xref>).Although they have not yet been applied directly to study MS, they present great potential for integrating NVU cells from MS patients to study the contribution of the genome to MS pathophysiology. In addition, these iPSC-derived endothelial cells can be manipulated by gene editing to introduce specific genetic mutations to study their effects on NVU function (<xref rid="B414" ref-type="bibr">414</xref>). One of the most recent advances in the field of brain organoids with relevance to multiple sclerosis is the induction of myelination in human cortical spheroids, which makes them good platforms for studying demyelination events in neurodegenerative disorders (<xref rid="B415" ref-type="bibr">415</xref>).</p><p>With advancements in microfluidic technology, BBB-on-a-chip models have emerged, allowing perfusion of the BBB in two-dimensional microfluidic models (<xref rid="B416" ref-type="bibr">416</xref>&#8211;<xref rid="B418" ref-type="bibr">418</xref>), hybrid systems (<xref rid="B419" ref-type="bibr">419</xref>, <xref rid="B420" ref-type="bibr">420</xref>), or self-organizing 3-D multicellular BBB models (<xref rid="B421" ref-type="bibr">421</xref>, <xref rid="B422" ref-type="bibr">422</xref>). 3D self-assembled BBB organoids could be incorporated into microfluidic chips. Six different human organoids, including a brain with six different cell types that form a 3D BBB, liver, heart, lung, vascular and testes, were incorporated into a single microfluidic body-on-a-chip system to study integrated functional parameters (<xref rid="B423" ref-type="bibr">423</xref>). The same integrated body-on-a-chip system was used to test the effect of prodrug metabolism by the liver and to prove its toxic effect on other organoids (<xref rid="B424" ref-type="bibr">424</xref>). The metabolism of the alkylating drug ifosfamide in liver organoids into chloroacetaldehyde results in BBB neurotoxicity downstream. Although there are no other multi-tissue organ-on-a-chip models reported to date that include the BBB with other organs, multiorgan-on-a-chip (multi-OoC) models represent strong candidates for investigating and better understanding the human body, systemic illnesses and organ communications. This system can support screening for drug efficacy and toxicity prior to translation to clinical trials and can help reduce the number of animals used for <italic toggle="yes">in vivo</italic> studies.</p><p>These microfluidic devices help investigate the BBB in a more physiologically relevant microenvironment, but they require special skills and equipment (<xref rid="B425" ref-type="bibr">425</xref>). Microfluidic BBB models have been used to study the transmigration of immune cells across the barrier. Flow has been demonstrated to enhance BBB integrity and upregulate the expression of tight junction proteins. Compared with that in static models, the transmigration of immune cells is reduced (<xref rid="B426" ref-type="bibr">426</xref>). Nair et&#160;al. used a microfluidic BBB model to test the effects of proinflammatory cytokines on BBB integrity and permeability. TNF&#945; and interleukin-1 beta (IL-1&#946;) disrupt BBB integrity and increase BBB permeability. The expression of cell adhesion molecules increases with the subsequent increase in the transmigration of human T cells and the inhibition of transmigration in the presence of natalizumab (<xref rid="B427" ref-type="bibr">427</xref>). Microfluidic BBB models have not yet been fully exploited in the study of the disease-specific pathophysiology of MS or immune cells in MS patients.</p><p>Even with the great advancements observed in the field of translational research and modeling platforms, a disease as complex as MS remains relatively uninvestigated. Owing to the failure of the translation of many MS drugs from animal models to humans, the lack of true therapeutic options to cure MS, the severe side effects imposed by the currently available therapeutics, and the lack of medications for the progressive forms of the disease, the exploitation of alternative modeling options with greater biological relevance to the human body has become a great opportunity for the scientific community. Improving translational and regenerative medicine approaches, such as multicellular human BBB models, create a very promising field to investigate and test therapeutics for MS. Such models could be used to study more biologically involved processes; brain organoids, which include an immune cell component, could be used to study neuroimmune interactions at the BBB interface and the crosstalk between immune cells and CNS parenchymal microglia, and myelinating brain organoids could be used to study demyelination pathogenesis and remyelination mechanisms in MS. Recent success in generating iPSCs from MS patients is a further promising step toward personalizing brain and BBB models for MS.</p></sec></body><back><sec sec-type="author-contributions" id="s11"><title>Author contributions</title><p>AE-T: Supervision, Writing &#8211; review &amp; editing, Conceptualization, Writing &#8211; original draft, Validation. PH: Writing &#8211; review &amp; editing. DP: Writing &#8211; review &amp; editing. MS: Writing &#8211; review &amp; editing, Supervision, Validation. AA: Validation, Supervision, Funding acquisition, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s13"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s14"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s15"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simone</surname><given-names>IL</given-names></name><name name-style="western"><surname>Carrara</surname><given-names>D</given-names></name><name name-style="western"><surname>Tortorella</surname><given-names>C</given-names></name><name name-style="western"><surname>Ceccarelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Livrea</surname><given-names>P</given-names></name></person-group>. <article-title>Early onset multiple sclerosis</article-title>. <source>Neurol Sci</source>. (<year>2000</year>) <volume>21</volume>:<page-range>S861&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s100720070027</pub-id><pub-id pub-id-type="pmid">11205364</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990-2019</article-title>. <source>Front Public Health</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>952161</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fpubh.2022.952161</pub-id><pub-id pub-id-type="pmid">36523572</pub-id><pub-id pub-id-type="pmcid">PMC9745318</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>LI</given-names></name><name name-style="western"><surname>Munger</surname><given-names>KL</given-names></name><name name-style="western"><surname>Rubertone</surname><given-names>MV</given-names></name><name name-style="western"><surname>Peck</surname><given-names>CA</given-names></name><name name-style="western"><surname>Lennette</surname><given-names>ET</given-names></name><name name-style="western"><surname>Spiegelman</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis</article-title>. <source>JAMA</source>. (<year>2005</year>) <volume>293</volume>:<page-range>2496&#8211;500</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.293.20.2496</pub-id><pub-id pub-id-type="pmid">15914750</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ascherio</surname><given-names>A</given-names></name><name name-style="western"><surname>Munger</surname><given-names>KL</given-names></name><name name-style="western"><surname>Lennette</surname><given-names>ET</given-names></name><name name-style="western"><surname>Spiegelman</surname><given-names>D</given-names></name><name name-style="western"><surname>Hernan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Olek</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study</article-title>. <source>JAMA</source>. (<year>2001</year>) <volume>286</volume>:<page-range>3083&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.286.24.3083</pub-id><pub-id pub-id-type="pmid">11754673</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundstrom</surname><given-names>P</given-names></name><name name-style="western"><surname>Juto</surname><given-names>P</given-names></name><name name-style="western"><surname>Wadell</surname><given-names>G</given-names></name><name name-style="western"><surname>Hallmans</surname><given-names>G</given-names></name><name name-style="western"><surname>Svenningsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Nystrom</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study</article-title>. <source>Neurology</source>. (<year>2004</year>) <volume>62</volume>:<page-range>2277&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/01.WNL.0000130496.51156.D7</pub-id><pub-id pub-id-type="pmid">15210894</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrie</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wolfson</surname><given-names>C</given-names></name></person-group>. <article-title>Multiple sclerosis and Epstein-Barr virus</article-title>. <source>Can J Infect Dis</source>. (<year>2002</year>) <volume>13</volume>:<page-range>111&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2002/745764</pub-id><pub-id pub-id-type="pmcid">PMC2094863</pub-id><pub-id pub-id-type="pmid">18159380</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thacker</surname><given-names>EL</given-names></name><name name-style="western"><surname>Mirzaei</surname><given-names>F</given-names></name><name name-style="western"><surname>Ascherio</surname><given-names>A</given-names></name></person-group>. <article-title>Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis</article-title>. <source>Ann Neurol</source>. (<year>2006</year>) <volume>59</volume>:<fpage>499</fpage>&#8211;<lpage>503</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.20820</pub-id><pub-id pub-id-type="pmid">16502434</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Handel</surname><given-names>AE</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Disanto</surname><given-names>G</given-names></name><name name-style="western"><surname>Handunnetthi</surname><given-names>L</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Ramagopalan</surname><given-names>SV</given-names></name></person-group>. <article-title>An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis</article-title>. <source>PLoS One</source>. (<year>2010</year>) <volume>5</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0012496</pub-id><pub-id pub-id-type="pmcid">PMC2931696</pub-id><pub-id pub-id-type="pmid">20824132</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>LI</given-names></name><name name-style="western"><surname>Munger</surname><given-names>KL</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Falk</surname><given-names>KI</given-names></name><name name-style="western"><surname>Ascherio</surname><given-names>A</given-names></name></person-group>. <article-title>Primary infection with the Epstein-Barr virus and risk of multiple sclerosis</article-title>. <source>Ann Neurol</source>. (<year>2010</year>) <volume>67</volume>:<page-range>824&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.21978</pub-id><pub-id pub-id-type="pmcid">PMC3089959</pub-id><pub-id pub-id-type="pmid">20517945</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lunemann</surname><given-names>JD</given-names></name><name name-style="western"><surname>Jelcic</surname><given-names>I</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>S</given-names></name><name name-style="western"><surname>Lutterotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Tackenberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Martin</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2</article-title>. <source>J Exp Med</source>. (<year>2008</year>) <volume>205</volume>:<page-range>1763&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20072397</pub-id><pub-id pub-id-type="pmcid">PMC2525578</pub-id><pub-id pub-id-type="pmid">18663124</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></name></person-group>. <article-title>The anatomical and cellular basis of immune surveillance in the central nervous system</article-title>. <source>Nat Rev Immunol</source>. (<year>2012</year>) <volume>12</volume>:<page-range>623&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri3265</pub-id><pub-id pub-id-type="pmid">22903150</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serafini</surname><given-names>B</given-names></name><name name-style="western"><surname>Rosicarelli</surname><given-names>B</given-names></name><name name-style="western"><surname>Franciotta</surname><given-names>D</given-names></name><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R</given-names></name><name name-style="western"><surname>Cinque</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain</article-title>. <source>J Exp Med</source>. (<year>2007</year>) <volume>204</volume>:<page-range>2899&#8211;912</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20071030</pub-id><pub-id pub-id-type="pmcid">PMC2118531</pub-id><pub-id pub-id-type="pmid">17984305</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serafini</surname><given-names>B</given-names></name><name name-style="western"><surname>Severa</surname><given-names>M</given-names></name><name name-style="western"><surname>Columba-Cabezas</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosicarelli</surname><given-names>B</given-names></name><name name-style="western"><surname>Veroni</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiappetta</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation</article-title>. <source>J Neuropathol Exp Neurol</source>. (<year>2010</year>) <volume>69</volume>:<page-range>677&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/NEN.0b013e3181e332ec</pub-id><pub-id pub-id-type="pmid">20535037</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willis</surname><given-names>SN</given-names></name><name name-style="western"><surname>Stadelmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Rodig</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Caron</surname><given-names>T</given-names></name><name name-style="western"><surname>Gattenloehner</surname><given-names>S</given-names></name><name name-style="western"><surname>Mallozzi</surname><given-names>SS</given-names></name><etal/></person-group>. <article-title>Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain</article-title>. <source>Brain</source>. (<year>2009</year>) <volume>132</volume>:<page-range>3318&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awp200</pub-id><pub-id pub-id-type="pmcid">PMC2792367</pub-id><pub-id pub-id-type="pmid">19638446</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Niedobitek</surname><given-names>G</given-names></name><name name-style="western"><surname>Aloisi</surname><given-names>F</given-names></name><name name-style="western"><surname>Middeldorp</surname><given-names>JM</given-names></name><collab>NeuroProMiSe EBVWG</collab></person-group>. <article-title>Epstein-Barr virus in the multiple sclerosis brain: a controversial issue&#8211;report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria</article-title>. <source>Brain</source>. (<year>2011</year>) <volume>134</volume>:<page-range>2772&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awr197</pub-id><pub-id pub-id-type="pmcid">PMC3170536</pub-id><pub-id pub-id-type="pmid">21846731</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartosik-Psujek</surname><given-names>H</given-names></name><name name-style="western"><surname>Psujek</surname><given-names>M</given-names></name></person-group>. <article-title>Vitamin D as an immune modulator in multiple sclerosis</article-title>. <source>Neurol Neurochir Pol</source>. (<year>2019</year>) <volume>53</volume>:<page-range>113&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.5603/PJNNS.a2019.0015</pub-id><pub-id pub-id-type="pmid">30916776</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamen</surname><given-names>DL</given-names></name><name name-style="western"><surname>Tangpricha</surname><given-names>V</given-names></name></person-group>. <article-title>Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity</article-title>. <source>J Mol Med (Berl)</source>. (<year>2010</year>) <volume>88</volume>:<page-range>441&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00109-010-0590-9</pub-id><pub-id pub-id-type="pmcid">PMC2861286</pub-id><pub-id pub-id-type="pmid">20119827</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>E</given-names></name><name name-style="western"><surname>Asadullah</surname><given-names>K</given-names></name><name name-style="western"><surname>Zugel</surname><given-names>U</given-names></name></person-group>. <article-title>Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs</article-title>. <source>Curr Drug Targets Inflammation Allergy</source>. (<year>2004</year>) <volume>3</volume>:<page-range>377&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/1568010042634596</pub-id><pub-id pub-id-type="pmid">15584887</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrie</surname><given-names>RA</given-names></name><name name-style="western"><surname>Rudick</surname><given-names>R</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>R</given-names></name><name name-style="western"><surname>Cutter</surname><given-names>G</given-names></name><name name-style="western"><surname>Tyry</surname><given-names>T</given-names></name><name name-style="western"><surname>Campagnolo</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis</article-title>. <source>Neurology</source>. (<year>2010</year>) <volume>74</volume>:<page-range>1041&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181d6b125</pub-id><pub-id pub-id-type="pmcid">PMC2848107</pub-id><pub-id pub-id-type="pmid">20350978</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundstrom</surname><given-names>P</given-names></name><name name-style="western"><surname>Nystrom</surname><given-names>L</given-names></name><name name-style="western"><surname>Hallmans</surname><given-names>G</given-names></name></person-group>. <article-title>Smoke exposure increases the risk for multiple sclerosis</article-title>. <source>Eur J Neurol</source>. (<year>2008</year>) <volume>15</volume>:<page-range>579&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02122.x</pub-id><pub-id pub-id-type="pmid">18474075</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Handel</surname><given-names>AE</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Disanto</surname><given-names>G</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>R</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Ramagopalan</surname><given-names>SV</given-names></name></person-group>. <article-title>Smoking and multiple sclerosis: an updated meta-analysis</article-title>. <source>PLoS One</source>. (<year>2011</year>) <volume>6</volume>:<elocation-id>e16149</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0016149</pub-id><pub-id pub-id-type="pmid">21249154</pub-id><pub-id pub-id-type="pmcid">PMC3020969</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>DT</given-names></name><name name-style="western"><surname>Warden</surname><given-names>GI</given-names></name><name name-style="western"><surname>Butler</surname><given-names>JM</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>E</given-names></name><name name-style="western"><surname>Asano</surname><given-names>Y</given-names></name></person-group>. <article-title>Multiple sclerosis exacerbation associated with high-altitude climbing exposure</article-title>. <source>Mil Med</source>. (<year>2020</year>) <volume>185</volume>:<page-range>e1322&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/milmed/usz421</pub-id><pub-id pub-id-type="pmid">31825081</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabel</surname><given-names>CE</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>JF</given-names></name><name name-style="western"><surname>Mason</surname><given-names>DF</given-names></name><name name-style="western"><surname>Willoughby</surname><given-names>E</given-names></name><name name-style="western"><surname>Abernethy</surname><given-names>DA</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>BV</given-names></name></person-group>. <article-title>The latitude gradient for multiple sclerosis prevalence is established in the early life course</article-title>. <source>Brain</source>. (<year>2021</year>) <volume>144</volume>:<page-range>2038&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awab104</pub-id><pub-id pub-id-type="pmid">33704407</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>H</given-names></name></person-group>. <article-title>Multiple sclerosis: Latitude and vitamin D influence disease course in multiple sclerosis</article-title>. <source>Nat Rev Neurol</source>. (<year>2017</year>) <volume>13</volume>:<fpage>3</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrneurol.2016.181</pub-id><pub-id pub-id-type="pmid">27857120</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willer</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Dyment</surname><given-names>DA</given-names></name><name name-style="western"><surname>Risch</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Sadovnick</surname><given-names>AD</given-names></name><name name-style="western"><surname>Ebers</surname><given-names>GC</given-names></name><collab>Canadian Collaborative Study G</collab></person-group>. <article-title>Twin concordance and sibling recurrence rates in multiple sclerosis</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2003</year>) <volume>100</volume>:<page-range>12877&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1932604100</pub-id><pub-id pub-id-type="pmcid">PMC240712</pub-id><pub-id pub-id-type="pmid">14569025</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cotsapas</surname><given-names>C</given-names></name><name name-style="western"><surname>Mitrovic</surname><given-names>M</given-names></name></person-group>. <article-title>Genome-wide association studies of multiple sclerosis</article-title>. <source>Clin Transl Immunol</source>. (<year>2018</year>) <volume>7</volume>:<elocation-id>e1018</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cti2.1018</pub-id><pub-id pub-id-type="pmcid">PMC6095721</pub-id><pub-id pub-id-type="pmid">30128152</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falcao</surname><given-names>AM</given-names></name><name name-style="western"><surname>van Bruggen</surname><given-names>D</given-names></name><name name-style="western"><surname>Marques</surname><given-names>S</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>M</given-names></name><name name-style="western"><surname>Jakel</surname><given-names>S</given-names></name><name name-style="western"><surname>Agirre</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis</article-title>. <source>Nat Med</source>. (<year>2018</year>) <volume>24</volume>:<page-range>1837&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-018-0236-y</pub-id><pub-id pub-id-type="pmcid">PMC6544508</pub-id><pub-id pub-id-type="pmid">30420755</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollenbach</surname><given-names>JA</given-names></name><name name-style="western"><surname>Oksenberg</surname><given-names>JR</given-names></name></person-group>. <article-title>The immunogenetics of multiple sclerosis: A comprehensive review</article-title>. <source>J Autoimmun</source>. (<year>2015</year>) <volume>64</volume>:<fpage>13</fpage>&#8211;<lpage>25</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jaut.2015.06.010</pub-id><pub-id pub-id-type="pmid">26142251</pub-id><pub-id pub-id-type="pmcid">PMC4687745</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shams</surname><given-names>H</given-names></name><name name-style="western"><surname>Didonna</surname><given-names>A</given-names></name><name name-style="western"><surname>Baranzini</surname><given-names>SE</given-names></name><name name-style="western"><surname>Cree</surname><given-names>BAC</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes</article-title>. <source>Commun Biol</source>. (<year>2023</year>) <volume>6</volume>:<fpage>342</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s42003-023-04713-5</pub-id><pub-id pub-id-type="pmid">36997638</pub-id><pub-id pub-id-type="pmcid">PMC10063586</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gresle</surname><given-names>M</given-names></name><name name-style="western"><surname>Cuellar-Partida</surname><given-names>G</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Stankovich</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Novel plasma and brain proteins that are implicated in multiple sclerosis</article-title>. <source>Brain</source>. (<year>2023</year>) <volume>146</volume>:<page-range>2464&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awac420</pub-id><pub-id pub-id-type="pmid">36346149</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>W</given-names></name><name name-style="western"><surname>Patsopoulos</surname><given-names>NA</given-names></name></person-group>. <article-title>Genetics and functional genomics of multiple sclerosis</article-title>. <source>Semin Immunopathol</source>. (<year>2022</year>) <volume>44</volume>:<fpage>63</fpage>&#8211;<lpage>79</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00281-021-00907-3</pub-id><pub-id pub-id-type="pmid">35022889</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goris</surname><given-names>A</given-names></name><name name-style="western"><surname>Vandebergh</surname><given-names>M</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>JL</given-names></name><name name-style="western"><surname>Saarela</surname><given-names>J</given-names></name><name name-style="western"><surname>Cotsapas</surname><given-names>C</given-names></name></person-group>. <article-title>Genetics of multiple sclerosis: lessons from polygenicity</article-title>. <source>Lancet Neurol</source>. (<year>2022</year>) <volume>21</volume>:<page-range>830&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(22)00255-1</pub-id><pub-id pub-id-type="pmid">35963264</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>RA</given-names></name><name name-style="western"><surname>Davies</surname><given-names>AL</given-names></name><name name-style="western"><surname>Tachrount</surname><given-names>M</given-names></name><name name-style="western"><surname>Kasti</surname><given-names>M</given-names></name><name name-style="western"><surname>Laulund</surname><given-names>F</given-names></name><name name-style="western"><surname>Golay</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Cause and prevention of demyelination in a model multiple sclerosis lesion</article-title>. <source>Ann Neurol</source>. (<year>2016</year>) <volume>79</volume>:<fpage>591</fpage>&#8211;<lpage>604</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.24607</pub-id><pub-id pub-id-type="pmid">26814844</pub-id><pub-id pub-id-type="pmcid">PMC4949637</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dendrou</surname><given-names>CA</given-names></name><name name-style="western"><surname>Fugger</surname><given-names>L</given-names></name><name name-style="western"><surname>Friese</surname><given-names>MA</given-names></name></person-group>. <article-title>Immunopathology of multiple sclerosis</article-title>. <source>Nat Rev Immunol</source>. (<year>2015</year>) <volume>15</volume>:<page-range>545&#8211;58</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri3871</pub-id><pub-id pub-id-type="pmid">26250739</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Banwell</surname><given-names>BL</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>WM</given-names></name><name name-style="western"><surname>Coetzee</surname><given-names>T</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria</article-title>. <source>Lancet Neurol</source>. (<year>2018</year>) <volume>17</volume>:<page-range>162&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(17)30470-2</pub-id><pub-id pub-id-type="pmid">29275977</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milo</surname><given-names>R</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A</given-names></name></person-group>. <article-title>Revised diagnostic criteria of multiple sclerosis</article-title>. <source>Autoimmun Rev</source>. (<year>2014</year>) <volume>13</volume>:<page-range>518&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.autrev.2014.01.012</pub-id><pub-id pub-id-type="pmid">24424194</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz Sand</surname><given-names>I</given-names></name></person-group>. <article-title>Classification, diagnosis, and differential diagnosis of multiple sclerosis</article-title>. <source>Curr Opin Neurol</source>. (<year>2015</year>) <volume>28</volume>:<fpage>193</fpage>&#8211;<lpage>205</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1097/WCO.0000000000000206</pub-id><pub-id pub-id-type="pmid">25887774</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldenberg</surname><given-names>MM</given-names></name></person-group>. <article-title>Multiple sclerosis review</article-title>. <source>P T</source>. (<year>2012</year>) <volume>37</volume>:<page-range>175&#8211;84</page-range>.<pub-id pub-id-type="pmcid">PMC3351877</pub-id><pub-id pub-id-type="pmid">22605909</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Pathogenic mechanisms associated with different clinical courses of multiple sclerosis</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>3116</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.03116</pub-id><pub-id pub-id-type="pmid">30687321</pub-id><pub-id pub-id-type="pmcid">PMC6335289</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutzelnigg</surname><given-names>A</given-names></name><name name-style="western"><surname>Lucchinetti</surname><given-names>CF</given-names></name><name name-style="western"><surname>Stadelmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>W</given-names></name><name name-style="western"><surname>Rauschka</surname><given-names>H</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cortical demyelination and diffuse white matter injury in multiple sclerosis</article-title>. <source>Brain</source>. (<year>2005</year>) <volume>128</volume>:<page-range>2705&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awh641</pub-id><pub-id pub-id-type="pmid">16230320</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>W</given-names></name><name name-style="western"><surname>Lucchinetti</surname><given-names>CF</given-names></name></person-group>. <article-title>The immunopathology of multiple sclerosis: an overview</article-title>. <source>Brain Pathol</source>. (<year>2007</year>) <volume>17</volume>:<page-range>210&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1750-3639.2007.00064.x</pub-id><pub-id pub-id-type="pmcid">PMC8095582</pub-id><pub-id pub-id-type="pmid">17388952</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmierer</surname><given-names>K</given-names></name><name name-style="western"><surname>Miquel</surname><given-names>ME</given-names></name></person-group>. <article-title>Magnetic resonance imaging correlates of neuro-axonal pathology in the MS spinal cord</article-title>. <source>Brain Pathol</source>. (<year>2018</year>) <volume>28</volume>:<page-range>765&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/bpa.2018.28.issue-5</pub-id><pub-id pub-id-type="pmcid">PMC8028680</pub-id><pub-id pub-id-type="pmid">30375114</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrikios</surname><given-names>P</given-names></name><name name-style="western"><surname>Stadelmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Kutzelnigg</surname><given-names>A</given-names></name><name name-style="western"><surname>Rauschka</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmidbauer</surname><given-names>M</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Remyelination is extensive in a subset of multiple sclerosis patients</article-title>. <source>Brain</source>. (<year>2006</year>) <volume>129</volume>:<page-range>3165&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awl217</pub-id><pub-id pub-id-type="pmid">16921173</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patani</surname><given-names>R</given-names></name><name name-style="western"><surname>Balaratnam</surname><given-names>M</given-names></name><name name-style="western"><surname>Vora</surname><given-names>A</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R</given-names></name></person-group>. <article-title>Remyelination can be extensive in multiple sclerosis despite a long disease course</article-title>. <source>Neuropathol Appl Neurobiol</source>. (<year>2007</year>) <volume>33</volume>:<page-range>277&#8211;87</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2990.2007.00805.x</pub-id><pub-id pub-id-type="pmid">17442065</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhlmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Ludwin</surname><given-names>S</given-names></name><name name-style="western"><surname>Prat</surname><given-names>A</given-names></name><name name-style="western"><surname>Antel</surname><given-names>J</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>W</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>An updated histological classification system for multiple sclerosis lesions</article-title>. <source>Acta Neuropathol</source>. (<year>2017</year>) <volume>133</volume>:<fpage>13</fpage>&#8211;<lpage>24</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-016-1653-y</pub-id><pub-id pub-id-type="pmid">27988845</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frischer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kale</surname><given-names>N</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>JE</given-names></name><name name-style="western"><surname>Pirko</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque</article-title>. <source>Ann Neurol</source>. (<year>2015</year>) <volume>78</volume>:<page-range>710&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.24497</pub-id><pub-id pub-id-type="pmcid">PMC4623970</pub-id><pub-id pub-id-type="pmid">26239536</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>WI</given-names></name><name name-style="western"><surname>Brochet</surname><given-names>B</given-names></name><name name-style="western"><surname>Filippi</surname><given-names>MMX</given-names></name><etal/></person-group>. <article-title>Primary progressive multiple sclerosis</article-title>. <source>Brain</source>. (<year>1997</year>) <volume>120</volume>:<page-range>1085&#8211;96</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/120.6.1085</pub-id><pub-id pub-id-type="pmid">9217691</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bramow</surname><given-names>S</given-names></name><name name-style="western"><surname>Frischer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Koch-Henriksen</surname><given-names>N</given-names></name><name name-style="western"><surname>Lucchinetti</surname><given-names>CF</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>PS</given-names></name><etal/></person-group>. <article-title>Demyelination versus remyelination in progressive multiple sclerosis</article-title>. <source>Brain</source>. (<year>2010</year>) <volume>133</volume>:<page-range>2983&#8211;98</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awq250</pub-id><pub-id pub-id-type="pmid">20855416</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luchetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Fransen</surname><given-names>NL</given-names></name><name name-style="western"><surname>van Eden</surname><given-names>CG</given-names></name><name name-style="western"><surname>Ramaglia</surname><given-names>V</given-names></name><name name-style="western"><surname>Mason</surname><given-names>M</given-names></name><name name-style="western"><surname>Huitinga</surname><given-names>I</given-names></name></person-group>. <article-title>Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis</article-title>. <source>Acta Neuropathol</source>. (<year>2018</year>) <volume>135</volume>:<page-range>511&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-018-1818-y</pub-id><pub-id pub-id-type="pmcid">PMC5978927</pub-id><pub-id pub-id-type="pmid">29441412</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Revesz</surname><given-names>T</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>D</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>RO</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>WI</given-names></name></person-group>. <article-title>A comparison of the pathology of primary and secondary progressive multiple sclerosis</article-title>. <source>Brain</source>. (<year>1994</year>) <volume>117</volume>:<page-range>759&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/117.4.759</pub-id><pub-id pub-id-type="pmid">7922463</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>C</given-names></name><name name-style="western"><surname>Burks</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>C</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name></person-group>. <article-title>Dual-label immunocytochemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens</article-title>. <source>Ann Neurol</source>. (<year>1988</year>) <volume>24</volume>:<page-range>523&#8211;31</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.410240408</pub-id><pub-id pub-id-type="pmid">3266456</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Booss</surname><given-names>J</given-names></name><name name-style="western"><surname>Esiri</surname><given-names>MM</given-names></name><name name-style="western"><surname>Tourtellotte</surname><given-names>WW</given-names></name><name name-style="western"><surname>Mason</surname><given-names>DY</given-names></name></person-group>. <article-title>Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis</article-title>. <source>J Neurol Sci</source>. (<year>1983</year>) <volume>62</volume>:<page-range>219&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0022-510X(83)90201-0</pub-id><pub-id pub-id-type="pmid">6607973</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MaChado-Santos</surname><given-names>J</given-names></name><name name-style="western"><surname>Saji</surname><given-names>E</given-names></name><name name-style="western"><surname>Troscher</surname><given-names>AR</given-names></name><name name-style="western"><surname>Paunovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Liblau</surname><given-names>R</given-names></name><name name-style="western"><surname>Gabriely</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells</article-title>. <source>Brain</source>. (<year>2018</year>) <volume>141</volume>:<page-range>2066&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awy151</pub-id><pub-id pub-id-type="pmcid">PMC6022681</pub-id><pub-id pub-id-type="pmid">29873694</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>International Multiple Sclerosis Genetics Consortium</collab><name name-style="western"><surname>Beecham</surname><given-names>AH</given-names></name><name name-style="western"><surname>Patsopoulos</surname><given-names>NA</given-names></name><name name-style="western"><surname>Xifara</surname><given-names>DK</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MF</given-names></name><name name-style="western"><surname>Kemppinen</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis</article-title>. <source>Nat Genet</source>. (<year>2013</year>) <volume>45</volume>:<page-range>1353&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ng.2770</pub-id><pub-id pub-id-type="pmcid">PMC3832895</pub-id><pub-id pub-id-type="pmid">24076602</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babbe</surname><given-names>H</given-names></name><name name-style="western"><surname>Roers</surname><given-names>A</given-names></name><name name-style="western"><surname>Waisman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Goebels</surname><given-names>N</given-names></name><name name-style="western"><surname>Hohlfeld</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction</article-title>. <source>J Exp Med</source>. (<year>2000</year>) <volume>192</volume>:<fpage>393</fpage>&#8211;<lpage>404</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.192.3.393</pub-id><pub-id pub-id-type="pmid">10934227</pub-id><pub-id pub-id-type="pmcid">PMC2193223</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names>M</given-names></name><name name-style="western"><surname>Cepok</surname><given-names>S</given-names></name><name name-style="western"><surname>Quak</surname><given-names>E</given-names></name><name name-style="western"><surname>Happel</surname><given-names>M</given-names></name><name name-style="western"><surname>Gaber</surname><given-names>R</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients</article-title>. <source>Brain</source>. (<year>2002</year>) <volume>125</volume>, <fpage>538</fpage>&#8211;<lpage>50</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awf059</pub-id><pub-id pub-id-type="pmid">11872611</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakim</surname><given-names>LM</given-names></name><name name-style="western"><surname>Woodward-Davis</surname><given-names>A</given-names></name><name name-style="western"><surname>Bevan</surname><given-names>MJ</given-names></name></person-group>. <article-title>Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2010</year>) <volume>107</volume>:<page-range>17872&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1010201107</pub-id><pub-id pub-id-type="pmcid">PMC2964240</pub-id><pub-id pub-id-type="pmid">20923878</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ST</given-names></name><name name-style="western"><surname>Costa</surname><given-names>GL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Fathman</surname><given-names>CG</given-names></name><name name-style="western"><surname>Glimcher</surname><given-names>LH</given-names></name></person-group>. <article-title>A novel transcription factor, T-bet, directs Th1 lineage commitment</article-title>. <source>Cell</source>. (<year>2000</year>) <volume>100</volume>:<page-range>655&#8211;69</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80702-3</pub-id><pub-id pub-id-type="pmid">10761931</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thieu</surname><given-names>VT</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>N</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>ET</given-names></name><name name-style="western"><surname>Sehra</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination</article-title>. <source>Immunity</source>. (<year>2008</year>) <volume>29</volume>:<page-range>679&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2008.08.017</pub-id><pub-id pub-id-type="pmcid">PMC2768040</pub-id><pub-id pub-id-type="pmid">18993086</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djuretic</surname><given-names>IM</given-names></name><name name-style="western"><surname>Levanon</surname><given-names>D</given-names></name><name name-style="western"><surname>Negreanu</surname><given-names>V</given-names></name><name name-style="western"><surname>Groner</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A</given-names></name><name name-style="western"><surname>Ansel</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells</article-title>. <source>Nat Immunol</source>. (<year>2007</year>) <volume>8</volume>:<page-range>145&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni1424</pub-id><pub-id pub-id-type="pmid">17195845</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarevic</surname><given-names>V</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Shim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>ES</given-names></name><name name-style="western"><surname>Jang</surname><given-names>E</given-names></name><name name-style="western"><surname>Bolm</surname><given-names>AN</given-names></name><etal/></person-group>. <article-title>T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORgammat</article-title>. <source>Nat Immunol</source>. (<year>2011</year>) <volume>12</volume>:<fpage>96</fpage>&#8211;<lpage>104</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.1969</pub-id><pub-id pub-id-type="pmid">21151104</pub-id><pub-id pub-id-type="pmcid">PMC3077962</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGeachy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bak-Jensen</surname><given-names>KS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tato</surname><given-names>CM</given-names></name><name name-style="western"><surname>Blumenschein</surname><given-names>W</given-names></name><name name-style="western"><surname>McClanahan</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology</article-title>. <source>Nat Immunol</source>. (<year>2007</year>) <volume>8</volume>:<page-range>1390&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni1539</pub-id><pub-id pub-id-type="pmid">17994024</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockinger</surname><given-names>B</given-names></name><name name-style="western"><surname>Omenetti</surname><given-names>S</given-names></name></person-group>. <article-title>The dichotomous nature of T helper 17 cells</article-title>. <source>Nat Rev Immunol</source>. (<year>2017</year>) <volume>17</volume>:<page-range>535&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri.2017.50</pub-id><pub-id pub-id-type="pmid">28555673</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>A</given-names></name><name name-style="western"><surname>Yosef</surname><given-names>N</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S</given-names></name><name name-style="western"><surname>Peters</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Induction and molecular signature of pathogenic TH17 cells</article-title>. <source>Nat Immunol</source>. (<year>2012</year>) <volume>13</volume>:<page-range>991&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.2416</pub-id><pub-id pub-id-type="pmcid">PMC3459594</pub-id><pub-id pub-id-type="pmid">22961052</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langrish</surname><given-names>CL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Blumenschein</surname><given-names>WM</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>J</given-names></name><name name-style="western"><surname>Basham</surname><given-names>B</given-names></name><name name-style="western"><surname>Sedgwick</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>IL-23 drives a pathogenic T cell population that induces autoimmune inflammation</article-title>. <source>J Exp Med</source>. (<year>2005</year>) <volume>201</volume>:<page-range>233&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20041257</pub-id><pub-id pub-id-type="pmcid">PMC2212798</pub-id><pub-id pub-id-type="pmid">15657292</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frischer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Bramow</surname><given-names>S</given-names></name><name name-style="western"><surname>Dal-Bianco</surname><given-names>A</given-names></name><name name-style="western"><surname>Lucchinetti</surname><given-names>CF</given-names></name><name name-style="western"><surname>Rauschka</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmidbauer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The relation between inflammation and neurodegeneration in multiple sclerosis brains</article-title>. <source>Brain</source>. (<year>2009</year>) <volume>132</volume>:<page-range>1175&#8211;89</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awp070</pub-id><pub-id pub-id-type="pmcid">PMC2677799</pub-id><pub-id pub-id-type="pmid">19339255</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funaro</surname><given-names>M</given-names></name><name name-style="western"><surname>Messina</surname><given-names>M</given-names></name><name name-style="western"><surname>Shabbir</surname><given-names>M</given-names></name><name name-style="western"><surname>Wright</surname><given-names>P</given-names></name><name name-style="western"><surname>Najjar</surname><given-names>S</given-names></name><name name-style="western"><surname>Tabansky</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The role of B cells in multiple sclerosis: more than antibodies</article-title>. <source>Discov Med</source>. (<year>2016</year>) <volume>22</volume>:<page-range>251&#8211;5</page-range>.<pub-id pub-id-type="pmid">28009967</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisak</surname><given-names>RP</given-names></name><name name-style="western"><surname>Benjamins</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nedelkoska</surname><given-names>L</given-names></name><name name-style="western"><surname>Barger</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ragheb</surname><given-names>S</given-names></name><name name-style="western"><surname>Fan</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia <italic toggle="yes">in vitro</italic>
</article-title>. <source>J Neuroimmunol</source>. (<year>2012</year>) <volume>246</volume>:<fpage>85</fpage>&#8211;<lpage>95</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2012.02.015</pub-id><pub-id pub-id-type="pmid">22458983</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisak</surname><given-names>RP</given-names></name><name name-style="western"><surname>Nedelkoska</surname><given-names>L</given-names></name><name name-style="western"><surname>Benjamins</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schalk</surname><given-names>D</given-names></name><name name-style="western"><surname>Bealmear</surname><given-names>B</given-names></name><name name-style="western"><surname>Touil</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons <italic toggle="yes">in vitro</italic>
</article-title>. <source>J Neuroimmunol</source>. (<year>2017</year>) <volume>309</volume>:<fpage>88</fpage>&#8211;<lpage>99</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2017.05.004</pub-id><pub-id pub-id-type="pmid">28601295</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Waubant</surname><given-names>E</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Vollmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Antel</surname><given-names>J</given-names></name><name name-style="western"><surname>Fox</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>B-cell depletion with rituximab in relapsing-remitting multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2008</year>) <volume>358</volume>:<page-range>676&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa0706383</pub-id><pub-id pub-id-type="pmid">18272891</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myhr</surname><given-names>KM</given-names></name><name name-style="western"><surname>Torkildsen</surname><given-names>O</given-names></name><name name-style="western"><surname>Lossius</surname><given-names>A</given-names></name><name name-style="western"><surname>Bo</surname><given-names>L</given-names></name><name name-style="western"><surname>Holmoy</surname><given-names>T</given-names></name></person-group>. <article-title>B cell depletion in the treatment of multiple sclerosis</article-title>. <source>Expert Opin Biol Ther</source>. (<year>2019</year>) <volume>19</volume>:<page-range>261&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14712598.2019.1568407</pub-id><pub-id pub-id-type="pmid">30632834</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montalban</surname><given-names>X</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Ocrelizumab versus placebo in primary progressive multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>376</volume>:<page-range>209&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1606468</pub-id><pub-id pub-id-type="pmid">28002688</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Probstel</surname><given-names>AK</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>NS</given-names></name><name name-style="western"><surname>Derfuss</surname><given-names>T</given-names></name></person-group>. <article-title>B cells and autoantibodies in multiple sclerosis</article-title>. <source>Int J Mol Sci</source>. (<year>2015</year>) <volume>16</volume>:<page-range>16576&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms160716576</pub-id><pub-id pub-id-type="pmcid">PMC4519967</pub-id><pub-id pub-id-type="pmid">26197319</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haider</surname><given-names>L</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>MT</given-names></name><name name-style="western"><surname>Frischer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>J</given-names></name><name name-style="western"><surname>Hoftberger</surname><given-names>R</given-names></name><name name-style="western"><surname>Botond</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Oxidative damage in multiple sclerosis lesions</article-title>. <source>Brain</source>. (<year>2011</year>) <volume>134</volume>:<page-range>1914&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awr128</pub-id><pub-id pub-id-type="pmcid">PMC3122372</pub-id><pub-id pub-id-type="pmid">21653539</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witte</surname><given-names>ME</given-names></name><name name-style="western"><surname>Nijland</surname><given-names>PG</given-names></name><name name-style="western"><surname>Drexhage</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gerritsen</surname><given-names>W</given-names></name><name name-style="western"><surname>Geerts</surname><given-names>D</given-names></name><name name-style="western"><surname>van Het Hof</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Reduced expression of PGC-1alpha partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex</article-title>. <source>Acta Neuropathol</source>. (<year>2013</year>) <volume>125</volume>:<page-range>231&#8211;43</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-012-1052-y</pub-id><pub-id pub-id-type="pmid">23073717</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esiri</surname><given-names>MM</given-names></name><name name-style="western"><surname>Gay</surname><given-names>D</given-names></name></person-group>. <article-title>Immunological and neuropathological significance of the Virchow-Robin space</article-title>. <source>J Neurol Sci</source>. (<year>1990</year>) <volume>100</volume>:<fpage>3</fpage>&#8211;<lpage>8</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0022-510X(90)90004-7</pub-id><pub-id pub-id-type="pmid">2089138</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serafini</surname><given-names>B</given-names></name><name name-style="western"><surname>Rosicarelli</surname><given-names>B</given-names></name><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Stigliano</surname><given-names>E</given-names></name><name name-style="western"><surname>Aloisi</surname><given-names>F</given-names></name></person-group>. <article-title>Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis</article-title>. <source>Brain Pathol</source>. (<year>2004</year>) <volume>14</volume>:<page-range>164&#8211;74</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1750-3639.2004.tb00049.x</pub-id><pub-id pub-id-type="pmcid">PMC8095922</pub-id><pub-id pub-id-type="pmid">15193029</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howell</surname><given-names>OW</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>CA</given-names></name><name name-style="western"><surname>Nicholas</surname><given-names>R</given-names></name><name name-style="western"><surname>Carassiti</surname><given-names>D</given-names></name><name name-style="western"><surname>Radotra</surname><given-names>B</given-names></name><name name-style="western"><surname>Gentleman</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis</article-title>. <source>Brain</source>. (<year>2011</year>) <volume>134</volume>:<page-range>2755&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awr182</pub-id><pub-id pub-id-type="pmid">21840891</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>SR</given-names></name><name name-style="western"><surname>Howell</surname><given-names>OW</given-names></name><name name-style="western"><surname>Carassiti</surname><given-names>D</given-names></name><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Gveric</surname><given-names>D</given-names></name><name name-style="western"><surname>Muraro</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis</article-title>. <source>Brain</source>. (<year>2012</year>) <volume>135</volume>:<page-range>2925&#8211;37</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/aws189</pub-id><pub-id pub-id-type="pmid">22907116</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trapp</surname><given-names>BD</given-names></name><name name-style="western"><surname>Vignos</surname><given-names>M</given-names></name><name name-style="western"><surname>Dudman</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>E</given-names></name><name name-style="western"><surname>Staugaitis</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study</article-title>. <source>Lancet Neurol</source>. (<year>2018</year>) <volume>17</volume>:<page-range>870&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30245-X</pub-id><pub-id pub-id-type="pmcid">PMC6197820</pub-id><pub-id pub-id-type="pmid">30143361</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucchinetti</surname><given-names>CF</given-names></name><name name-style="western"><surname>Popescu</surname><given-names>BF</given-names></name><name name-style="western"><surname>Bunyan</surname><given-names>RF</given-names></name><name name-style="western"><surname>Moll</surname><given-names>NM</given-names></name><name name-style="western"><surname>Roemer</surname><given-names>SF</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Inflammatory cortical demyelination in early multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2011</year>) <volume>365</volume>:<page-range>2188&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1100648</pub-id><pub-id pub-id-type="pmcid">PMC3282172</pub-id><pub-id pub-id-type="pmid">22150037</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haider</surname><given-names>L</given-names></name><name name-style="western"><surname>Simeonidou</surname><given-names>C</given-names></name><name name-style="western"><surname>Steinberger</surname><given-names>G</given-names></name><name name-style="western"><surname>Hametner</surname><given-names>S</given-names></name><name name-style="western"><surname>Grigoriadis</surname><given-names>N</given-names></name><name name-style="western"><surname>Deretzi</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2014</year>) <volume>85</volume>:<page-range>1386&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jnnp-2014-307712</pub-id><pub-id pub-id-type="pmcid">PMC4251183</pub-id><pub-id pub-id-type="pmid">24899728</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vercellino</surname><given-names>M</given-names></name><name name-style="western"><surname>Masera</surname><given-names>S</given-names></name><name name-style="western"><surname>Lorenzatti</surname><given-names>M</given-names></name><name name-style="western"><surname>Condello</surname><given-names>C</given-names></name><name name-style="western"><surname>Merola</surname><given-names>A</given-names></name><name name-style="western"><surname>Mattioda</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter</article-title>. <source>J Neuropathol Exp Neurol</source>. (<year>2009</year>) <volume>68</volume>:<fpage>489</fpage>&#8211;<lpage>502</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1097/NEN.0b013e3181a19a5a</pub-id><pub-id pub-id-type="pmid">19525897</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>W</given-names></name><name name-style="western"><surname>Raven</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JS</given-names></name><name name-style="western"><surname>Bundell</surname><given-names>C</given-names></name><name name-style="western"><surname>Hollingsworth</surname><given-names>P</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>WM</given-names></name><etal/></person-group>. <article-title>Hypothalamic lesions in multiple sclerosis</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2011</year>) <volume>82</volume>:<page-range>819&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jnnp.2009.198192</pub-id><pub-id pub-id-type="pmid">20547621</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallego-Delgado</surname><given-names>P</given-names></name><name name-style="western"><surname>James</surname><given-names>R</given-names></name><name name-style="western"><surname>Browne</surname><given-names>E</given-names></name><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name><name name-style="western"><surname>Umashankar</surname><given-names>S</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Neuroinflammation in the normal-appearing white matter (NAWM) of the multiple sclerosis brain causes abnormalities at the nodes of Ranvier</article-title>. <source>PLoS Biol</source>. (<year>2020</year>) <volume>18</volume>:<elocation-id>e3001008</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pbio.3001008</pub-id><pub-id pub-id-type="pmid">33315860</pub-id><pub-id pub-id-type="pmcid">PMC7769608</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Howell</surname><given-names>O</given-names></name><name name-style="western"><surname>Vora</surname><given-names>A</given-names></name><name name-style="western"><surname>Serafini</surname><given-names>B</given-names></name><name name-style="western"><surname>Nicholas</surname><given-names>R</given-names></name><name name-style="western"><surname>Puopolo</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology</article-title>. <source>Brain</source>. (<year>2007</year>) <volume>130</volume>:<page-range>1089&#8211;104</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awm038</pub-id><pub-id pub-id-type="pmid">17438020</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Howell</surname><given-names>OW</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>C</given-names></name><name name-style="western"><surname>Roncaroli</surname><given-names>F</given-names></name><name name-style="western"><surname>Nicholas</surname><given-names>R</given-names></name><name name-style="western"><surname>Serafini</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis</article-title>. <source>Ann Neurol</source>. (<year>2010</year>) <volume>68</volume>:<page-range>477&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.22230</pub-id><pub-id pub-id-type="pmid">20976767</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidaurre</surname><given-names>OG</given-names></name><name name-style="western"><surname>Haines</surname><given-names>JD</given-names></name><name name-style="western"><surname>Katz Sand</surname><given-names>I</given-names></name><name name-style="western"><surname>Adula</surname><given-names>KP</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>JL</given-names></name><name name-style="western"><surname>McGraw</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics</article-title>. <source>Brain</source>. (<year>2014</year>) <volume>137</volume>:<page-range>2271&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awu139</pub-id><pub-id pub-id-type="pmcid">PMC4164163</pub-id><pub-id pub-id-type="pmid">24893707</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiou</surname><given-names>B</given-names></name><name name-style="western"><surname>Lucassen</surname><given-names>E</given-names></name><name name-style="western"><surname>Sather</surname><given-names>M</given-names></name><name name-style="western"><surname>Kallianpur</surname><given-names>A</given-names></name><name name-style="western"><surname>Connor</surname><given-names>J</given-names></name></person-group>. <article-title>Semaphorin4A and H-ferritin utilize Tim-1 on human oligodendrocytes: A novel neuro-immune axis</article-title>. <source>Glia</source>. (<year>2018</year>) <volume>66</volume>:<page-range>1317&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/glia.23313</pub-id><pub-id pub-id-type="pmcid">PMC7009020</pub-id><pub-id pub-id-type="pmid">29457657</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name><name name-style="western"><surname>Paty</surname><given-names>DW</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Compston</surname><given-names>DA</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study</article-title>. <source>Neurology</source>. (<year>1995</year>) <volume>45</volume>:<page-range>255&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.45.2.255</pub-id><pub-id pub-id-type="pmid">7854522</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rovaris</surname><given-names>M</given-names></name><name name-style="western"><surname>Bozzali</surname><given-names>M</given-names></name><name name-style="western"><surname>Santuccio</surname><given-names>G</given-names></name><name name-style="western"><surname>Ghezzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>D</given-names></name><name name-style="western"><surname>Montanari</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">In vivo</italic> assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis</article-title>. <source>Brain</source>. (<year>2001</year>) <volume>124</volume>:<page-range>2540&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/124.12.2540</pub-id><pub-id pub-id-type="pmid">11701606</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name></person-group>. <article-title>Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis</article-title>. <source>J Neurol</source>. (<year>2003</year>) <volume>250</volume>:<page-range>1407&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00415-003-0243-9</pub-id><pub-id pub-id-type="pmid">14673572</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccarelli</surname><given-names>O</given-names></name><name name-style="western"><surname>Werring</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Barker</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wheeler-Kingshott</surname><given-names>CA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name><etal/></person-group>. <article-title>A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging&#8211;evidence of Wallerian degeneration</article-title>. <source>J Neurol</source>. (<year>2003</year>) <volume>250</volume>:<page-range>287&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00415-003-0992-5</pub-id><pub-id pub-id-type="pmid">12638018</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>Y</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>RI</given-names></name><name name-style="western"><surname>Babb</surname><given-names>JS</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Mannon</surname><given-names>LJ</given-names></name></person-group>. <article-title>Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis</article-title>. <source>AJNR Am J Neuroradiol</source>. (<year>2003</year>) <volume>24</volume>:<page-range>1935&#8211;40</page-range>.<pub-id pub-id-type="pmcid">PMC8148922</pub-id><pub-id pub-id-type="pmid">14625213</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjartmar</surname><given-names>C</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>G</given-names></name><name name-style="western"><surname>Mork</surname><given-names>S</given-names></name><name name-style="western"><surname>Rudick</surname><given-names>R</given-names></name><name name-style="western"><surname>Trapp</surname><given-names>BD</given-names></name></person-group>. <article-title>Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients</article-title>. <source>Ann Neurol</source>. (<year>2000</year>) <volume>48</volume>:<fpage>893</fpage>&#8211;<lpage>901</lpage>. doi:&#160;<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1531-8249(200012)48:6&amp;#x0003c;893::AID-ANA10&amp;#x0003e;3.0.CO;2-B</pub-id><pub-id pub-id-type="pmid">11117546</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mews</surname><given-names>I</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Bunkowski</surname><given-names>S</given-names></name><name name-style="western"><surname>Gullotta</surname><given-names>F</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>W</given-names></name></person-group>. <article-title>Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions</article-title>. <source>Mult Scler</source>. (<year>1998</year>) <volume>4</volume>:<fpage>55</fpage>&#8211;<lpage>62</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/135245859800400203</pub-id><pub-id pub-id-type="pmid">9599334</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>IV</given-names></name><name name-style="western"><surname>McQuaid</surname><given-names>S</given-names></name><name name-style="western"><surname>Mirakhur</surname><given-names>M</given-names></name><name name-style="western"><surname>Nevin</surname><given-names>G</given-names></name></person-group>. <article-title>Pathological abnormalities in the normal-appearing white matter in multiple sclerosis</article-title>. <source>Neurol Sci</source>. (<year>2001</year>) <volume>22</volume>:<page-range>141&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s100720170012</pub-id><pub-id pub-id-type="pmid">11603615</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evangelou</surname><given-names>N</given-names></name><name name-style="western"><surname>Konz</surname><given-names>D</given-names></name><name name-style="western"><surname>Esiri</surname><given-names>MM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name><name name-style="western"><surname>Palace</surname><given-names>J</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>PM</given-names></name></person-group>. <article-title>Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis</article-title>. <source>Brain</source>. (<year>2000</year>) <volume>123</volume>:<page-range>1845&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/123.9.1845</pub-id><pub-id pub-id-type="pmid">10960048</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Androdias</surname><given-names>G</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R</given-names></name><name name-style="western"><surname>Chanal</surname><given-names>M</given-names></name><name name-style="western"><surname>Ritleng</surname><given-names>C</given-names></name><name name-style="western"><surname>Confavreux</surname><given-names>C</given-names></name><name name-style="western"><surname>Nataf</surname><given-names>S</given-names></name></person-group>. <article-title>Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords</article-title>. <source>Ann Neurol</source>. (<year>2010</year>) <volume>68</volume>:<page-range>465&#8211;76</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.22054</pub-id><pub-id pub-id-type="pmid">20687208</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>GR</given-names></name><name name-style="western"><surname>Laule</surname><given-names>C</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>A</given-names></name><name name-style="western"><surname>Leung</surname><given-names>E</given-names></name><name name-style="western"><surname>Li</surname><given-names>DK</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name></person-group>. <article-title>Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss</article-title>. <source>J Neurol</source>. (<year>2008</year>) <volume>255</volume>:<page-range>1802&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00415-008-0002-z</pub-id><pub-id pub-id-type="pmid">18821049</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laule</surname><given-names>C</given-names></name><name name-style="western"><surname>Vavasour</surname><given-names>IM</given-names></name><name name-style="western"><surname>Leung</surname><given-names>E</given-names></name><name name-style="western"><surname>Li</surname><given-names>DK</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>P</given-names></name><name name-style="western"><surname>Traboulsee</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology</article-title>. <source>Mult Scler</source>. (<year>2011</year>) <volume>17</volume>:<page-range>144&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1352458510384008</pub-id><pub-id pub-id-type="pmid">20965961</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cramer</surname><given-names>SP</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>H</given-names></name><name name-style="western"><surname>Frederiksen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rostrup</surname><given-names>E</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>HB</given-names></name></person-group>. <article-title>Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI</article-title>. <source>NeuroImage Clin</source>. (<year>2014</year>) <volume>4</volume>:<page-range>182&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nicl.2013.12.001</pub-id><pub-id pub-id-type="pmcid">PMC3872721</pub-id><pub-id pub-id-type="pmid">24371801</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>AP</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>MH</given-names></name><name name-style="western"><surname>Parratt</surname><given-names>JD</given-names></name><name name-style="western"><surname>Prineas</surname><given-names>JW</given-names></name></person-group>. <article-title>Multiple sclerosis: distribution of inflammatory cells in newly forming lesions</article-title>. <source>Ann Neurol</source>. (<year>2009</year>) <volume>66</volume>:<page-range>739&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.21800</pub-id><pub-id pub-id-type="pmid">20035511</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Valk</surname><given-names>P</given-names></name><name name-style="western"><surname>Amor</surname><given-names>S</given-names></name></person-group>. <article-title>Preactive lesions in multiple sclerosis</article-title>. <source>Curr Opin Neurol</source>. (<year>2009</year>) <volume>22</volume>:<page-range>207&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/WCO.0b013e32832b4c76</pub-id><pub-id pub-id-type="pmid">19417567</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballabh</surname><given-names>P</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group>. <article-title>The blood-brain barrier: an overview: structure, regulation, and clinical implications</article-title>. <source>Neurobiol Dis</source>. (<year>2004</year>) <volume>16</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nbd.2003.12.016</pub-id><pub-id pub-id-type="pmid">15207256</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harhaj</surname><given-names>NS</given-names></name><name name-style="western"><surname>Antonetti</surname><given-names>DA</given-names></name></person-group>. <article-title>Regulation of tight junctions and loss of barrier function in pathophysiology</article-title>. <source>Int J Biochem Cell Biol</source>. (<year>2004</year>) <volume>36</volume>:<page-range>1206&#8211;37</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biocel.2003.08.007</pub-id><pub-id pub-id-type="pmid">15109567</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vorbrodt</surname><given-names>AW</given-names></name><name name-style="western"><surname>Dobrogowska</surname><given-names>DH</given-names></name></person-group>. <article-title>Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist&#8217;s view</article-title>. <source>Brain Res Brain Res Rev</source>. (<year>2003</year>) <volume>42</volume>:<page-range>221&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0165-0173(03)00177-2</pub-id><pub-id pub-id-type="pmid">12791441</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolburg</surname><given-names>H</given-names></name><name name-style="western"><surname>Lippoldt</surname><given-names>A</given-names></name></person-group>. <article-title>Tight junctions of the blood-brain barrier: development, composition and regulation</article-title>. <source>Vascul Pharmacol</source>. (<year>2002</year>) <volume>38</volume>:<page-range>323&#8211;37</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1537-1891(02)00200-8</pub-id><pub-id pub-id-type="pmid">12529927</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulze</surname><given-names>C</given-names></name><name name-style="western"><surname>Firth</surname><given-names>JA</given-names></name></person-group>. <article-title>Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat</article-title>. <source>J Cell Sci</source>. (<year>1993</year>) <volume>104</volume>:<page-range>773&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1242/jcs.104.3.773</pub-id><pub-id pub-id-type="pmid">8314872</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gloor</surname><given-names>SM</given-names></name><name name-style="western"><surname>Wachtel</surname><given-names>M</given-names></name><name name-style="western"><surname>Bolliger</surname><given-names>MF</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>H</given-names></name><name name-style="western"><surname>Landmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Frei</surname><given-names>K</given-names></name></person-group>. <article-title>Molecular and cellular permeability control at the blood-brain barrier</article-title>. <source>Brain Res Brain Res Rev</source>. (<year>2001</year>) <volume>36</volume>:<page-range>258&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0165-0173(01)00102-3</pub-id><pub-id pub-id-type="pmid">11690623</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butt</surname><given-names>AM</given-names></name><name name-style="western"><surname>Jones</surname><given-names>HC</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name></person-group>. <article-title>Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study</article-title>. <source>J Physiol</source>. (<year>1990</year>) <volume>429</volume>:<fpage>47</fpage>&#8211;<lpage>62</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1113/jphysiol.1990.sp018243</pub-id><pub-id pub-id-type="pmid">2277354</pub-id><pub-id pub-id-type="pmcid">PMC1181686</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuse</surname><given-names>M</given-names></name><name name-style="western"><surname>Hirase</surname><given-names>T</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagafuchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Yonemura</surname><given-names>S</given-names></name><name name-style="western"><surname>Tsukita</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Occludin: a novel integral membrane protein localizing at tight junctions</article-title>. <source>J Cell Biol</source>. (<year>1993</year>) <volume>123</volume>:<page-range>1777&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1083/jcb.123.6.1777</pub-id><pub-id pub-id-type="pmcid">PMC2290891</pub-id><pub-id pub-id-type="pmid">8276896</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuse</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>K</given-names></name><name name-style="western"><surname>Hiiragi</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsukita</surname><given-names>S</given-names></name></person-group>. <article-title>Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin</article-title>. <source>J Cell Biol</source>. (<year>1998</year>) <volume>141</volume>:<page-range>1539&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1083/jcb.141.7.1539</pub-id><pub-id pub-id-type="pmcid">PMC2132999</pub-id><pub-id pub-id-type="pmid">9647647</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saitou</surname><given-names>M</given-names></name><name name-style="western"><surname>Furuse</surname><given-names>M</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Schulzke</surname><given-names>JD</given-names></name><name name-style="western"><surname>Fromm</surname><given-names>M</given-names></name><name name-style="western"><surname>Takano</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Complex phenotype of mice lacking occludin, a component of tight junction strands</article-title>. <source>Mol Biol Cell</source>. (<year>2000</year>) <volume>11</volume>:<page-range>4131&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1091/mbc.11.12.4131</pub-id><pub-id pub-id-type="pmcid">PMC15062</pub-id><pub-id pub-id-type="pmid">11102513</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gow</surname><given-names>A</given-names></name><name name-style="western"><surname>Southwood</surname><given-names>CM</given-names></name><name name-style="western"><surname>Li</surname><given-names>JS</given-names></name><name name-style="western"><surname>Pariali</surname><given-names>M</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>GP</given-names></name><name name-style="western"><surname>Brodie</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>CNS myelin and sertoli cell tight junction strands are absent in Osp/claudin-11 null mice</article-title>. <source>Cell</source>. (<year>1999</year>) <volume>99</volume>:<page-range>649&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0092-8674(00)81553-6</pub-id><pub-id pub-id-type="pmid">10612400</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>JD</given-names></name><name name-style="western"><surname>Egleton</surname><given-names>RD</given-names></name><name name-style="western"><surname>Davis</surname><given-names>TP</given-names></name></person-group>. <article-title>Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier</article-title>. <source>Trends Neurosci</source>. (<year>2001</year>) <volume>24</volume>:<page-range>719&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0166-2236(00)02004-X</pub-id><pub-id pub-id-type="pmid">11718877</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greene</surname><given-names>C</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>N</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>M</given-names></name></person-group>. <article-title>Claudin-5: gatekeeper of neurological function</article-title>. <source>Fluids Barriers CNS</source>. (<year>2019</year>) <volume>16</volume>:<fpage>3</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12987-019-0123-z</pub-id><pub-id pub-id-type="pmid">30691500</pub-id><pub-id pub-id-type="pmcid">PMC6350359</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>K</given-names></name><name name-style="western"><surname>Krug</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kunisawa</surname><given-names>J</given-names></name><name name-style="western"><surname>Fromm</surname><given-names>M</given-names></name><name name-style="western"><surname>Kondoh</surname><given-names>M</given-names></name></person-group>. <article-title>Potential for tight junction protein-directed drug development using claudin binders and angubindin-1</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms20164016</pub-id><pub-id pub-id-type="pmcid">PMC6719960</pub-id><pub-id pub-id-type="pmid">31426497</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greene</surname><given-names>C</given-names></name><name name-style="western"><surname>Kealy</surname><given-names>J</given-names></name><name name-style="western"><surname>Humphries</surname><given-names>MM</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia</article-title>. <source>Mol Psychiatry</source>. (<year>2018</year>) <volume>23</volume>:<page-range>2156&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/mp.2017.156</pub-id><pub-id pub-id-type="pmcid">PMC6298981</pub-id><pub-id pub-id-type="pmid">28993710</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fanning</surname><given-names>AS</given-names></name><name name-style="western"><surname>Jameson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jesaitis</surname><given-names>LA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>JM</given-names></name></person-group>. <article-title>The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton</article-title>. <source>J Biol Chem</source>. (<year>1998</year>) <volume>273</volume>:<page-range>29745&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1074/jbc.273.45.29745</pub-id><pub-id pub-id-type="pmid">9792688</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citi</surname><given-names>S</given-names></name><name name-style="western"><surname>Sabanay</surname><given-names>H</given-names></name><name name-style="western"><surname>Kendrick-Jones</surname><given-names>J</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>B</given-names></name></person-group>. <article-title>Cingulin: characterization and localization</article-title>. <source>J Cell Sci</source>. (<year>1989</year>) <volume>93</volume>:<page-range>107&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1242/jcs.93.1.107</pub-id><pub-id pub-id-type="pmid">2693465</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>T</given-names></name><name name-style="western"><surname>Minase</surname><given-names>T</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>N</given-names></name><name name-style="western"><surname>Enomoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Mori</surname><given-names>M</given-names></name></person-group>. <article-title>Monoclonal antibody 7H6 reacts with a novel tight junction-associated protein distinct from ZO-1, cingulin and ZO-2</article-title>. <source>J Cell Biol</source>. (<year>1993</year>) <volume>120</volume>:<page-range>477&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1083/jcb.120.2.477</pub-id><pub-id pub-id-type="pmcid">PMC2119523</pub-id><pub-id pub-id-type="pmid">8421059</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aurrand-Lions</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson-Leger</surname><given-names>C</given-names></name><name name-style="western"><surname>Wong</surname><given-names>C</given-names></name><name name-style="western"><surname>Du Pasquier</surname><given-names>L</given-names></name><name name-style="western"><surname>Imhof</surname><given-names>BA</given-names></name></person-group>. <article-title>Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members</article-title>. <source>Blood</source>. (<year>2001</year>) <volume>98</volume>:<page-range>3699&#8211;707</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood.V98.13.3699</pub-id><pub-id pub-id-type="pmid">11739175</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bazzoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Martinez-Estrada</surname><given-names>OM</given-names></name><name name-style="western"><surname>Orsenigo</surname><given-names>F</given-names></name><name name-style="western"><surname>Cordenonsi</surname><given-names>M</given-names></name><name name-style="western"><surname>Citi</surname><given-names>S</given-names></name><name name-style="western"><surname>Dejana</surname><given-names>E</given-names></name></person-group>. <article-title>Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludin</article-title>. <source>J Biol Chem</source>. (<year>2000</year>) <volume>275</volume>:<page-range>20520&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1074/jbc.M905251199</pub-id><pub-id pub-id-type="pmid">10877843</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>CD</given-names></name><name name-style="western"><surname>Doyonnas</surname><given-names>R</given-names></name><name name-style="western"><surname>Newton</surname><given-names>JP</given-names></name><name name-style="western"><surname>Blystone</surname><given-names>SD</given-names></name><name name-style="western"><surname>Brown</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Watt</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Identification of alpha v beta 3 as a heterotypic ligand for CD31/PECAM-1</article-title>. <source>J Cell Sci</source>. (<year>1996</year>) <volume>109</volume>:<page-range>437&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1242/jcs.109.2.437</pub-id><pub-id pub-id-type="pmid">8838667</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graesser</surname><given-names>D</given-names></name><name name-style="western"><surname>Solowiej</surname><given-names>A</given-names></name><name name-style="western"><surname>Bruckner</surname><given-names>M</given-names></name><name name-style="western"><surname>Osterweil</surname><given-names>E</given-names></name><name name-style="western"><surname>Juedes</surname><given-names>A</given-names></name><name name-style="western"><surname>Davis</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice</article-title>. <source>J Clin Invest</source>. (<year>2002</year>) <volume>109</volume>:<page-range>383&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI0213595</pub-id><pub-id pub-id-type="pmcid">PMC150854</pub-id><pub-id pub-id-type="pmid">11827998</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>EE</given-names></name><name name-style="western"><surname>Prineas</surname><given-names>JW</given-names></name></person-group>. <article-title>Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study</article-title>. <source>J Neuropathol Exp Neurol</source>. (<year>1994</year>) <volume>53</volume>:<page-range>625&#8211;36</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/00005072-199411000-00010</pub-id><pub-id pub-id-type="pmid">7964903</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Horssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Brink</surname><given-names>BP</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>HE</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>P</given-names></name><name name-style="western"><surname>Bo</surname><given-names>L</given-names></name></person-group>. <article-title>The blood-brain barrier in cortical multiple sclerosis lesions</article-title>. <source>J Neuropathol Exp Neurol</source>. (<year>2007</year>) <volume>66</volume>:<page-range>321&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/nen.0b013e318040b2de</pub-id><pub-id pub-id-type="pmid">17413323</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larochelle</surname><given-names>C</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>JI</given-names></name><name name-style="western"><surname>Prat</surname><given-names>A</given-names></name></person-group>. <article-title>How do immune cells overcome the blood-brain barrier in multiple sclerosis</article-title>? <source>FEBS Lett</source>. (<year>2011</year>) <volume>585</volume>:<page-range>3770&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.febslet.2011.04.066</pub-id><pub-id pub-id-type="pmid">21550344</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stys</surname><given-names>PK</given-names></name><name name-style="western"><surname>Zamponi</surname><given-names>GW</given-names></name><name name-style="western"><surname>van Minnen</surname><given-names>J</given-names></name><name name-style="western"><surname>Geurts</surname><given-names>JJ</given-names></name></person-group>. <article-title>Will the real multiple sclerosis please stand up</article-title>? <source>Nat Rev Neurosci</source>. (<year>2012</year>) <volume>13</volume>:<page-range>507&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrn3275</pub-id><pub-id pub-id-type="pmid">22714021</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kermode</surname><given-names>AG</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Tofts</surname><given-names>P</given-names></name><name name-style="western"><surname>MacManus</surname><given-names>DG</given-names></name><name name-style="western"><surname>Kendall</surname><given-names>BE</given-names></name><name name-style="western"><surname>Kingsley</surname><given-names>DP</given-names></name><etal/></person-group>. <article-title>Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis</article-title>. <source>Pathogenetic Clin implications. Brain</source>. (<year>1990</year>) <volume>113</volume>:<page-range>1477&#8211;89</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/113.5.1477</pub-id><pub-id pub-id-type="pmid">2245307</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodkin</surname><given-names>DE</given-names></name><name name-style="western"><surname>Rooney</surname><given-names>WD</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>R</given-names></name><name name-style="western"><surname>Bacchetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Gee</surname><given-names>L</given-names></name><name name-style="western"><surname>Vermathen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A serial study of new MS lesions and the white matter from which they arise</article-title>. <source>Neurology</source>. (<year>1998</year>) <volume>51</volume>:<page-range>1689&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.51.6.1689</pub-id><pub-id pub-id-type="pmid">9855524</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaech</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name></person-group>. <article-title>Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells</article-title>. <source>Nat Immunol</source>. (<year>2001</year>) <volume>2</volume>:<page-range>415&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/87720</pub-id><pub-id pub-id-type="pmcid">PMC3760150</pub-id><pub-id pub-id-type="pmid">11323695</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dore-Duffy</surname><given-names>P</given-names></name><name name-style="western"><surname>Washington</surname><given-names>R</given-names></name><name name-style="western"><surname>Dragovic</surname><given-names>L</given-names></name></person-group>. <article-title>Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis</article-title>. <source>Adv Exp Med Biol</source>. (<year>1993</year>) <volume>331</volume>:<page-range>243&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-4615-2920-0_38</pub-id><pub-id pub-id-type="pmid">8333339</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldner</surname><given-names>H</given-names></name><name name-style="western"><surname>Collins</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group>. <article-title>Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease</article-title>. <source>J Clin Invest</source>. (<year>2004</year>) <volume>113</volume>:<page-range>990&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI19388</pub-id><pub-id pub-id-type="pmcid">PMC379316</pub-id><pub-id pub-id-type="pmid">15057305</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korn</surname><given-names>T</given-names></name><name name-style="western"><surname>Bettelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Oukka</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group>. <article-title>IL-17 and th17 cells</article-title>. <source>Annu Rev Immunol</source>. (<year>2009</year>) <volume>27</volume>:<fpage>485</fpage>&#8211;<lpage>517</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132710</pub-id><pub-id pub-id-type="pmid">19132915</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Stipdonk</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lemmens</surname><given-names>EE</given-names></name><name name-style="western"><surname>Schoenberger</surname><given-names>SP</given-names></name></person-group>. <article-title>Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation</article-title>. <source>Nat Immunol</source>. (<year>2001</year>) <volume>2</volume>:<page-range>423&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/87730</pub-id><pub-id pub-id-type="pmid">11323696</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steffen</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Butcher</surname><given-names>EC</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></name></person-group>. <article-title>Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse</article-title>. <source>Am J Pathol</source>. (<year>1994</year>) <volume>145</volume>:<fpage>189</fpage>&#8211;<lpage>201</lpage>.<pub-id pub-id-type="pmid">7518194</pub-id><pub-id pub-id-type="pmcid">PMC1887301</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Calder</surname><given-names>VL</given-names></name></person-group>. <article-title>Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. off</article-title>. <source>Immunology</source>. (<year>1995</year>) <volume>86</volume>:<page-range>408&#8211;15</page-range>.<pub-id pub-id-type="pmcid">PMC1383944</pub-id><pub-id pub-id-type="pmid">8550078</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larochelle</surname><given-names>C</given-names></name><name name-style="western"><surname>Cayrol</surname><given-names>R</given-names></name><name name-style="western"><surname>Kebir</surname><given-names>H</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>JI</given-names></name><name name-style="western"><surname>Lecuyer</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ifergan</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system</article-title>. <source>Brain</source>. (<year>2012</year>) <volume>135</volume>:<page-range>2906&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/aws212</pub-id><pub-id pub-id-type="pmid">22975388</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larochelle</surname><given-names>C</given-names></name><name name-style="western"><surname>Lecuyer</surname><given-names>MA</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>JI</given-names></name><name name-style="western"><surname>Charabati</surname><given-names>M</given-names></name><name name-style="western"><surname>Saint-Laurent</surname><given-names>O</given-names></name><name name-style="western"><surname>Ghannam</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation</article-title>. <source>Ann Neurol</source>. (<year>2015</year>) <volume>78</volume>:<fpage>39</fpage>&#8211;<lpage>53</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.24415</pub-id><pub-id pub-id-type="pmid">25869475</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>F</given-names></name><name name-style="western"><surname>Garg</surname><given-names>AV</given-names></name><name name-style="western"><surname>Kosar</surname><given-names>K</given-names></name><name name-style="western"><surname>Majumder</surname><given-names>S</given-names></name><name name-style="western"><surname>Kugler</surname><given-names>DG</given-names></name><name name-style="western"><surname>Mir</surname><given-names>GH</given-names></name><etal/></person-group>. <article-title>Inflammatory th17 cells express integrin alphavbeta3 for pathogenic function</article-title>. <source>Cell Rep</source>. (<year>2016</year>) <volume>16</volume>:<page-range>1339&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2016.06.065</pub-id><pub-id pub-id-type="pmcid">PMC5627357</pub-id><pub-id pub-id-type="pmid">27452457</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsukada</surname><given-names>N</given-names></name><name name-style="western"><surname>Miyagi</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>M</given-names></name><name name-style="western"><surname>Yanagisawa</surname><given-names>N</given-names></name></person-group>. <article-title>Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy</article-title>. <source>Ann Neurol</source>. (<year>1993</year>) <volume>33</volume>:<page-range>646&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.410330614</pub-id><pub-id pub-id-type="pmid">8098933</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Reiners</surname><given-names>K</given-names></name><name name-style="western"><surname>Archelos</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Michels</surname><given-names>M</given-names></name><name name-style="western"><surname>Seeldrayers</surname><given-names>P</given-names></name><name name-style="western"><surname>Heidenreich</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging</article-title>. <source>Ann Neurol</source>. (<year>1995</year>) <volume>38</volume>:<page-range>186&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.410380210</pub-id><pub-id pub-id-type="pmid">7544573</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Lai</surname><given-names>M</given-names></name><name name-style="western"><surname>Thorpe</surname><given-names>J</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>D</given-names></name><name name-style="western"><surname>Chamoun</surname><given-names>V</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging</article-title>. <source>Neurology</source>. (<year>1997</year>) <volume>48</volume>:<page-range>1557&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.48.6.1557</pub-id><pub-id pub-id-type="pmid">9191766</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winger</surname><given-names>RC</given-names></name><name name-style="western"><surname>Koblinski</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kanda</surname><given-names>T</given-names></name><name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></name><name name-style="western"><surname>Muller</surname><given-names>WA</given-names></name></person-group>. <article-title>Rapid remodeling of tight junctions during paracellular diapedesis in a human model of the blood-brain barrier</article-title>. <source>J Immunol</source>. (<year>2014</year>) <volume>193</volume>:<page-range>2427&#8211;37</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1400700</pub-id><pub-id pub-id-type="pmcid">PMC4138548</pub-id><pub-id pub-id-type="pmid">25063869</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>WA</given-names></name></person-group>. <article-title>Transendothelial migration: unifying principles from the endothelial perspective</article-title>. <source>Immunol Rev</source>. (<year>2016</year>) <volume>273</volume>:<fpage>61</fpage>&#8211;<lpage>75</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/imr.2016.273.issue-1</pub-id><pub-id pub-id-type="pmid">27558328</pub-id><pub-id pub-id-type="pmcid">PMC5090979</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abadier</surname><given-names>M</given-names></name><name name-style="western"><surname>Haghayegh Jahromi</surname><given-names>N</given-names></name><name name-style="western"><surname>Cardoso Alves</surname><given-names>L</given-names></name><name name-style="western"><surname>Boscacci</surname><given-names>R</given-names></name><name name-style="western"><surname>Vestweber</surname><given-names>D</given-names></name><name name-style="western"><surname>Barnum</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier</article-title>. <source>Eur J Immunol</source>. (<year>2015</year>) <volume>45</volume>:<page-range>1043&#8211;58</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.201445125</pub-id><pub-id pub-id-type="pmid">25545837</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonar</surname><given-names>SA</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>S</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>N</given-names></name><name name-style="western"><surname>Atre</surname><given-names>AN</given-names></name><name name-style="western"><surname>Lal</surname><given-names>G</given-names></name></person-group>. <article-title>IFN-gamma promotes transendothelial migration of CD4(+) T cells across the blood-brain barrier</article-title>. <source>Immunol Cell Biol</source>. (<year>2017</year>) <volume>95</volume>:<page-range>843&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/icb.2017.56</pub-id><pub-id pub-id-type="pmid">28682305</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frohman</surname><given-names>EM</given-names></name><name name-style="western"><surname>Racke</surname><given-names>MK</given-names></name><name name-style="western"><surname>Raine</surname><given-names>CS</given-names></name></person-group>. <article-title>Multiple sclerosis&#8211;the plaque and its pathogenesis</article-title>. <source>N Engl J Med</source>. (<year>2006</year>) <volume>354</volume>:<page-range>942&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMra052130</pub-id><pub-id pub-id-type="pmid">16510748</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group>. <article-title>The blood-brain barrier in health and chronic neurodegenerative disorders</article-title>. <source>Neuron</source>. (<year>2008</year>) <volume>57</volume>:<fpage>178</fpage>&#8211;<lpage>201</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neuron.2008.01.003</pub-id><pub-id pub-id-type="pmid">18215617</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshima</surname><given-names>T</given-names></name><name name-style="western"><surname>Laroux</surname><given-names>FS</given-names></name><name name-style="western"><surname>Coe</surname><given-names>LL</given-names></name><name name-style="western"><surname>Morise</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kawachi</surname><given-names>S</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function</article-title>. <source>Microvasc Res</source>. (<year>2001</year>) <volume>61</volume>:<page-range>130&#8211;43</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1006/mvre.2000.2288</pub-id><pub-id pub-id-type="pmid">11162203</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mankertz</surname><given-names>J</given-names></name><name name-style="western"><surname>Tavalali</surname><given-names>S</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>H</given-names></name><name name-style="western"><surname>Mankertz</surname><given-names>A</given-names></name><name name-style="western"><surname>Riecken</surname><given-names>EO</given-names></name><name name-style="western"><surname>Fromm</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma</article-title>. <source>J Cell Sci</source>. (<year>2000</year>) <volume>113</volume>:<page-range>2085&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1242/jcs.113.11.2085</pub-id><pub-id pub-id-type="pmid">10806119</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wachtel</surname><given-names>M</given-names></name><name name-style="western"><surname>Bolliger</surname><given-names>MF</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>H</given-names></name><name name-style="western"><surname>Frei</surname><given-names>K</given-names></name><name name-style="western"><surname>Bluethmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Gloor</surname><given-names>SM</given-names></name></person-group>. <article-title>Down-regulation of occludin expression in astrocytes by tumour necrosis factor (TNF) is mediated via TNF type-1 receptor and nuclear factor-kappaB activation</article-title>. <source>J Neurochem</source>. (<year>2001</year>) <volume>78</volume>:<page-range>155&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00399.x</pub-id><pub-id pub-id-type="pmid">11432982</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nwariaku</surname><given-names>FE</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>SL</given-names></name><name name-style="western"><surname>Halaihel</surname><given-names>NH</given-names></name><etal/></person-group>. <article-title>The role of p38 map kinase in tumor necrosis factor-induced redistribution of vascular endothelial cadherin and increased endothelial permeability</article-title>. <source>Shock</source>. (<year>2002</year>) <volume>18</volume>:<page-range>82&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/00024382-200207000-00015</pub-id><pub-id pub-id-type="pmid">12095140</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusrat</surname><given-names>A</given-names></name><name name-style="western"><surname>Turner</surname><given-names>JR</given-names></name><name name-style="western"><surname>Madara</surname><given-names>JL</given-names></name></person-group>. <article-title>Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. (<year>2000</year>) <volume>279</volume>:<page-range>G851&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1152/ajpgi.2000.279.5.G851</pub-id><pub-id pub-id-type="pmid">11052980</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unlu</surname><given-names>H</given-names></name><name name-style="western"><surname>Bozcuk</surname><given-names>AN</given-names></name></person-group>. <article-title>Genetics of longevity in Drosophila&#8211;I. The effects of w, m and f mutant genes in various genotype combinations</article-title>. <source>Exp Gerontol</source>. (<year>1979</year>) <volume>14</volume>:<page-range>117&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0531-5565(79)90026-3</pub-id><pub-id pub-id-type="pmid">110608</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>MS</given-names></name><name name-style="western"><surname>Toninelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Balda</surname><given-names>MS</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines</article-title>. <source>Am J Physiol</source>. (<year>1997</year>) <volume>273</volume>:<page-range>H286&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1152/ajpheart.1997.273.1.H286</pub-id><pub-id pub-id-type="pmid">9249502</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruewer</surname><given-names>M</given-names></name><name name-style="western"><surname>Luegering</surname><given-names>A</given-names></name><name name-style="western"><surname>Kucharzik</surname><given-names>T</given-names></name><name name-style="western"><surname>Parkos</surname><given-names>CA</given-names></name><name name-style="western"><surname>Madara</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms</article-title>. <source>J Immunol</source>. (<year>2003</year>) <volume>171</volume>:<page-range>6164&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.171.11.6164</pub-id><pub-id pub-id-type="pmid">14634132</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kebir</surname><given-names>H</given-names></name><name name-style="western"><surname>Kreymborg</surname><given-names>K</given-names></name><name name-style="western"><surname>Ifergan</surname><given-names>I</given-names></name><name name-style="western"><surname>Dodelet-Devillers</surname><given-names>A</given-names></name><name name-style="western"><surname>Cayrol</surname><given-names>R</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation</article-title>. <source>Nat Med</source>. (<year>2007</year>) <volume>13</volume>:<page-range>1173&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nm1651</pub-id><pub-id pub-id-type="pmcid">PMC5114125</pub-id><pub-id pub-id-type="pmid">17828272</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huppert</surname><given-names>J</given-names></name><name name-style="western"><surname>Closhen</surname><given-names>D</given-names></name><name name-style="western"><surname>Croxford</surname><given-names>A</given-names></name><name name-style="western"><surname>White</surname><given-names>R</given-names></name><name name-style="western"><surname>Kulig</surname><given-names>P</given-names></name><name name-style="western"><surname>Pietrowski</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cellular mechanisms of IL-17-induced blood-brain barrier disruption</article-title>. <source>FASEB J</source>. (<year>2010</year>) <volume>24</volume>:<page-range>1023&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1096/fj.09-141978</pub-id><pub-id pub-id-type="pmid">19940258</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolton</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>DC</given-names></name><name name-style="western"><surname>Perry</surname><given-names>VH</given-names></name></person-group>. <article-title>Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown <italic toggle="yes">in vivo</italic>
</article-title>. <source>Neuroscience</source>. (<year>1998</year>) <volume>86</volume>:<page-range>1245&#8211;57</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0306-4522(98)00058-X</pub-id><pub-id pub-id-type="pmid">9697130</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sozen</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuchiyama</surname><given-names>R</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>V</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Role of interleukin-1beta in early brain injury after subarachnoid hemorrhage in mice</article-title>. <source>Stroke</source>. (<year>2009</year>) <volume>40</volume>:<page-range>2519&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1161/STROKEAHA.109.549592</pub-id><pub-id pub-id-type="pmcid">PMC2763121</pub-id><pub-id pub-id-type="pmid">19461019</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T</given-names></name><name name-style="western"><surname>Sumii</surname><given-names>T</given-names></name><name name-style="western"><surname>Jung</surname><given-names>JC</given-names></name><name name-style="western"><surname>Moskowitz</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia</article-title>. <source>J Neurosci</source>. (<year>2001</year>) <volume>21</volume>:<page-range>7724&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-19-07724.2001</pub-id><pub-id pub-id-type="pmcid">PMC6762894</pub-id><pub-id pub-id-type="pmid">11567062</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Estrada</surname><given-names>EY</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>JF</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group>. <article-title>Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat</article-title>. <source>J Cereb Blood Flow Metab</source>. (<year>2007</year>) <volume>27</volume>:<fpage>697</fpage>&#8211;<lpage>709</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600375</pub-id><pub-id pub-id-type="pmid">16850029</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonetti</surname><given-names>DA</given-names></name><name name-style="western"><surname>Barber</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hollinger</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wolpert</surname><given-names>EB</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>TW</given-names></name></person-group>. <article-title>Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors</article-title>. <source>J Biol Chem</source>. (<year>1999</year>) <volume>274</volume>:<page-range>23463&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1074/jbc.274.33.23463</pub-id><pub-id pub-id-type="pmid">10438525</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>F</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Sano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ju</surname><given-names>M</given-names></name><name name-style="western"><surname>Nishihara</surname><given-names>H</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier</article-title>. <source>PLoS One</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>e92872</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0092872</pub-id><pub-id pub-id-type="pmid">24686948</pub-id><pub-id pub-id-type="pmcid">PMC3970956</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minagar</surname><given-names>A</given-names></name><name name-style="western"><surname>Ostanin</surname><given-names>D</given-names></name><name name-style="western"><surname>Long</surname><given-names>AC</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>RE</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells</article-title>. <source>Mult Scler</source>. (<year>2003</year>) <volume>9</volume>:<page-range>235&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1191/1352458503ms916oa</pub-id><pub-id pub-id-type="pmid">12814168</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>P</given-names></name><name name-style="western"><surname>Durbeej</surname><given-names>M</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N</given-names></name><name name-style="western"><surname>Ivars</surname><given-names>F</given-names></name><name name-style="western"><surname>Opdenakker</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis</article-title>. <source>J Exp Med</source>. (<year>2006</year>) <volume>203</volume>:<page-range>1007&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20051342</pub-id><pub-id pub-id-type="pmcid">PMC2118280</pub-id><pub-id pub-id-type="pmid">16585265</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conforti</surname><given-names>R</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Saturnino</surname><given-names>PP</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>R</given-names></name><name name-style="western"><surname>Negro</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Dilated Virchow-Robin spaces and multiple sclerosis: 3 T magnetic resonance study</article-title>. <source>Radiol Med</source>. (<year>2014</year>) <volume>119</volume>:<page-range>408&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11547-013-0357-9</pub-id><pub-id pub-id-type="pmid">24297592</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Horssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Bo</surname><given-names>L</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>CD</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>HE</given-names></name></person-group>. <article-title>Extensive extracellular matrix depositions in active multiple sclerosis lesions</article-title>. <source>Neurobiol Dis</source>. (<year>2006</year>) <volume>24</volume>:<page-range>484&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nbd.2006.08.005</pub-id><pub-id pub-id-type="pmid">17005408</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Horssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>CD</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>HE</given-names></name></person-group>. <article-title>The extracellular matrix in multiple sclerosis pathology</article-title>. <source>J Neurochem</source>. (<year>2007</year>) <volume>103</volume>:<page-range>1293&#8211;301</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04897.x</pub-id><pub-id pub-id-type="pmid">17854386</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilsdonk</surname><given-names>ID</given-names></name><name name-style="western"><surname>Steenwijk</surname><given-names>MD</given-names></name><name name-style="western"><surname>Pouwels</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Zwanenburg</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Visser</surname><given-names>F</given-names></name><name name-style="western"><surname>Luijten</surname><given-names>PR</given-names></name><etal/></person-group>. <article-title>Perivascular spaces in MS patients at 7 Tesla MRI: a marker of neurodegeneration</article-title>? <source>Mult Scler</source>. (<year>2015</year>) <volume>21</volume>:<page-range>155&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1352458514540358</pub-id><pub-id pub-id-type="pmid">25013150</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korotkov</surname><given-names>SM</given-names></name><name name-style="western"><surname>Glazunov</surname><given-names>VV</given-names></name><name name-style="western"><surname>Rozengart</surname><given-names>EV</given-names></name><name name-style="western"><surname>Suvorov</surname><given-names>AA</given-names></name></person-group>. <article-title>The action of organic cadmium complexes of different degrees of hydrophobicity on rat liver mitochondria</article-title>. <source>Tsitologiia</source>. (<year>1996</year>) <volume>38</volume>:<page-range>1075&#8211;83</page-range>.<pub-id pub-id-type="pmid">9045421</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montagne</surname><given-names>A</given-names></name><name name-style="western"><surname>Toga</surname><given-names>AW</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group>. <article-title>Blood-brain barrier permeability and gadolinium: benefits and potential pitfalls in research</article-title>. <source>JAMA Neurol</source>. (<year>2016</year>) <volume>73</volume>:<page-range>13&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jamaneurol.2015.2960</pub-id><pub-id pub-id-type="pmcid">PMC4736734</pub-id><pub-id pub-id-type="pmid">26524294</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holman</surname><given-names>DW</given-names></name><name name-style="western"><surname>Klein</surname><given-names>RS</given-names></name><name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group>. <article-title>The blood-brain barrier, chemokines and multiple sclerosis</article-title>. <source>Biochim Biophys Acta</source>. (<year>2011</year>) <volume>1812</volume>:<page-range>220&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbadis.2010.07.019</pub-id><pub-id pub-id-type="pmcid">PMC3005102</pub-id><pub-id pub-id-type="pmid">20692338</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luster</surname><given-names>AD</given-names></name></person-group>. <article-title>Chemokines&#8211;chemotactic cytokines that mediate inflammation</article-title>. <source>N Engl J Med</source>. (<year>1998</year>) <volume>338</volume>:<page-range>436&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJM199802123380706</pub-id><pub-id pub-id-type="pmid">9459648</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Sumrani</surname><given-names>N</given-names></name><name name-style="western"><surname>Hong</surname><given-names>JH</given-names></name></person-group>. <article-title>Prolonged simple cryothermic immersion storage of rat heart isografts: a preliminary study</article-title>. <source>J Invest Surg</source>. (<year>1991</year>) <volume>4</volume>:<page-range>171&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3109/08941939109140777</pub-id><pub-id pub-id-type="pmid">2069927</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szczucinski</surname><given-names>A</given-names></name><name name-style="western"><surname>Losy</surname><given-names>J</given-names></name></person-group>. <article-title>Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies</article-title>. <source>Acta Neurol Scand</source>. (<year>2007</year>) <volume>115</volume>:<page-range>137&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1600-0404.2006.00749.x</pub-id><pub-id pub-id-type="pmid">17295707</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliver</surname><given-names>AR</given-names></name><name name-style="western"><surname>Lyon</surname><given-names>GM</given-names></name><name name-style="western"><surname>Ruddle</surname><given-names>NH</given-names></name></person-group>. <article-title>Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice</article-title>. <source>J Immunol</source>. (<year>2003</year>) <volume>171</volume>:<page-range>462&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.171.1.462</pub-id><pub-id pub-id-type="pmid">12817031</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothhammer</surname><given-names>V</given-names></name><name name-style="western"><surname>Heink</surname><given-names>S</given-names></name><name name-style="western"><surname>Petermann</surname><given-names>F</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R</given-names></name><name name-style="western"><surname>Claussen</surname><given-names>MC</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE</article-title>. <source>J Exp Med</source>. (<year>2011</year>) <volume>208</volume>:<page-range>2465&#8211;76</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20110434</pub-id><pub-id pub-id-type="pmcid">PMC3256959</pub-id><pub-id pub-id-type="pmid">22025301</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reboldi</surname><given-names>A</given-names></name><name name-style="western"><surname>Coisne</surname><given-names>C</given-names></name><name name-style="western"><surname>Baumjohann</surname><given-names>D</given-names></name><name name-style="western"><surname>Benvenuto</surname><given-names>F</given-names></name><name name-style="western"><surname>Bottinelli</surname><given-names>D</given-names></name><name name-style="western"><surname>Lira</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE</article-title>. <source>Nat Immunol</source>. (<year>2009</year>) <volume>10</volume>:<page-range>514&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.1716</pub-id><pub-id pub-id-type="pmid">19305396</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kieseier</surname><given-names>BC</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>T</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name></person-group>. <article-title>Matrix metalloproteinases in inflammatory demyelination: targets for treatment</article-title>. <source>Neurology</source>. (<year>1999</year>) <volume>53</volume>:<page-range>20&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.53.1.20</pub-id><pub-id pub-id-type="pmid">10408531</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wucherpfennig</surname><given-names>KW</given-names></name><name name-style="western"><surname>Strominger</surname><given-names>JL</given-names></name></person-group>. <article-title>Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein</article-title>. <source>Cell</source>. (<year>1995</year>) <volume>80</volume>:<fpage>695</fpage>&#8211;<lpage>705</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0092-8674(95)90348-8</pub-id><pub-id pub-id-type="pmid">7534214</pub-id><pub-id pub-id-type="pmcid">PMC7133435</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berer</surname><given-names>K</given-names></name><name name-style="western"><surname>Mues</surname><given-names>M</given-names></name><name name-style="western"><surname>Koutrolos</surname><given-names>M</given-names></name><name name-style="western"><surname>Rasbi</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Boziki</surname><given-names>M</given-names></name><name name-style="western"><surname>Johner</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination</article-title>. <source>Nature</source>. (<year>2011</year>) <volume>479</volume>:<page-range>538&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature10554</pub-id><pub-id pub-id-type="pmid">22031325</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odoardi</surname><given-names>F</given-names></name><name name-style="western"><surname>Sie</surname><given-names>C</given-names></name><name name-style="western"><surname>Streyl</surname><given-names>K</given-names></name><name name-style="western"><surname>Ulaganathan</surname><given-names>VK</given-names></name><name name-style="western"><surname>Schlager</surname><given-names>C</given-names></name><name name-style="western"><surname>Lodygin</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>T cells become licensed in the lung to enter the central nervous system</article-title>. <source>Nature</source>. (<year>2012</year>) <volume>488</volume>:<page-range>675&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature11337</pub-id><pub-id pub-id-type="pmid">22914092</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westland</surname><given-names>KW</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>JD</given-names></name><name name-style="western"><surname>Sander</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonner</surname><given-names>JG</given-names></name><name name-style="western"><surname>Linington</surname><given-names>C</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>JG</given-names></name></person-group>. <article-title>Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies</article-title>. <source>Brain</source>. (<year>1999</year>) <volume>122</volume>:<page-range>1283&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/122.7.1283</pub-id><pub-id pub-id-type="pmid">10388794</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickey</surname><given-names>WF</given-names></name></person-group>. <article-title>Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation</article-title>. <source>Brain Pathol</source>. (<year>1991</year>) <volume>1</volume>:<fpage>97</fpage>&#8211;<lpage>105</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1750-3639.1991.tb00646.x</pub-id><pub-id pub-id-type="pmid">1669702</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sospedra</surname><given-names>M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>R</given-names></name></person-group>. <article-title>Immunology of multiple sclerosis</article-title>. <source>Semin Neurol</source>. (<year>2016</year>) <volume>36</volume>:<page-range>115&#8211;27</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1055/s-0036-1579739</pub-id><pub-id pub-id-type="pmid">27116718</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trotter</surname><given-names>JL</given-names></name><name name-style="western"><surname>Pelfrey</surname><given-names>CM</given-names></name><name name-style="western"><surname>Trotter</surname><given-names>AL</given-names></name><name name-style="western"><surname>Selvidge</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gushleff</surname><given-names>KC</given-names></name><name name-style="western"><surname>Mohanakumar</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects</article-title>. <source>J Neuroimmunol</source>. (<year>1998</year>) <volume>84</volume>:<page-range>172&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0165-5728(97)00260-9</pub-id><pub-id pub-id-type="pmid">9628460</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelfrey</surname><given-names>CM</given-names></name><name name-style="western"><surname>Tranquill</surname><given-names>LR</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>AB</given-names></name><name name-style="western"><surname>McFarland</surname><given-names>HF</given-names></name></person-group>. <article-title>T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls</article-title>. <source>Mult Scler</source>. (<year>1996</year>) <volume>1</volume>:<page-range>270&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/135245859600100503</pub-id><pub-id pub-id-type="pmid">9345429</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bielekova</surname><given-names>B</given-names></name><name name-style="western"><surname>Sung</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kadom</surname><given-names>N</given-names></name><name name-style="western"><surname>Simon</surname><given-names>R</given-names></name><name name-style="western"><surname>McFarland</surname><given-names>H</given-names></name><name name-style="western"><surname>Martin</surname><given-names>R</given-names></name></person-group>. <article-title>Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis</article-title>. <source>J Immunol</source>. (<year>2004</year>) <volume>172</volume>:<page-range>3893&#8211;904</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.172.6.3893</pub-id><pub-id pub-id-type="pmid">15004197</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goods</surname><given-names>BA</given-names></name><name name-style="western"><surname>Raddassi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nepom</surname><given-names>GT</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>WW</given-names></name><name name-style="western"><surname>Love</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis</article-title>. <source>Sci Transl Med</source>. (<year>2015</year>) <volume>7</volume>:<fpage>287ra74</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa8038</pub-id><pub-id pub-id-type="pmcid">PMC4497538</pub-id><pub-id pub-id-type="pmid">25972006</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viglietta</surname><given-names>V</given-names></name><name name-style="western"><surname>Baecher-Allan</surname><given-names>C</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>HL</given-names></name><name name-style="western"><surname>Hafler</surname><given-names>DA</given-names></name></person-group>. <article-title>Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis</article-title>. <source>J Exp Med</source>. (<year>2004</year>) <volume>199</volume>:<page-range>971&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20031579</pub-id><pub-id pub-id-type="pmcid">PMC2211881</pub-id><pub-id pub-id-type="pmid">15067033</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>A</given-names></name><name name-style="western"><surname>Long</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cerosaletti</surname><given-names>K</given-names></name><name name-style="western"><surname>Ni</surname><given-names>CT</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>P</given-names></name><name name-style="western"><surname>Kita</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling</article-title>. <source>Sci Transl Med</source>. (<year>2013</year>) <volume>5</volume>:<fpage>170ra15</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.3004970</pub-id><pub-id pub-id-type="pmid">23363979</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohme</surname><given-names>M</given-names></name><name name-style="western"><surname>Hotz</surname><given-names>C</given-names></name><name name-style="western"><surname>Stevanovic</surname><given-names>S</given-names></name><name name-style="western"><surname>Binder</surname><given-names>T</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Okoniewski</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis</article-title>. <source>Brain</source>. (<year>2013</year>) <volume>136</volume>:<page-range>1783&#8211;98</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awt108</pub-id><pub-id pub-id-type="pmid">23739916</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jelcic</surname><given-names>I</given-names></name><name name-style="western"><surname>Al Nimer</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lentsch</surname><given-names>V</given-names></name><name name-style="western"><surname>Planas</surname><given-names>R</given-names></name><name name-style="western"><surname>Jelcic</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis</article-title>. <source>Cell</source>. (<year>2018</year>) <volume>175</volume>:<fpage>85</fpage>&#8211;<lpage>100.e23</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2018.08.011</pub-id><pub-id pub-id-type="pmid">30173916</pub-id><pub-id pub-id-type="pmcid">PMC6191934</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stinissen</surname><given-names>P</given-names></name><name name-style="western"><surname>Hellings</surname><given-names>N</given-names></name></person-group>. <article-title>Activation of myelin reactive T cells in multiple sclerosis: a possible role for T cell degeneracy</article-title>? <source>Eur J Immunol</source>. (<year>2008</year>) <volume>38</volume>:<page-range>1190&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.200838371</pub-id><pub-id pub-id-type="pmid">18425726</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Ivars</surname><given-names>F</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>P</given-names></name><name name-style="western"><surname>Hallmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Vestweber</surname><given-names>D</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain</article-title>. <source>Nat Med</source>. (<year>2009</year>) <volume>15</volume>:<page-range>519&#8211;27</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nm.1957</pub-id><pub-id pub-id-type="pmid">19396173</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkhurst</surname><given-names>CN</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Ninan</surname><given-names>I</given-names></name><name name-style="western"><surname>Savas</surname><given-names>JN</given-names></name><name name-style="western"><surname>Yates</surname><given-names>JR</given-names></name><name name-style="western"><surname>Lafaille</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor</article-title>. <source>Cell</source>. (<year>2013</year>) <volume>155</volume>:<page-range>1596&#8211;609</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2013.11.030</pub-id><pub-id pub-id-type="pmcid">PMC4033691</pub-id><pub-id pub-id-type="pmid">24360280</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>International Multiple Sclerosis Genetics Consortium</collab><collab>Wellcome Trust Case Control C</collab><name name-style="western"><surname>Sawcer</surname><given-names>S</given-names></name><name name-style="western"><surname>Hellenthal</surname><given-names>G</given-names></name><name name-style="western"><surname>Pirinen</surname><given-names>M</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>CC</given-names></name><etal/></person-group>. <article-title>Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis</article-title>. <source>Nature</source>. (<year>2011</year>) <volume>476</volume>:<page-range>214&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature10251</pub-id><pub-id pub-id-type="pmcid">PMC3182531</pub-id><pub-id pub-id-type="pmid">21833088</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Korpos</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>SM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration</article-title>. <source>Cell Rep</source>. (<year>2015</year>) <volume>10</volume>:<page-range>1040&#8211;54</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.037</pub-id><pub-id pub-id-type="pmid">25704809</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Losy</surname><given-names>J</given-names></name></person-group>. <article-title>Is MS an inflammatory or primary degenerative disease</article-title>? <source>J Neural Transm (Vienna)</source>. (<year>2013</year>) <volume>120</volume>:<page-range>1459&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00702-013-1079-9</pub-id><pub-id pub-id-type="pmcid">PMC3779312</pub-id><pub-id pub-id-type="pmid">24057507</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bever</surname><given-names>CT</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group>. <article-title>Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury</article-title>? <source>Neurology</source>. (<year>1999</year>) <volume>53</volume>:<page-range>1380&#8211;1</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.53.7.1380</pub-id><pub-id pub-id-type="pmid">10534237</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cepok</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosche</surname><given-names>B</given-names></name><name name-style="western"><surname>Grummel</surname><given-names>V</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Sayn</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis</article-title>. <source>Brain</source>. (<year>2005</year>) <volume>128</volume>:<page-range>1667&#8211;76</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awh486</pub-id><pub-id pub-id-type="pmid">15800022</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schirmer</surname><given-names>L</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B</given-names></name></person-group>. <article-title>To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis</article-title>. <source>Mult Scler</source>. (<year>2014</year>) <volume>20</volume>:<page-range>271&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1352458514522104</pub-id><pub-id pub-id-type="pmid">24589684</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Clark</surname><given-names>RA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wagers</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Fuhlbrigge</surname><given-names>RC</given-names></name><name name-style="western"><surname>Kupper</surname><given-names>TS</given-names></name></person-group>. <article-title>Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity</article-title>. <source>Nature</source>. (<year>2012</year>) <volume>483</volume>:<page-range>227&#8211;31</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature10851</pub-id><pub-id pub-id-type="pmcid">PMC3437663</pub-id><pub-id pub-id-type="pmid">22388819</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>MH</given-names></name><name name-style="western"><surname>Prineas</surname><given-names>JW</given-names></name></person-group>. <article-title>Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion</article-title>. <source>Ann Neurol</source>. (<year>2004</year>) <volume>55</volume>:<page-range>458&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.20016</pub-id><pub-id pub-id-type="pmid">15048884</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucchinetti</surname><given-names>C</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>W</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>J</given-names></name><name name-style="western"><surname>Scheithauer</surname><given-names>B</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>M</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination</article-title>. <source>Ann Neurol</source>. (<year>2000</year>) <volume>47</volume>:<page-range>707&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1531-8249(200006)47:6&amp;#x0003c;707::AID-ANA3&amp;#x0003e;3.0.CO;2-Q</pub-id><pub-id pub-id-type="pmid">10852536</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pachter</surname><given-names>JS</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>HE</given-names></name><name name-style="western"><surname>Fabry</surname><given-names>Z</given-names></name></person-group>. <article-title>The blood-brain barrier and its role in immune privilege in the central nervous system</article-title>. <source>J Neuropathol Exp Neurol</source>. (<year>2003</year>) <volume>62</volume>:<fpage>593</fpage>&#8211;<lpage>604</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/jnen/62.6.593</pub-id><pub-id pub-id-type="pmid">12834104</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatterer</surname><given-names>E</given-names></name><name name-style="western"><surname>Davoust</surname><given-names>N</given-names></name><name name-style="western"><surname>Didier-Bazes</surname><given-names>M</given-names></name><name name-style="western"><surname>Vuaillat</surname><given-names>C</given-names></name><name name-style="western"><surname>Malcus</surname><given-names>C</given-names></name><name name-style="western"><surname>Belin</surname><given-names>MF</given-names></name><etal/></person-group>. <article-title>How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes</article-title>. <source>Blood</source>. (<year>2006</year>) <volume>107</volume>:<page-range>806&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2005-01-0154</pub-id><pub-id pub-id-type="pmid">16204309</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prodinger</surname><given-names>C</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>J</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>M</given-names></name><name name-style="western"><surname>Schiefenhovel</surname><given-names>F</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>C</given-names></name><name name-style="western"><surname>Laman</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system</article-title>. <source>Acta Neuropathol</source>. (<year>2011</year>) <volume>121</volume>:<page-range>445&#8211;58</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-010-0774-y</pub-id><pub-id pub-id-type="pmid">21076838</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammad</surname><given-names>MG</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>VW</given-names></name><name name-style="western"><surname>Ruitenberg</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hassanpour</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Hart</surname><given-names>PH</given-names></name><etal/></person-group>. <article-title>Immune cell trafficking from the brain maintains CNS immune tolerance</article-title>. <source>J Clin Invest</source>. (<year>2014</year>) <volume>124</volume>:<page-range>1228&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI71544</pub-id><pub-id pub-id-type="pmcid">PMC3934177</pub-id><pub-id pub-id-type="pmid">24569378</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheway</surname><given-names>J</given-names></name><name name-style="western"><surname>Obeid</surname><given-names>S</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>PO</given-names></name><name name-style="western"><surname>Combes</surname><given-names>V</given-names></name><name name-style="western"><surname>Grau</surname><given-names>GE</given-names></name></person-group>. <article-title>The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation</article-title>. <source>PLoS One</source>. (<year>2013</year>) <volume>8</volume>:<elocation-id>e52586</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0052586</pub-id><pub-id pub-id-type="pmid">23320074</pub-id><pub-id pub-id-type="pmcid">PMC3540051</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes Pinheiro</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kamermans</surname><given-names>A</given-names></name><name name-style="western"><surname>Garcia-Vallejo</surname><given-names>JJ</given-names></name><name name-style="western"><surname>van Het Hof</surname><given-names>B</given-names></name><name name-style="western"><surname>Wierts</surname><given-names>L</given-names></name><name name-style="western"><surname>O'Toole</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Internalization and presentation of myelin antigens by the brain endothelium guides antigen-specific T cell migration</article-title>. <source>Elife</source>. (<year>2016</year>) <volume>5</volume>. doi:&#160;<pub-id pub-id-type="doi">10.7554/eLife.13149</pub-id><pub-id pub-id-type="pmcid">PMC4959842</pub-id><pub-id pub-id-type="pmid">27336724</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Male</surname><given-names>D</given-names></name><name name-style="western"><surname>Pryce</surname><given-names>G</given-names></name></person-group>. <article-title>Kinetics of MHC gene expression and mRNA synthesis in brain endothelium</article-title>. <source>Immunology</source>. (<year>1988</year>) <volume>63</volume>:<fpage>37</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">3123371</pub-id><pub-id pub-id-type="pmcid">PMC1454708</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locatelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Wortge</surname><given-names>S</given-names></name><name name-style="western"><surname>Buch</surname><given-names>T</given-names></name><name name-style="western"><surname>Ingold</surname><given-names>B</given-names></name><name name-style="western"><surname>Frommer</surname><given-names>F</given-names></name><name name-style="western"><surname>Sobottka</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Primary oligodendrocyte death does not elicit anti-CNS immunity</article-title>. <source>Nat Neurosci</source>. (<year>2012</year>) <volume>15</volume>:<page-range>543&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nn.3062</pub-id><pub-id pub-id-type="pmid">22366759</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eichler</surname><given-names>F</given-names></name><name name-style="western"><surname>Van Haren</surname><given-names>K</given-names></name></person-group>. <article-title>Immune response in leukodystrophies</article-title>. <source>Pediatr Neurol</source>. (<year>2007</year>) <volume>37</volume>:<page-range>235&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2007.06.011</pub-id><pub-id pub-id-type="pmid">17903666</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Templeton</surname><given-names>SP</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Pathogenesis of acute and chronic central nervous system infection with variants of mouse hepatitis virus, strain JHM</article-title>. <source>Immunol Res</source>. (<year>2007</year>) <volume>39</volume>:<page-range>160&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12026-007-0079-y</pub-id><pub-id pub-id-type="pmcid">PMC7090838</pub-id><pub-id pub-id-type="pmid">17917063</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minagar</surname><given-names>A</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>JS</given-names></name></person-group>. <article-title>Blood-brain barrier disruption in multiple sclerosis</article-title>. <source>Mult Scler</source>. (<year>2003</year>) <volume>9</volume>:<page-range>540&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1191/1352458503ms965oa</pub-id><pub-id pub-id-type="pmid">14664465</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>RI</given-names></name><name name-style="western"><surname>Reingold</surname><given-names>SC</given-names></name><name name-style="western"><surname>McFarland</surname><given-names>HF</given-names></name></person-group>. <article-title>The role of magnetic resonance techniques in understanding and managing multiple sclerosis</article-title>. <source>Brain</source>. (<year>1998</year>) <volume>121</volume>:<fpage>3</fpage>&#8211;<lpage>24</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/121.1.3</pub-id><pub-id pub-id-type="pmid">9549485</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawson</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Perry</surname><given-names>VH</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S</given-names></name></person-group>. <article-title>Turnover of resident microglia in the normal adult mouse brain</article-title>. <source>Neuroscience</source>. (<year>1992</year>) <volume>48</volume>:<page-range>405&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0306-4522(92)90500-2</pub-id><pub-id pub-id-type="pmid">1603325</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez Perdiguero</surname><given-names>E</given-names></name><name name-style="western"><surname>Klapproth</surname><given-names>K</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>C</given-names></name><name name-style="western"><surname>Busch</surname><given-names>K</given-names></name><name name-style="western"><surname>Azzoni</surname><given-names>E</given-names></name><name name-style="western"><surname>Crozet</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors</article-title>. <source>Nature</source>. (<year>2015</year>) <volume>518</volume>:<page-range>547&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature13989</pub-id><pub-id pub-id-type="pmcid">PMC5997177</pub-id><pub-id pub-id-type="pmid">25470051</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoeffel</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Lavin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Low</surname><given-names>D</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>FF</given-names></name><name name-style="western"><surname>See</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages</article-title>. <source>Immunity</source>. (<year>2015</year>) <volume>42</volume>:<page-range>665&#8211;78</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2015.03.011</pub-id><pub-id pub-id-type="pmcid">PMC4545768</pub-id><pub-id pub-id-type="pmid">25902481</pub-id></mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Askew</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Olmos-Alonso</surname><given-names>A</given-names></name><name name-style="western"><surname>Garcia-Moreno</surname><given-names>F</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain</article-title>. <source>Cell Rep</source>. (<year>2017</year>) <volume>18</volume>:<fpage>391</fpage>&#8211;<lpage>405</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.041</pub-id><pub-id pub-id-type="pmid">28076784</pub-id><pub-id pub-id-type="pmcid">PMC5263237</pub-id></mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>VH</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>JA</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C</given-names></name></person-group>. <article-title>Microglia in neurodegenerative disease</article-title>. <source>Nat Rev Neurol</source>. (<year>2010</year>) <volume>6</volume>:<fpage>193</fpage>&#8211;<lpage>201</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrneurol.2010.17</pub-id><pub-id pub-id-type="pmid">20234358</pub-id></mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louveau</surname><given-names>A</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>I</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Eccles</surname><given-names>JD</given-names></name><name name-style="western"><surname>Rouhani</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Peske</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Structural and functional features of central nervous system lymphatic vessels</article-title>. <source>Nature</source>. (<year>2015</year>) <volume>523</volume>:<page-range>337&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature14432</pub-id><pub-id pub-id-type="pmcid">PMC4506234</pub-id><pub-id pub-id-type="pmid">26030524</pub-id></mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Barres</surname><given-names>BA</given-names></name></person-group>. <article-title>Microglia and macrophages in brain homeostasis and disease</article-title>. <source>Nat Rev Immunol</source>. (<year>2018</year>) <volume>18</volume>:<page-range>225&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri.2017.125</pub-id><pub-id pub-id-type="pmid">29151590</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enger</surname><given-names>E</given-names></name><name name-style="western"><surname>Freden</surname><given-names>H</given-names></name><name name-style="western"><surname>Haljamae</surname><given-names>H</given-names></name><name name-style="western"><surname>Ingervall</surname><given-names>B</given-names></name></person-group>. <article-title>Effects of mandibular displacement on the metabolic activity of the masseter muscle in rat</article-title>. <source>Arch Biol</source>. (<year>1975</year>) <volume>20</volume>:<fpage>7</fpage>&#8211;<lpage>10</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0003-9969(75)90144-2</pub-id><pub-id pub-id-type="pmid">235250</pub-id></mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schafer</surname><given-names>DP</given-names></name><name name-style="western"><surname>Lehrman</surname><given-names>EK</given-names></name><name name-style="western"><surname>Kautzman</surname><given-names>AG</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>R</given-names></name><name name-style="western"><surname>Mardinly</surname><given-names>AR</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner</article-title>. <source>Neuron</source>. (<year>2012</year>) <volume>74</volume>:<fpage>691</fpage>&#8211;<lpage>705</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.026</pub-id><pub-id pub-id-type="pmid">22632727</pub-id><pub-id pub-id-type="pmcid">PMC3528177</pub-id></mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pridans</surname><given-names>C</given-names></name><name name-style="western"><surname>Raper</surname><given-names>A</given-names></name><name name-style="western"><surname>Davis</surname><given-names>GM</given-names></name><name name-style="western"><surname>Alves</surname><given-names>J</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Pleiotropic impacts of macrophage and microglial deficiency on development in rats with targeted mutation of the csf1r locus</article-title>. <source>J Immunol</source>. (<year>2018</year>) <volume>201</volume>:<page-range>2683&#8211;99</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1701783</pub-id><pub-id pub-id-type="pmcid">PMC6196293</pub-id><pub-id pub-id-type="pmid">30249809</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madry</surname><given-names>C</given-names></name><name name-style="western"><surname>Kyrargyri</surname><given-names>V</given-names></name><name name-style="western"><surname>Arancibia-Carcamo</surname><given-names>IL</given-names></name><name name-style="western"><surname>Jolivet</surname><given-names>R</given-names></name><name name-style="western"><surname>Kohsaka</surname><given-names>S</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Microglial ramification, surveillance, and interleukin-1beta release are regulated by the two-pore domain K(+) channel THIK-1</article-title>. <source>Neuron</source>. (<year>2018</year>) <volume>97</volume>:<fpage>299</fpage>&#8211;<lpage>312.e6</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neuron.2017.12.002</pub-id><pub-id pub-id-type="pmid">29290552</pub-id><pub-id pub-id-type="pmcid">PMC5783715</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veremeyko</surname><given-names>T</given-names></name><name name-style="western"><surname>Yung</surname><given-names>AWY</given-names></name><name name-style="western"><surname>Dukhinova</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuznetsova</surname><given-names>IS</given-names></name><name name-style="western"><surname>Pomytkin</surname><given-names>I</given-names></name><name name-style="western"><surname>Lyundup</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Cyclic AMP pathway suppress autoimmune neuroinflammation by inhibiting functions of encephalitogenic CD4 T cells and enhancing M2 macrophage polarization at the site of inflammation</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>50</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.00050</pub-id><pub-id pub-id-type="pmid">29422898</pub-id><pub-id pub-id-type="pmcid">PMC5788911</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group>. <article-title>A polarizing question: do M1 and M2 microglia exist</article-title>? <source>Nat Neurosci</source>. (<year>2016</year>) <volume>19</volume>:<page-range>987&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nn.4338</pub-id><pub-id pub-id-type="pmid">27459405</pub-id></mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Metz</surname><given-names>I</given-names></name><name name-style="western"><surname>Amor</surname><given-names>S</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>P</given-names></name><name name-style="western"><surname>Stadelmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>W</given-names></name></person-group>. <article-title>Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons</article-title>. <source>Acta Neuropathol</source>. (<year>2013</year>) <volume>125</volume>:<fpage>595</fpage>&#8211;<lpage>608</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-013-1082-0</pub-id><pub-id pub-id-type="pmid">23354834</pub-id><pub-id pub-id-type="pmcid">PMC3611040</pub-id></mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zrzavy</surname><given-names>T</given-names></name><name name-style="western"><surname>Hametner</surname><given-names>S</given-names></name><name name-style="western"><surname>Wimmer</surname><given-names>I</given-names></name><name name-style="western"><surname>Butovsky</surname><given-names>O</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>HL</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Loss of &#8216;homeostatic&#8217; microglia and patterns of their activation in active multiple sclerosis</article-title>. <source>Brain</source>. (<year>2017</year>) <volume>140</volume>:<page-range>1900&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awx113</pub-id><pub-id pub-id-type="pmcid">PMC6057548</pub-id><pub-id pub-id-type="pmid">28541408</pub-id></mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bevan</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>L</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>LM</given-names></name><name name-style="western"><surname>Rees</surname><given-names>MI</given-names></name><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Meningeal inflammation and cortical demyelination in acute multiple sclerosis</article-title>. <source>Ann Neurol</source>. (<year>2018</year>) <volume>84</volume>:<page-range>829&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.25365</pub-id><pub-id pub-id-type="pmid">30362156</pub-id></mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shemer</surname><given-names>A</given-names></name><name name-style="western"><surname>Levy-Efrati</surname><given-names>L</given-names></name><name name-style="western"><surname>Gross</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Engel</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Microglial MHC class II is dispensable for experimental autoimmune encephalomyelitis and cuprizone-induced demyelination</article-title>. <source>Eur J Immunol</source>. (<year>2018</year>) <volume>48</volume>:<page-range>1308&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.201847540</pub-id><pub-id pub-id-type="pmid">29697861</pub-id></mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blomgren</surname><given-names>K</given-names></name><name name-style="western"><surname>Hagberg</surname><given-names>H</given-names></name></person-group>. <article-title>Free radicals, mitochondria, and hypoxia-ischemia in the developing brain</article-title>. <source>Free Radic Biol Med</source>. (<year>2006</year>) <volume>40</volume>:<page-range>388&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2005.08.040</pub-id><pub-id pub-id-type="pmid">16443153</pub-id></mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rochfort</surname><given-names>KD</given-names></name><name name-style="western"><surname>Collins</surname><given-names>LE</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>RP</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>PM</given-names></name></person-group>. <article-title>Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation: consequences for interendothelial adherens and tight junctions</article-title>. <source>PLoS One</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>e101815</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0101815</pub-id><pub-id pub-id-type="pmid">24992685</pub-id><pub-id pub-id-type="pmcid">PMC4081725</pub-id></mixed-citation></ref><ref id="B241"><label>241</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>A</given-names></name><name name-style="western"><surname>Goncalves da Silva</surname><given-names>A</given-names></name><name name-style="western"><surname>Nuttall</surname><given-names>RK</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>DR</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>SD</given-names></name><name name-style="western"><surname>Rivest</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization</article-title>. <source>FASEB J</source>. (<year>2005</year>) <volume>19</volume>:<page-range>1668&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1096/fj.04-2030fje</pub-id><pub-id pub-id-type="pmid">16081501</pub-id></mixed-citation></ref><ref id="B242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Horssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Vos</surname><given-names>CM</given-names></name><name name-style="western"><surname>Admiraal</surname><given-names>L</given-names></name><name name-style="western"><surname>van Haastert</surname><given-names>ES</given-names></name><name name-style="western"><surname>Montagne</surname><given-names>L</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions</article-title>. <source>Neuropathol Appl Neurobiol</source>. (<year>2006</year>) <volume>32</volume>:<page-range>585&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2990.2006.00766.x</pub-id><pub-id pub-id-type="pmid">17083473</pub-id></mixed-citation></ref><ref id="B243"><label>243</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fakhoury</surname><given-names>M</given-names></name></person-group>. <article-title>Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases</article-title>. <source>Neurodegener Dis</source>. (<year>2015</year>) <volume>15</volume>:<page-range>63&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1159/000369933</pub-id><pub-id pub-id-type="pmid">25591815</pub-id></mixed-citation></ref><ref id="B244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>EC</given-names></name><name name-style="western"><surname>Hunot</surname><given-names>S</given-names></name></person-group>. <article-title>Neuroinflammation in Parkinson&#8217;s disease: a target for neuroprotection</article-title>? <source>Lancet Neurol</source>. (<year>2009</year>) <volume>8</volume>:<page-range>382&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(09)70062-6</pub-id><pub-id pub-id-type="pmid">19296921</pub-id></mixed-citation></ref><ref id="B245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venegas</surname><given-names>C</given-names></name><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name></person-group>. <article-title>Danger-associated molecular patterns in Alzheimer&#8217;s disease</article-title>. <source>J Leukoc Biol</source>. (<year>2017</year>) <volume>101</volume>:<fpage>87</fpage>&#8211;<lpage>98</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1189/jlb.3MR0416-204R</pub-id><pub-id pub-id-type="pmid">28049142</pub-id></mixed-citation></ref><ref id="B246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greter</surname><given-names>M</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>FL</given-names></name><name name-style="western"><surname>Lemos</surname><given-names>MP</given-names></name><name name-style="western"><surname>Odermatt</surname><given-names>BM</given-names></name><name name-style="western"><surname>Goebels</surname><given-names>N</given-names></name><name name-style="western"><surname>Laufer</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis</article-title>. <source>Nat Med</source>. (<year>2005</year>) <volume>11</volume>:<page-range>328&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nm1197</pub-id><pub-id pub-id-type="pmid">15735653</pub-id></mixed-citation></ref><ref id="B247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhlmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Lingfeld</surname><given-names>G</given-names></name><name name-style="western"><surname>Bitsch</surname><given-names>A</given-names></name><name name-style="western"><surname>Schuchardt</surname><given-names>J</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>W</given-names></name></person-group>. <article-title>Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time</article-title>. <source>Brain</source>. (<year>2002</year>) <volume>125</volume>:<page-range>2202&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awf235</pub-id><pub-id pub-id-type="pmid">12244078</pub-id></mixed-citation></ref><ref id="B248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></name><name name-style="western"><surname>Perry</surname><given-names>VH</given-names></name></person-group>. <article-title>Microglial physiology: unique stimuli, specialized responses</article-title>. <source>Annu Rev Immunol</source>. (<year>2009</year>) <volume>27</volume>:<page-range>119&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132528</pub-id><pub-id pub-id-type="pmid">19302036</pub-id></mixed-citation></ref><ref id="B249"><label>249</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siffrin</surname><given-names>V</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>AU</given-names></name><name name-style="western"><surname>Radbruch</surname><given-names>H</given-names></name><name name-style="western"><surname>Herz</surname><given-names>J</given-names></name><name name-style="western"><surname>Boldakowa</surname><given-names>N</given-names></name><name name-style="western"><surname>Leuenberger</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Differential immune cell dynamics in the CNS cause CD4+ T cell compartmentalization</article-title>. <source>Brain</source>. (<year>2009</year>) <volume>132</volume>:<page-range>1247&#8211;58</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awn354</pub-id><pub-id pub-id-type="pmid">19179377</pub-id></mixed-citation></ref><ref id="B250"><label>250</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kivisakk</surname><given-names>P</given-names></name><name name-style="western"><surname>Mahad</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>MK</given-names></name><name name-style="western"><surname>Trebst</surname><given-names>C</given-names></name><name name-style="western"><surname>Tucky</surname><given-names>B</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2003</year>) <volume>100</volume>:<page-range>8389&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1433000100</pub-id><pub-id pub-id-type="pmcid">PMC166239</pub-id><pub-id pub-id-type="pmid">12829791</pub-id></mixed-citation></ref><ref id="B251"><label>251</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>HL</given-names></name></person-group>. <article-title>Role of microglia in neurological disorders and their potentials as a therapeutic target</article-title>. <source>Mol Neurobiol</source>. (<year>2017</year>) <volume>54</volume>:<page-range>7567&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12035-016-0245-0</pub-id><pub-id pub-id-type="pmid">27830532</pub-id></mixed-citation></ref><ref id="B252"><label>252</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>H</given-names></name><name name-style="western"><surname>Kotter</surname><given-names>MR</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>RJ</given-names></name></person-group>. <article-title>Debris clearance by microglia: an essential link between degeneration and regeneration</article-title>. <source>Brain</source>. (<year>2009</year>) <volume>132</volume>:<page-range>288&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awn109</pub-id><pub-id pub-id-type="pmcid">PMC2640215</pub-id><pub-id pub-id-type="pmid">18567623</pub-id></mixed-citation></ref><ref id="B253"><label>253</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lampron</surname><given-names>A</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>A</given-names></name><name name-style="western"><surname>Laflamme</surname><given-names>N</given-names></name><name name-style="western"><surname>Prefontaine</surname><given-names>P</given-names></name><name name-style="western"><surname>Plante</surname><given-names>MM</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Inefficient clearance of myelin debris by microglia impairs remyelinating processes</article-title>. <source>J Exp Med</source>. (<year>2015</year>) <volume>212</volume>:<page-range>481&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20141656</pub-id><pub-id pub-id-type="pmcid">PMC4387282</pub-id><pub-id pub-id-type="pmid">25779633</pub-id></mixed-citation></ref><ref id="B254"><label>254</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>SA</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>B</given-names></name><name name-style="western"><surname>Akpinarli</surname><given-names>A</given-names></name><name name-style="western"><surname>Kammertoens</surname><given-names>T</given-names></name><name name-style="western"><surname>Nassenstein</surname><given-names>C</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis</article-title>. <source>J Immunol</source>. (<year>2009</year>) <volume>182</volume>:<page-range>3979&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0801218</pub-id><pub-id pub-id-type="pmid">19299695</pub-id></mixed-citation></ref><ref id="B255"><label>255</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratchford</surname><given-names>JN</given-names></name><name name-style="western"><surname>Endres</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Hammoud</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pomper</surname><given-names>MG</given-names></name><name name-style="western"><surname>Shiee</surname><given-names>N</given-names></name><name name-style="western"><surname>McGready</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Decreased microglial activation in MS patients treated with glatiramer acetate</article-title>. <source>J Neurol</source>. (<year>2012</year>) <volume>259</volume>:<page-range>1199&#8211;205</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00415-011-6337-x</pub-id><pub-id pub-id-type="pmcid">PMC3478150</pub-id><pub-id pub-id-type="pmid">22160466</pub-id></mixed-citation></ref><ref id="B256"><label>256</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kornberg</surname><given-names>MD</given-names></name><name name-style="western"><surname>Smith</surname><given-names>MD</given-names></name><name name-style="western"><surname>Shirazi</surname><given-names>HA</given-names></name><name name-style="western"><surname>Calabresi</surname><given-names>PA</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>PM</given-names></name></person-group>. <article-title>Bryostatin-1 alleviates experimental multiple sclerosis</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2018</year>) <volume>115</volume>:<page-range>2186&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1719902115</pub-id><pub-id pub-id-type="pmcid">PMC5834718</pub-id><pub-id pub-id-type="pmid">29440425</pub-id></mixed-citation></ref><ref id="B257"><label>257</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djedovic</surname><given-names>N</given-names></name><name name-style="western"><surname>Stanisavljevic</surname><given-names>S</given-names></name><name name-style="western"><surname>Jevtic</surname><given-names>B</given-names></name><name name-style="western"><surname>Momcilovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Lavrnja</surname><given-names>I</given-names></name><name name-style="western"><surname>Miljkovic</surname><given-names>D</given-names></name></person-group>. <article-title>Anti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut</article-title>. <source>BioMed Pharmacother</source>. (<year>2017</year>) <volume>96</volume>:<fpage>78</fpage>&#8211;<lpage>85</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.110</pub-id><pub-id pub-id-type="pmid">28965011</pub-id></mixed-citation></ref><ref id="B258"><label>258</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>WW</given-names></name><name name-style="western"><surname>Setzu</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>RJ</given-names></name></person-group>. <article-title>Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination</article-title>. <source>J Neuroimmunol</source>. (<year>2005</year>) <volume>158</volume>:<fpage>58</fpage>&#8211;<lpage>66</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2004.08.011</pub-id><pub-id pub-id-type="pmid">15589038</pub-id></mixed-citation></ref><ref id="B259"><label>259</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Imagama</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohgomori</surname><given-names>T</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>K</given-names></name><name name-style="western"><surname>Uchimura</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Minocycline selectively inhibits M1 polarization of microglia</article-title>. <source>Cell Death Dis</source>. (<year>2013</year>) <volume>4</volume>:<elocation-id>e525</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1038/cddis.2013.54</pub-id><pub-id pub-id-type="pmid">23470532</pub-id><pub-id pub-id-type="pmcid">PMC3613832</pub-id></mixed-citation></ref><ref id="B260"><label>260</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miron</surname><given-names>VE</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>JW</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ruckh</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shadrach</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination</article-title>. <source>Nat Neurosci</source>. (<year>2013</year>) <volume>16</volume>:<page-range>1211&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nn.3469</pub-id><pub-id pub-id-type="pmcid">PMC3977045</pub-id><pub-id pub-id-type="pmid">23872599</pub-id></mixed-citation></ref><ref id="B261"><label>261</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YL</given-names></name><name name-style="western"><surname>Li</surname><given-names>AH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HL</given-names></name><etal/></person-group>. <article-title>Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons</article-title>. <source>J Neuroinflammation</source>. (<year>2014</year>) <volume>11</volume>:<fpage>7</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1742-2094-11-7</pub-id><pub-id pub-id-type="pmid">24405660</pub-id><pub-id pub-id-type="pmcid">PMC3896825</pub-id></mixed-citation></ref><ref id="B262"><label>262</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sloka</surname><given-names>S</given-names></name><name name-style="western"><surname>Metz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Hader</surname><given-names>W</given-names></name><name name-style="western"><surname>Starreveld</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yong</surname><given-names>VW</given-names></name></person-group>. <article-title>Reduction of microglial activity in a model of multiple sclerosis by dipyridamole</article-title>. <source>J Neuroinflammation</source>. (<year>2013</year>) <volume>10</volume>:<fpage>89</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1742-2094-10-89</pub-id><pub-id pub-id-type="pmid">23866809</pub-id><pub-id pub-id-type="pmcid">PMC3724584</pub-id></mixed-citation></ref><ref id="B263"><label>263</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Metz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Hader</surname><given-names>W</given-names></name><name name-style="western"><surname>Starreveld</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yong</surname><given-names>VW</given-names></name><etal/></person-group>. <article-title>Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke</article-title>. <source>Brain Behav Immun</source>. (<year>2014</year>) <volume>40</volume>:<page-range>131&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbi.2014.03.003</pub-id><pub-id pub-id-type="pmid">24632338</pub-id></mixed-citation></ref><ref id="B264"><label>264</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The IFNB Multiple Sclerosis Study Group</collab></person-group><article-title>Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group</article-title>. <source>Neurology</source>. (<year>1993</year>) <volume>43</volume>:<page-range>655&#8211;61</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.43.4.655</pub-id><pub-id pub-id-type="pmid">8469318</pub-id></mixed-citation></ref><ref id="B265"><label>265</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>LD</given-names></name><name name-style="western"><surname>The IFNB Multiple Sclerosis Study Group</surname></name><etal/></person-group>. <article-title>Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)</article-title>. <source>Ann Neurol</source>. (<year>1996</year>) <volume>39</volume>:<page-range>285&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.410390304</pub-id><pub-id pub-id-type="pmid">8602746</pub-id></mixed-citation></ref><ref id="B266"><label>266</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>PRISMS Study Group</collab></person-group><article-title>Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group</article-title>. <source>Lancet</source>. (<year>1998</year>) <volume>352</volume>:<page-range>1498&#8211;504</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1433000100</pub-id><pub-id pub-id-type="pmid">9820297</pub-id></mixed-citation></ref><ref id="B267"><label>267</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>PW</given-names></name><name name-style="western"><surname>Havrdova</surname><given-names>E</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name><etal/></person-group>. <article-title>A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2006</year>) <volume>354</volume>:<fpage>899</fpage>&#8211;<lpage>910</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa044397</pub-id><pub-id pub-id-type="pmid">16510744</pub-id></mixed-citation></ref><ref id="B268"><label>268</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>BO</given-names></name><name name-style="western"><surname>Montalban</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2010</year>) <volume>362</volume>:<page-range>402&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa0907839</pub-id><pub-id pub-id-type="pmid">20089954</pub-id></mixed-citation></ref><ref id="B269"><label>269</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Radue</surname><given-names>EW</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>P</given-names></name><name name-style="western"><surname>Polman</surname><given-names>C</given-names></name><name name-style="western"><surname>Hohlfeld</surname><given-names>R</given-names></name><name name-style="western"><surname>Calabresi</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2010</year>) <volume>362</volume>:<fpage>387</fpage>&#8211;<lpage>401</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa0909494</pub-id><pub-id pub-id-type="pmid">20089952</pub-id></mixed-citation></ref><ref id="B270"><label>270</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cross</surname><given-names>A</given-names></name><name name-style="western"><surname>Riley</surname><given-names>C</given-names></name></person-group>. <article-title>Treatment of multiple sclerosis</article-title>. <source>Continuum (Minneap Minn)</source>. (<year>2022</year>) <volume>28</volume>:<page-range>1025&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/CON.0000000000001170</pub-id><pub-id pub-id-type="pmid">35938656</pub-id></mixed-citation></ref><ref id="B271"><label>271</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Cree</surname><given-names>BAC</given-names></name></person-group>. <article-title>Treatment of multiple sclerosis: A review</article-title>. <source>Am J Med</source>. (<year>2020</year>) <volume>133</volume>:<fpage>1380</fpage>&#8211;<lpage>1390.e2</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.amjmed.2020.05.049</pub-id><pub-id pub-id-type="pmid">32682869</pub-id><pub-id pub-id-type="pmcid">PMC7704606</pub-id></mixed-citation></ref><ref id="B272"><label>272</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Fox</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Burcklen</surname><given-names>M</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Havrdova</surname><given-names>EK</given-names></name><name name-style="western"><surname>Hennessy</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial</article-title>. <source>JAMA Neurol</source>. (<year>2021</year>) <volume>78</volume>:<page-range>558&#8211;67</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jamaneurol.2021.0405</pub-id><pub-id pub-id-type="pmcid">PMC8008435</pub-id><pub-id pub-id-type="pmid">33779698</pub-id></mixed-citation></ref><ref id="B273"><label>273</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Confavreux</surname><given-names>C</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>P</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Miller</surname><given-names>AE</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>TP</given-names></name><etal/></person-group>. <article-title>Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source>Lancet Neurol</source>. (<year>2014</year>) <volume>13</volume>:<page-range>247&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(13)70308-9</pub-id><pub-id pub-id-type="pmid">24461574</pub-id></mixed-citation></ref><ref id="B274"><label>274</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>P</given-names></name><name name-style="western"><surname>Wolinsky</surname><given-names>JS</given-names></name><name name-style="western"><surname>Confavreux</surname><given-names>C</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>TP</given-names></name><etal/></person-group>. <article-title>Randomized trial of oral teriflunomide for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2011</year>) <volume>365</volume>:<page-range>1293&#8211;303</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1014656</pub-id><pub-id pub-id-type="pmid">21991951</pub-id></mixed-citation></ref><ref id="B275"><label>275</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AE</given-names></name><name name-style="western"><surname>Wolinsky</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>TP</given-names></name><etal/></person-group>. <article-title>Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source>Lancet Neurol</source>. (<year>2014</year>) <volume>13</volume>:<page-range>977&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70191-7</pub-id><pub-id pub-id-type="pmid">25192851</pub-id></mixed-citation></ref><ref id="B276"><label>276</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubey</surname><given-names>D</given-names></name><name name-style="western"><surname>Kieseier</surname><given-names>BC</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B</given-names></name><name name-style="western"><surname>Warnke</surname><given-names>C</given-names></name><name name-style="western"><surname>Menge</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety</article-title>. <source>Expert Rev Neurother</source>. (<year>2015</year>) <volume>15</volume>:<page-range>339&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/14737175.2015.1025755</pub-id><pub-id pub-id-type="pmid">25800129</pub-id></mixed-citation></ref><ref id="B277"><label>277</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warnke</surname><given-names>C</given-names></name><name name-style="western"><surname>Kieseier</surname><given-names>BC</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B</given-names></name><name name-style="western"><surname>Warnke</surname><given-names>C</given-names></name><name name-style="western"><surname>Menge</surname><given-names>T</given-names></name></person-group>. <article-title>Identification of targets and new developments in the treatment of multiple sclerosis&#8211;focus on cladribine</article-title>. <source>Drug Des Devel Ther</source>. (<year>2010</year>) <volume>4</volume>:<page-range>117&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2147/dddt.s6627</pub-id><pub-id pub-id-type="pmcid">PMC2915536</pub-id><pub-id pub-id-type="pmid">20689698</pub-id></mixed-citation></ref><ref id="B278"><label>278</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brousil</surname><given-names>JA</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Schlein</surname><given-names>AL</given-names></name></person-group>. <article-title>Cladribine: an investigational immunomodulatory agent for multiple sclerosis</article-title>. <source>Ann Pharmacother</source>. (<year>2006</year>) <volume>40</volume>:<page-range>1814&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1345/aph.1H037</pub-id><pub-id pub-id-type="pmid">16985095</pub-id></mixed-citation></ref><ref id="B279"><label>279</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wiendl</surname><given-names>H</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Stuve</surname><given-names>O</given-names></name><name name-style="western"><surname>Kieseier</surname><given-names>BC</given-names></name><etal/></person-group>. <article-title>Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial</article-title>. <source>Lancet</source>. (<year>2012</year>) <volume>380</volume>:<page-range>1819&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61769-3</pub-id><pub-id pub-id-type="pmid">23122652</pub-id></mixed-citation></ref><ref id="B280"><label>280</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coles</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Twyman</surname><given-names>CL</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Confavreux</surname><given-names>C</given-names></name><name name-style="western"><surname>Fox</surname><given-names>EJ</given-names></name><etal/></person-group>. <article-title>Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial</article-title>. <source>Lancet</source>. (<year>2012</year>) <volume>380</volume>:<page-range>1829&#8211;39</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61768-1</pub-id><pub-id pub-id-type="pmid">23122650</pub-id></mixed-citation></ref><ref id="B281"><label>281</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Aktas</surname><given-names>O</given-names></name><name name-style="western"><surname>Boyko</surname><given-names>AN</given-names></name></person-group>. <article-title>Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis</article-title>. <source>Mult Scler</source>. (<year>2015</year>) <volume>21</volume>:<fpage>22</fpage>&#8211;<lpage>34</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1352458514549398</pub-id><pub-id pub-id-type="pmid">25344374</pub-id><pub-id pub-id-type="pmcid">PMC4361497</pub-id></mixed-citation></ref><ref id="B282"><label>282</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Munster</surname><given-names>CE</given-names></name><name name-style="western"><surname>Uitdehaag</surname><given-names>BM</given-names></name></person-group>. <article-title>Outcome measures in clinical trials for multiple sclerosis</article-title>. <source>CNS Drugs</source>. (<year>2017</year>) <volume>31</volume>:<page-range>217&#8211;36</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s40263-017-0412-5</pub-id><pub-id pub-id-type="pmcid">PMC5336539</pub-id><pub-id pub-id-type="pmid">28185158</pub-id></mixed-citation></ref><ref id="B283"><label>283</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Twyman</surname><given-names>CL</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Confavreux</surname><given-names>C</given-names></name><name name-style="western"><surname>Fox</surname><given-names>EJ</given-names></name><etal/></person-group>. <article-title>A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS</article-title>. <source>Neurology</source>. (<year>2011</year>) <volume>77</volume>:<page-range>1551&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.0b013e318233b240</pub-id><pub-id pub-id-type="pmid">21975206</pub-id></mixed-citation></ref><ref id="B284"><label>284</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hommes</surname><given-names>OR</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Fazekas</surname><given-names>F</given-names></name><name name-style="western"><surname>Enriquez</surname><given-names>MM</given-names></name><name name-style="western"><surname>Koelmel</surname><given-names>HW</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial</article-title>. <source>Lancet</source>. (<year>2004</year>) <volume>364</volume>:<page-range>1149&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(04)17101-8</pub-id><pub-id pub-id-type="pmid">15451222</pub-id></mixed-citation></ref><ref id="B285"><label>285</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zajicek</surname><given-names>J</given-names></name><name name-style="western"><surname>Ball</surname><given-names>S</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D</given-names></name><name name-style="western"><surname>Vickery</surname><given-names>J</given-names></name><name name-style="western"><surname>Nunn</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial</article-title>. <source>Lancet Neurol</source>. (<year>2013</year>) <volume>12</volume>:<page-range>857&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(13)70159-5</pub-id><pub-id pub-id-type="pmcid">PMC3744749</pub-id><pub-id pub-id-type="pmid">23856559</pub-id></mixed-citation></ref><ref id="B286"><label>286</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>GP</given-names></name><name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name></person-group>. <article-title>Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group</article-title>. <source>Neurology</source>. (<year>2000</year>) <volume>54</volume>:<page-range>1145&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.54.5.1145</pub-id><pub-id pub-id-type="pmid">10720289</pub-id></mixed-citation></ref><ref id="B287"><label>287</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Mantia</surname><given-names>L</given-names></name><name name-style="western"><surname>Vacchi</surname><given-names>L</given-names></name><name name-style="western"><surname>Rovaris</surname><given-names>M</given-names></name><name name-style="western"><surname>Di Pietrantonj</surname><given-names>C</given-names></name><name name-style="western"><surname>Ebers</surname><given-names>G</given-names></name><name name-style="western"><surname>Fredrikson</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Interferon beta for secondary progressive multiple sclerosis: a systematic review</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2013</year>) <volume>84</volume>:<page-range>420&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jnnp-2012-303291</pub-id><pub-id pub-id-type="pmid">22952326</pub-id></mixed-citation></ref><ref id="B288"><label>288</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name><name name-style="western"><surname>Leary</surname><given-names>SM</given-names></name></person-group>. <article-title>Primary-progressive multiple sclerosis</article-title>. <source>Lancet Neurol</source>. (<year>2007</year>) <volume>6</volume>:<page-range>903&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(07)70243-0</pub-id><pub-id pub-id-type="pmid">17884680</pub-id></mixed-citation></ref><ref id="B289"><label>289</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Gonsette</surname><given-names>R</given-names></name><name name-style="western"><surname>Konig</surname><given-names>N</given-names></name><name name-style="western"><surname>Kwiecinski</surname><given-names>H</given-names></name><name name-style="western"><surname>Guseo</surname><given-names>A</given-names></name><name name-style="western"><surname>Morrissey</surname><given-names>SP</given-names></name><etal/></person-group>. <article-title>Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial</article-title>. <source>Lancet</source>. (<year>2002</year>) <volume>360</volume>:<page-range>2018&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(02)12023-X</pub-id><pub-id pub-id-type="pmid">12504397</pub-id></mixed-citation></ref><ref id="B290"><label>290</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group</collab></person-group>. <article-title>Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results</article-title>. <source>Neurology</source>. (<year>2001</year>) <volume>56</volume>:<page-range>1496&#8211;504</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.56.11.1496</pub-id><pub-id pub-id-type="pmid">11402106</pub-id></mixed-citation></ref><ref id="B291"><label>291</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lublin</surname><given-names>F</given-names></name><name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Cree</surname><given-names>BAC</given-names></name><name name-style="western"><surname>Wolinsky</surname><given-names>JS</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. (<year>2016</year>) <volume>387</volume>:<page-range>1075&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(15)01314-8</pub-id><pub-id pub-id-type="pmid">26827074</pub-id></mixed-citation></ref><ref id="B292"><label>292</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapoor</surname><given-names>R</given-names></name><name name-style="western"><surname>Ho</surname><given-names>PR</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>N</given-names></name><name name-style="western"><surname>Chang</surname><given-names>I</given-names></name><name name-style="western"><surname>Deykin</surname><given-names>A</given-names></name><name name-style="western"><surname>Forrestal</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension</article-title>. <source>Lancet Neurol</source>. (<year>2018</year>) <volume>17</volume>:<page-range>405&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30069-3</pub-id><pub-id pub-id-type="pmid">29545067</pub-id></mixed-citation></ref><ref id="B293"><label>293</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akaishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>I</given-names></name></person-group>. <article-title>Efficiency of antibody therapy in demyelinating diseases</article-title>. <source>Int Immunol</source>. (<year>2017</year>) <volume>29</volume>:<page-range>327&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/intimm/dxx037</pub-id><pub-id pub-id-type="pmid">28910968</pub-id></mixed-citation></ref><ref id="B294"><label>294</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ho</surname><given-names>PR</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>N</given-names></name><name name-style="western"><surname>Chang</surname><given-names>I</given-names></name><name name-style="western"><surname>Deykin</surname><given-names>A</given-names></name><name name-style="western"><surname>Forrestal</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>376</volume>:<page-range>221&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1601277</pub-id><pub-id pub-id-type="pmid">28002679</pub-id></mixed-citation></ref><ref id="B295"><label>295</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Ofatumumab versus teriflunomide in multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>546&#8211;57</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1917246</pub-id><pub-id pub-id-type="pmid">32757523</pub-id></mixed-citation></ref><ref id="B296"><label>296</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>L</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Correale</surname><given-names>J</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>PK</given-names></name><etal/></person-group>. <article-title>Ublituximab versus teriflunomide in relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2022</year>) <volume>387</volume>:<page-range>704&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2201904</pub-id><pub-id pub-id-type="pmid">36001711</pub-id></mixed-citation></ref><ref id="B297"><label>297</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clifford</surname><given-names>DB</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>DM</given-names></name><name name-style="western"><surname>Arendt</surname><given-names>G</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A</given-names></name></person-group>. <article-title>Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases</article-title>. <source>Lancet Neurol</source>. (<year>2010</year>) <volume>9</volume>:<page-range>438&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(10)70028-4</pub-id><pub-id pub-id-type="pmid">20298967</pub-id></mixed-citation></ref><ref id="B298"><label>298</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloomgren</surname><given-names>G</given-names></name><name name-style="western"><surname>Richman</surname><given-names>S</given-names></name><name name-style="western"><surname>Hotermans</surname><given-names>C</given-names></name><name name-style="western"><surname>Subramanyam</surname><given-names>M</given-names></name><name name-style="western"><surname>Goelz</surname><given-names>S</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Risk of natalizumab-associated progressive multifocal leukoencephalopathy</article-title>. <source>N Engl J Med</source>. (<year>2012</year>) <volume>366</volume>:<page-range>1870&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1107829</pub-id><pub-id pub-id-type="pmid">22591293</pub-id></mixed-citation></ref><ref id="B299"><label>299</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghadiri</surname><given-names>M</given-names></name><name name-style="western"><surname>Fitz-Gerald</surname><given-names>L</given-names></name><name name-style="western"><surname>Rezk</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Nyirenda</surname><given-names>M</given-names></name><name name-style="western"><surname>Haegert</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod</article-title>. <source>Mult Scler</source>. (<year>2017</year>) <volume>23</volume>:<page-range>1225&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1352458517713147</pub-id><pub-id pub-id-type="pmid">28749311</pub-id></mixed-citation></ref><ref id="B300"><label>300</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Cree</surname><given-names>BAC</given-names></name><name name-style="western"><surname>Fox</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study</article-title>. <source>Lancet</source>. (<year>2018</year>) <volume>391</volume>:<page-range>1263&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(18)30475-6</pub-id><pub-id pub-id-type="pmid">29576505</pub-id></mixed-citation></ref><ref id="B301"><label>301</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mix</surname><given-names>E</given-names></name><name name-style="western"><surname>Meyer-Rienecker</surname><given-names>H</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Zettl</surname><given-names>UK</given-names></name></person-group>. <article-title>Animal models of multiple sclerosis&#8211;potentials and limitations</article-title>. <source>Prog Neurobiol</source>. (<year>2010</year>) <volume>92</volume>:<fpage>386</fpage>&#8211;<lpage>404</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.pneurobio.2010.06.005</pub-id><pub-id pub-id-type="pmid">20558237</pub-id><pub-id pub-id-type="pmcid">PMC7117060</pub-id></mixed-citation></ref><ref id="B302"><label>302</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanabria-Castro</surname><given-names>A</given-names></name><name name-style="western"><surname>Flores-Diaz</surname><given-names>M</given-names></name><name name-style="western"><surname>Alape-Giron</surname><given-names>A</given-names></name></person-group>. <article-title>Biological models in multiple sclerosis</article-title>. <source>J Neurosci Res</source>. (<year>2020</year>) <volume>98</volume>:<fpage>491</fpage>&#8211;<lpage>508</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jnr.24528</pub-id><pub-id pub-id-type="pmid">31571267</pub-id></mixed-citation></ref><ref id="B303"><label>303</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjelobaba</surname><given-names>I</given-names></name><name name-style="western"><surname>Begovic-Kupresanin</surname><given-names>V</given-names></name><name name-style="western"><surname>Pekovic</surname><given-names>S</given-names></name><name name-style="western"><surname>Lavrnja</surname><given-names>I</given-names></name></person-group>. <article-title>Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis</article-title>. <source>J Neurosci Res</source>. (<year>2018</year>) <volume>96</volume>:<page-range>1021&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jnr.24224</pub-id><pub-id pub-id-type="pmid">29446144</pub-id></mixed-citation></ref><ref id="B304"><label>304</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>D</given-names></name><name name-style="western"><surname>Amor</surname><given-names>S</given-names></name></person-group>. <article-title>Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely</article-title>. <source>Mult Scler Relat Disord</source>. (<year>2014</year>) <volume>3</volume>:<page-range>555&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.msard.2014.05.002</pub-id><pub-id pub-id-type="pmid">26265267</pub-id></mixed-citation></ref><ref id="B305"><label>305</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stromnes</surname><given-names>IM</given-names></name><name name-style="western"><surname>Goverman</surname><given-names>JM</given-names></name></person-group>. <article-title>Active induction of experimental allergic encephalomyelitis</article-title>. <source>Nat Protoc</source>. (<year>2006</year>) <volume>1</volume>:<page-range>1810&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nprot.2006.285</pub-id><pub-id pub-id-type="pmid">17487163</pub-id></mixed-citation></ref><ref id="B306"><label>306</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stromnes</surname><given-names>IM</given-names></name><name name-style="western"><surname>Goverman</surname><given-names>JM</given-names></name></person-group>. <article-title>Passive induction of experimental allergic encephalomyelitis</article-title>. <source>Nat Protoc</source>. (<year>2006</year>) <volume>1</volume>:<page-range>1952&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nprot.2006.284</pub-id><pub-id pub-id-type="pmid">17487182</pub-id></mixed-citation></ref><ref id="B307"><label>307</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kipp</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Star</surname><given-names>B</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>DY</given-names></name><name name-style="western"><surname>Puentes</surname><given-names>F</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>P</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Experimental <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> models of multiple sclerosis: EAE and beyond</article-title>. <source>Mult Scler Relat Disord</source>. (<year>2012</year>) <volume>1</volume>:<fpage>15</fpage>&#8211;<lpage>28</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.msard.2011.09.002</pub-id><pub-id pub-id-type="pmid">25876447</pub-id></mixed-citation></ref><ref id="B308"><label>308</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Einstein</surname><given-names>ER</given-names></name><name name-style="western"><surname>Dalal</surname><given-names>KB</given-names></name><name name-style="western"><surname>Csejtey</surname><given-names>J</given-names></name></person-group>. <article-title>Increased protease activity and changes in basic proteins and lipids in multiple sclerosis plaques</article-title>. <source>J Neurol Sci</source>. (<year>1970</year>) <volume>11</volume>:<page-range>109&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0022-510X(70)90121-8</pub-id><pub-id pub-id-type="pmid">5456542</pub-id></mixed-citation></ref><ref id="B309"><label>309</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laatsch</surname><given-names>RH</given-names></name><name name-style="western"><surname>Kies</surname><given-names>MW</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S</given-names></name><name name-style="western"><surname>Alvord</surname><given-names>EC</given-names></name></person-group>. <article-title>The encephalomyelitic activity of myelin isolated by ultracentrifugation</article-title>. <source>J Exp Med</source>. (<year>1962</year>) <volume>115</volume>:<page-range>777&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.115.4.777</pub-id><pub-id pub-id-type="pmcid">PMC2137521</pub-id><pub-id pub-id-type="pmid">14461228</pub-id></mixed-citation></ref><ref id="B310"><label>310</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuohy</surname><given-names>VK</given-names></name><name name-style="western"><surname>Kies</surname><given-names>MW</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S</given-names></name><name name-style="western"><surname>Alvord</surname><given-names>EC</given-names></name></person-group>. <article-title>A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis</article-title>. <source>J Immunol</source>. (<year>1988</year>) <volume>141</volume>:<page-range>1126&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.141.4.1126</pub-id><pub-id pub-id-type="pmid">2456341</pub-id></mixed-citation></ref><ref id="B311"><label>311</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linthicum</surname><given-names>DS</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>L</given-names></name><name name-style="western"><surname>Carnegie</surname><given-names>PR</given-names></name></person-group>. <article-title>Detection of antibodies to myelin basic protein by solid-phase radioimmunoassay with [125I]protein A</article-title>. <source>J Neuroimmunol</source>. (<year>1981</year>) <volume>1</volume>:<fpage>17</fpage>&#8211;<lpage>26</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0165-5728(81)90004-7</pub-id><pub-id pub-id-type="pmid">6173394</pub-id></mixed-citation></ref><ref id="B312"><label>312</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didonna</surname><given-names>A</given-names></name></person-group>. <article-title>Preclinical models of multiple sclerosis: advantages and limitations towards better therapies</article-title>. <source>Curr Med Chem</source>. (<year>2016</year>) <volume>23</volume>:<page-range>1442&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/0929867323666160406121218</pub-id><pub-id pub-id-type="pmid">27048376</pub-id></mixed-citation></ref><ref id="B313"><label>313</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis</article-title>. <source>Schriftenr Neurol</source>. (<year>1983</year>) <volume>25</volume>:<fpage>1</fpage>&#8211;<lpage>135</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-3-642-45558-2</pub-id><pub-id pub-id-type="pmid">6605578</pub-id></mixed-citation></ref><ref id="B314"><label>314</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Constantinescu</surname><given-names>CS</given-names></name><name name-style="western"><surname>Farooqi</surname><given-names>N</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>K</given-names></name><name name-style="western"><surname>Gran</surname><given-names>B</given-names></name></person-group>. <article-title>Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)</article-title>. <source>Br J Pharmacol</source>. (<year>2011</year>) <volume>164</volume>:<page-range>1079&#8211;106</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01302.x</pub-id><pub-id pub-id-type="pmcid">PMC3229753</pub-id><pub-id pub-id-type="pmid">21371012</pub-id></mixed-citation></ref><ref id="B315"><label>315</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plant</surname><given-names>GT</given-names></name></person-group>. <article-title>Optic neuritis and multiple sclerosis</article-title>. <source>Curr Opin Neurol</source>. (<year>2008</year>) <volume>21</volume>:<fpage>16</fpage>&#8211;<lpage>21</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1097/WCO.0b013e3282f419ca</pub-id><pub-id pub-id-type="pmid">18180647</pub-id></mixed-citation></ref><ref id="B316"><label>316</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>C</given-names></name><name name-style="western"><surname>Strazielle</surname><given-names>N</given-names></name><name name-style="western"><surname>Ghersi-Egea</surname><given-names>JF</given-names></name></person-group>. <article-title>Brain leukocyte infiltration initiated by peripheral inflammation or experimental autoimmune encephalomyelitis occurs through pathways connected to the CSF-filled compartments of the forebrain and midbrain</article-title>. <source>J Neuroinflammation</source>. (<year>2012</year>) <volume>9</volume>:<fpage>187</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1742-2094-9-187</pub-id><pub-id pub-id-type="pmid">22870891</pub-id><pub-id pub-id-type="pmcid">PMC3458946</pub-id></mixed-citation></ref><ref id="B317"><label>317</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Linington</surname><given-names>C</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research</article-title>. <source>Brain</source>. (<year>2006</year>) <volume>129</volume>:<page-range>1953&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awl075</pub-id><pub-id pub-id-type="pmid">16632554</pub-id></mixed-citation></ref><ref id="B318"><label>318</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrero-Herranz</surname><given-names>E</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>LA</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Linker</surname><given-names>RA</given-names></name></person-group>. <article-title>Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis</article-title>. <source>Neurobiol Dis</source>. (<year>2008</year>) <volume>30</volume>:<page-range>162&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nbd.2008.01.001</pub-id><pub-id pub-id-type="pmid">18342527</pub-id></mixed-citation></ref><ref id="B319"><label>319</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pomeroy</surname><given-names>IM</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>PM</given-names></name><name name-style="western"><surname>Frank</surname><given-names>JA</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>EK</given-names></name><name name-style="western"><surname>Esiri</surname><given-names>MM</given-names></name></person-group>. <article-title>Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis</article-title>. <source>Brain</source>. (<year>2005</year>) <volume>128</volume>:<page-range>2713&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awh626</pub-id><pub-id pub-id-type="pmid">16150849</pub-id></mixed-citation></ref><ref id="B320"><label>320</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabira</surname><given-names>T</given-names></name><name name-style="western"><surname>Itoyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kuroiwa</surname><given-names>Y</given-names></name></person-group>. <article-title>Necessity of continuous antigenic stimulation by the locally retained antigens in chronic relapsing experimental allergic encephalomyelitis</article-title>. <source>J Neurol Sci</source>. (<year>1984</year>) <volume>66</volume>:<fpage>97</fpage>&#8211;<lpage>106</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0022-510X(84)90145-X</pub-id><pub-id pub-id-type="pmid">6084050</pub-id></mixed-citation></ref><ref id="B321"><label>321</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabira</surname><given-names>T</given-names></name><name name-style="western"><surname>Itoyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kuroiwa</surname><given-names>Y</given-names></name></person-group>. <article-title>The role of locally retained antigens in chronic relapsing experimental allergic encephalomyelitis in Guinea pigs</article-title>. <source>Prog Clin Biol Res</source>. (<year>1984</year>) <volume>146</volume>:<page-range>43&#8211;8</page-range>.<pub-id pub-id-type="pmid">6201912</pub-id></mixed-citation></ref><ref id="B322"><label>322</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bannerman</surname><given-names>PG</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S</given-names></name><name name-style="western"><surname>Morley</surname><given-names>M</given-names></name><name name-style="western"><surname>Bonnemann</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice</article-title>. <source>Brain</source>. (<year>2005</year>) <volume>128</volume>:<page-range>1877&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awh550</pub-id><pub-id pub-id-type="pmid">15901645</pub-id></mixed-citation></ref><ref id="B323"><label>323</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>DP</given-names></name><name name-style="western"><surname>Richards</surname><given-names>MH</given-names></name><name name-style="western"><surname>Miller</surname><given-names>SD</given-names></name></person-group>. <article-title>Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler&#8217;s virus-induced demyelinating disease</article-title>. <source>Methods Mol Biol</source>. (<year>2012</year>) <volume>900</volume>:<fpage>381</fpage>&#8211;<lpage>401</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-60761-720-4_19</pub-id><pub-id pub-id-type="pmid">22933080</pub-id><pub-id pub-id-type="pmcid">PMC3583382</pub-id></mixed-citation></ref><ref id="B324"><label>324</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsunoda</surname><given-names>I</given-names></name><name name-style="western"><surname>Fujinami</surname><given-names>RS</given-names></name></person-group>. <article-title>Neuropathogenesis of Theiler&#8217;s murine encephalomyelitis virus infection, an animal model for multiple sclerosis</article-title>. <source>J Neuroimmune Pharmacol</source>. (<year>2010</year>) <volume>5</volume>:<page-range>355&#8211;69</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11481-009-9179-x</pub-id><pub-id pub-id-type="pmcid">PMC2888670</pub-id><pub-id pub-id-type="pmid">19894121</pub-id></mixed-citation></ref><ref id="B325"><label>325</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haring</surname><given-names>J</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Mouse hepatitis virus</article-title>. <source>Curr Opin Microbiol</source>. (<year>2001</year>) <volume>4</volume>:<page-range>462&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1369-5274(00)00236-8</pub-id><pub-id pub-id-type="pmcid">PMC7129732</pub-id><pub-id pub-id-type="pmid">11495812</pub-id></mixed-citation></ref><ref id="B326"><label>326</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matas-Rico</surname><given-names>E</given-names></name><name name-style="western"><surname>Garcia-Diaz</surname><given-names>B</given-names></name><name name-style="western"><surname>Llebrez-Zayas</surname><given-names>P</given-names></name><name name-style="western"><surname>Lopez-Barroso</surname><given-names>D</given-names></name><name name-style="western"><surname>Santin</surname><given-names>L</given-names></name><name name-style="western"><surname>Pedraza</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus</article-title>. <source>Mol Cell Neurosci</source>. (<year>2008</year>) <volume>39</volume>:<page-range>342&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.mcn.2008.07.014</pub-id><pub-id pub-id-type="pmcid">PMC3667670</pub-id><pub-id pub-id-type="pmid">18708146</pub-id></mixed-citation></ref><ref id="B327"><label>327</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osorio-Querejeta</surname><given-names>I</given-names></name><name name-style="western"><surname>Saenz-Cuesta</surname><given-names>M</given-names></name><name name-style="western"><surname>Munoz-Culla</surname><given-names>M</given-names></name><name name-style="western"><surname>Otaegui</surname><given-names>D</given-names></name></person-group>. <article-title>Models for studying myelination, demyelination and remyelination</article-title>. <source>Neuromolecular Med</source>. (<year>2017</year>) <volume>19</volume>:<page-range>181&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12017-017-8442-1</pub-id><pub-id pub-id-type="pmid">28536996</pub-id></mixed-citation></ref><ref id="B328"><label>328</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magalon</surname><given-names>K</given-names></name><name name-style="western"><surname>Cantarella</surname><given-names>C</given-names></name><name name-style="western"><surname>Monti</surname><given-names>G</given-names></name><name name-style="western"><surname>Cayre</surname><given-names>M</given-names></name><name name-style="western"><surname>Durbec</surname><given-names>P</given-names></name></person-group>. <article-title>Enriched environment promotes adult neural progenitor cell mobilization in mouse demyelination models</article-title>. <source>Eur J Neurosci</source>. (<year>2007</year>) <volume>25</volume>:<page-range>761&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1460-9568.2007.05335.x</pub-id><pub-id pub-id-type="pmid">17298600</pub-id></mixed-citation></ref><ref id="B329"><label>329</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blakemore</surname><given-names>WF</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>RJ</given-names></name></person-group>. <article-title>Remyelination in experimental models of toxin-induced demyelination</article-title>. <source>Curr Top Microbiol Immunol</source>. (<year>2008</year>) <volume>318</volume>:<fpage>193</fpage>&#8211;<lpage>212</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-3-540-73677-6_8</pub-id><pub-id pub-id-type="pmid">18219819</pub-id></mixed-citation></ref><ref id="B330"><label>330</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodruff</surname><given-names>RH</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>RJ</given-names></name></person-group>. <article-title>Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: a comparative study</article-title>. <source>Glia</source>. (<year>1999</year>) <volume>25</volume>:<page-range>216&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1098-1136(19990201)25:3&amp;#x0003c;216::AID-GLIA2&amp;#x0003e;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">9932868</pub-id></mixed-citation></ref><ref id="B331"><label>331</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>JM</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R</given-names></name></person-group>. <article-title>Activation and proliferation of endogenous oligodendrocyte precursor cells during ethidium bromide-induced demyelination</article-title>. <source>Exp Neurol</source>. (<year>1999</year>) <volume>160</volume>:<page-range>333&#8211;47</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1006/exnr.1999.7224</pub-id><pub-id pub-id-type="pmid">10619551</pub-id></mixed-citation></ref><ref id="B332"><label>332</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lafaille</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>K</given-names></name><name name-style="western"><surname>Katsuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Tonegawa</surname><given-names>S</given-names></name></person-group>. <article-title>High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice</article-title>. <source>Cell</source>. (<year>1994</year>) <volume>78</volume>:<fpage>399</fpage>&#8211;<lpage>408</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0092-8674(94)90419-7</pub-id><pub-id pub-id-type="pmid">7520367</pub-id></mixed-citation></ref><ref id="B333"><label>333</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldner</surname><given-names>H</given-names></name><name name-style="western"><surname>Whitters</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sobel</surname><given-names>RA</given-names></name><name name-style="western"><surname>Collins</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group>. <article-title>Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2000</year>) <volume>97</volume>:<page-range>3412&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.97.7.3412</pub-id><pub-id pub-id-type="pmcid">PMC16253</pub-id><pub-id pub-id-type="pmid">10737797</pub-id></mixed-citation></ref><ref id="B334"><label>334</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Whitters</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sobel</surname><given-names>RA</given-names></name><name name-style="western"><surname>Collins</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group>. <article-title>Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis</article-title>. <source>J Exp Med</source>. (<year>2003</year>) <volume>197</volume>:<page-range>1073&#8211;81</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20021603</pub-id><pub-id pub-id-type="pmcid">PMC2193967</pub-id><pub-id pub-id-type="pmid">12732654</pub-id></mixed-citation></ref><ref id="B335"><label>335</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Nun</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaushansky</surname><given-names>N</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>N</given-names></name><name name-style="western"><surname>Krishnamoorthy</surname><given-names>G</given-names></name><name name-style="western"><surname>Berer</surname><given-names>K</given-names></name><name name-style="western"><surname>Liblau</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development</article-title>. <source>J Autoimmun</source>. (<year>2014</year>) <volume>54</volume>:<fpage>33</fpage>&#8211;<lpage>50</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jaut.2014.06.004</pub-id><pub-id pub-id-type="pmid">25175979</pub-id></mixed-citation></ref><ref id="B336"><label>336</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellmerich</surname><given-names>S</given-names></name><name name-style="western"><surname>Takacs</surname><given-names>K</given-names></name><name name-style="western"><surname>Mycko</surname><given-names>M</given-names></name><name name-style="western"><surname>Waldner</surname><given-names>H</given-names></name><name name-style="western"><surname>Wahid</surname><given-names>F</given-names></name><name name-style="western"><surname>Boyton</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis</article-title>. <source>Eur J Immunol</source>. (<year>2004</year>) <volume>34</volume>:<page-range>1839&#8211;48</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.200324044</pub-id><pub-id pub-id-type="pmid">15214032</pub-id></mixed-citation></ref><ref id="B337"><label>337</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kieseier</surname><given-names>BC</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name></person-group>. <article-title>Current disease-modifying therapies in multiple sclerosis</article-title>. <source>Semin Neurol</source>. (<year>2003</year>) <volume>23</volume>:<page-range>133&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1055/s-2003-41138</pub-id><pub-id pub-id-type="pmid">12894379</pub-id></mixed-citation></ref><ref id="B338"><label>338</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>L</given-names></name><name name-style="western"><surname>Zamvil</surname><given-names>SS</given-names></name></person-group>. <article-title>How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis</article-title>. <source>Ann Neurol</source>. (<year>2006</year>) <volume>60</volume>:<fpage>12</fpage>&#8211;<lpage>21</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.20913</pub-id><pub-id pub-id-type="pmid">16802293</pub-id></mixed-citation></ref><ref id="B339"><label>339</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>J</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Schonrock</surname><given-names>L</given-names></name><name name-style="western"><surname>Zettl</surname><given-names>UK</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Toyka</surname><given-names>KV</given-names></name></person-group>. <article-title>T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy</article-title>. <source>Brain</source>. (<year>2000</year>) <volume>123</volume>:<page-range>1431&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/123.7.1431</pub-id><pub-id pub-id-type="pmid">10869055</pub-id></mixed-citation></ref><ref id="B340"><label>340</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Meide</surname><given-names>PH</given-names></name><name name-style="western"><surname>de Labie</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ruuls</surname><given-names>SR</given-names></name><name name-style="western"><surname>Groenestein</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Botman</surname><given-names>CA</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms</article-title>. <source>J Neuroimmunol</source>. (<year>1998</year>) <volume>84</volume>:<fpage>14</fpage>&#8211;<lpage>23</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0165-5728(97)00207-5</pub-id><pub-id pub-id-type="pmid">9600704</pub-id></mixed-citation></ref><ref id="B341"><label>341</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Oosten</surname><given-names>BW</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Truyen</surname><given-names>L</given-names></name><name name-style="western"><surname>Boringa</surname><given-names>JB</given-names></name><name name-style="western"><surname>Bertelsmann</surname><given-names>FW</given-names></name><name name-style="western"><surname>von Blomberg</surname><given-names>BM</given-names></name><etal/></person-group>. <article-title>Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2</article-title>. <source>Neurology</source>. (<year>1996</year>) <volume>47</volume>:<page-range>1531&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.47.6.1531</pub-id><pub-id pub-id-type="pmid">8960740</pub-id></mixed-citation></ref><ref id="B342"><label>342</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunig</surname><given-names>T</given-names></name></person-group>. <article-title>The storm has cleared: lessons from the CD28 superagonist TGN1412 trial</article-title>. <source>Nat Rev Immunol</source>. (<year>2012</year>) <volume>12</volume>:<page-range>317&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri3192</pub-id><pub-id pub-id-type="pmid">22487653</pub-id></mixed-citation></ref><ref id="B343"><label>343</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>AM</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>HL</given-names></name></person-group>. <article-title>Oral tolerance: therapeutic implications for autoimmune diseases</article-title>. <source>Clin Dev Immunol</source>. (<year>2006</year>) <volume>13</volume>:<page-range>143&#8211;57</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/17402520600876804</pub-id><pub-id pub-id-type="pmcid">PMC2270752</pub-id><pub-id pub-id-type="pmid">17162357</pub-id></mixed-citation></ref><ref id="B344"><label>344</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noseworthy</surname><given-names>JH</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>P</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D</given-names></name><name name-style="western"><surname>Sneve</surname><given-names>D</given-names></name><name name-style="western"><surname>Ebers</surname><given-names>GC</given-names></name><etal/></person-group>. <article-title>The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis</article-title>. <source>Neurology</source>. (<year>1998</year>) <volume>51</volume>:<page-range>1342&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.51.5.1342</pub-id><pub-id pub-id-type="pmid">9818858</pub-id></mixed-citation></ref><ref id="B345"><label>345</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dedoni</surname><given-names>S</given-names></name><name name-style="western"><surname>Scherma</surname><given-names>M</given-names></name><name name-style="western"><surname>Camoglio</surname><given-names>C</given-names></name><name name-style="western"><surname>Siddi</surname><given-names>C</given-names></name><name name-style="western"><surname>Dazzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Puliga</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>An overall view of the most common experimental models for multiple sclerosis</article-title>. <source>Neurobiol Dis</source>. (<year>2023</year>) <volume>184</volume>:<fpage>106230</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nbd.2023.106230</pub-id><pub-id pub-id-type="pmid">37453561</pub-id></mixed-citation></ref><ref id="B346"><label>346</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Bradl</surname><given-names>M</given-names></name></person-group>. <article-title>Multiple sclerosis: experimental models and reality</article-title>. <source>Acta Neuropathol</source>. (<year>2017</year>) <volume>133</volume>:<page-range>223&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-016-1631-4</pub-id><pub-id pub-id-type="pmcid">PMC5250666</pub-id><pub-id pub-id-type="pmid">27766432</pub-id></mixed-citation></ref><ref id="B347"><label>347</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name></person-group>. <article-title>The pathobiology of vascular dementia</article-title>. <source>Neuron</source>. (<year>2013</year>) <volume>80</volume>:<page-range>844&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neuron.2013.10.008</pub-id><pub-id pub-id-type="pmcid">PMC3842016</pub-id><pub-id pub-id-type="pmid">24267647</pub-id></mixed-citation></ref><ref id="B348"><label>348</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montagne</surname><given-names>A</given-names></name><name name-style="western"><surname>Scherma</surname><given-names>M</given-names></name><name name-style="western"><surname>Camoglio</surname><given-names>C</given-names></name><name name-style="western"><surname>Siddi</surname><given-names>C</given-names></name><name name-style="western"><surname>Dazzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Puliga</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Blood-brain barrier breakdown in the aging human hippocampus</article-title>. <source>Neuron</source>. (<year>2015</year>) <volume>85</volume>:<fpage>296</fpage>&#8211;<lpage>302</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neuron.2014.12.032</pub-id><pub-id pub-id-type="pmid">25611508</pub-id><pub-id pub-id-type="pmcid">PMC4350773</pub-id></mixed-citation></ref><ref id="B349"><label>349</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Koroshetz</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Babcock</surname><given-names>D</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></name><name name-style="western"><surname>Galpern</surname><given-names>WR</given-names></name><name name-style="western"><surname>Glymour</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Recommendations of the Alzheimer&#8217;s disease-related dementias conference</article-title>. <source>Neurology</source>. (<year>2014</year>) <volume>83</volume>:<page-range>851&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1212/WNL.0000000000000733</pub-id><pub-id pub-id-type="pmcid">PMC4155046</pub-id><pub-id pub-id-type="pmid">25080517</pub-id></mixed-citation></ref><ref id="B350"><label>350</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>HR</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>A</given-names></name><name name-style="western"><surname>Hankin</surname><given-names>BL</given-names></name></person-group>. <article-title>Advancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approaches</article-title>. <source>Front Psychol</source>. (<year>2015</year>) <volume>6</volume>:<elocation-id>328</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fpsyg.2015.00328</pub-id><pub-id pub-id-type="pmid">25859234</pub-id><pub-id pub-id-type="pmcid">PMC4374537</pub-id></mixed-citation></ref><ref id="B351"><label>351</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkler</surname><given-names>EA</given-names></name><name name-style="western"><surname>Sengillo</surname><given-names>JD</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Henkel</surname><given-names>JS</given-names></name><name name-style="western"><surname>Appel</surname><given-names>SH</given-names></name><name name-style="western"><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group>. <article-title>Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis</article-title>. <source>Acta Neuropathol</source>. (<year>2013</year>) <volume>125</volume>:<page-range>111&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-012-1039-8</pub-id><pub-id pub-id-type="pmcid">PMC3535352</pub-id><pub-id pub-id-type="pmid">22941226</pub-id></mixed-citation></ref><ref id="B352"><label>352</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korczyn</surname><given-names>AD</given-names></name></person-group>. <article-title>Vascular parkinsonism&#8211;characteristics, pathogenesis and treatment</article-title>. <source>Nat Rev Neurol</source>. (<year>2015</year>) <volume>11</volume>:<page-range>319&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrneurol.2015.61</pub-id><pub-id pub-id-type="pmid">25917706</pub-id></mixed-citation></ref><ref id="B353"><label>353</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drouin-Ouellet</surname><given-names>J</given-names></name><name name-style="western"><surname>Sawiak</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Cisbani</surname><given-names>G</given-names></name><name name-style="western"><surname>Lagace</surname><given-names>M</given-names></name><name name-style="western"><surname>Kuan</surname><given-names>WL</given-names></name><name name-style="western"><surname>Saint-Pierre</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cerebrovascular and blood-brain barrier impairments in Huntington&#8217;s disease: Potential implications for its pathophysiology</article-title>. <source>Ann Neurol</source>. (<year>2015</year>) <volume>78</volume>:<page-range>160&#8211;77</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ana.24406</pub-id><pub-id pub-id-type="pmid">25866151</pub-id></mixed-citation></ref><ref id="B354"><label>354</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Granata</surname><given-names>T</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>C</given-names></name><name name-style="western"><surname>Janigro</surname><given-names>D</given-names></name></person-group>. <article-title>Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches</article-title>. <source>Epilepsia</source>. (<year>2012</year>) <volume>53</volume>:<page-range>1877&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03637.x</pub-id><pub-id pub-id-type="pmcid">PMC4842020</pub-id><pub-id pub-id-type="pmid">22905812</pub-id></mixed-citation></ref><ref id="B355"><label>355</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erdo</surname><given-names>F</given-names></name><name name-style="western"><surname>Denes</surname><given-names>L</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>E</given-names></name></person-group>. <article-title>Age-associated physiological and pathological changes at the blood-brain barrier: A review</article-title>. <source>J Cereb Blood Flow Metab</source>. (<year>2017</year>) <volume>37</volume>:<fpage>4</fpage>&#8211;<lpage>24</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0271678X16679420</pub-id><pub-id pub-id-type="pmid">27837191</pub-id><pub-id pub-id-type="pmcid">PMC5363756</pub-id></mixed-citation></ref><ref id="B356"><label>356</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Banks</surname><given-names>WA</given-names></name></person-group>. <article-title>Age-associated changes in the immune system and blood(-)Brain barrier functions</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms20071632</pub-id><pub-id pub-id-type="pmcid">PMC6479894</pub-id><pub-id pub-id-type="pmid">30986918</pub-id></mixed-citation></ref><ref id="B357"><label>357</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenbaum</surname><given-names>SS</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>CH</given-names></name></person-group>. <article-title>Intraoperative tissue expansion using a Foley catheter following excision of a basal cell carcinoma</article-title>. <source>J Dermatol Surg Oncol</source>. (<year>1990</year>) <volume>16</volume>:<page-range>45&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1524-4725.1990.tb00007.x</pub-id><pub-id pub-id-type="pmid">2299022</pub-id></mixed-citation></ref><ref id="B358"><label>358</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaufer</surname><given-names>D</given-names></name></person-group>. <article-title>Blood-brain barrier breakdown and blood-brain communication in neurological and psychiatric diseases</article-title>. <source>Cardiovasc Psychiatry Neurol 2011</source>. (<year>2011</year>) <volume>p</volume>:<fpage>431470</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2011/431470</pub-id><pub-id pub-id-type="pmcid">PMC3130971</pub-id><pub-id pub-id-type="pmid">21747970</pub-id></mixed-citation></ref><ref id="B359"><label>359</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomkins</surname><given-names>O</given-names></name><name name-style="western"><surname>Feintuch</surname><given-names>A</given-names></name><name name-style="western"><surname>Benifla</surname><given-names>M</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>A</given-names></name><name name-style="western"><surname>Shelef</surname><given-names>I</given-names></name></person-group>. <article-title>Blood-brain barrier breakdown following traumatic brain injury: a possible role in posttraumatic epilepsy</article-title>. <source>Cardiovasc Psychiatry Neurol</source>. (<year>2011</year>) <volume>2011</volume>:<fpage>765923</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2011/765923</pub-id><pub-id pub-id-type="pmid">21436875</pub-id><pub-id pub-id-type="pmcid">PMC3056210</pub-id></mixed-citation></ref><ref id="B360"><label>360</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majumdar</surname><given-names>R</given-names></name></person-group>. <article-title>Neutron hole strength distribution of the 2f7/2 state of 207Pb</article-title>. <source>Phys Rev C Nucl Phys</source>. (<year>1990</year>) <volume>42</volume>:<page-range>631&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1103/PhysRevC.42.631</pub-id><pub-id pub-id-type="pmid">9966749</pub-id></mixed-citation></ref><ref id="B361"><label>361</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaisar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sajja</surname><given-names>RK</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name><name name-style="western"><surname>Abhyankar</surname><given-names>VV</given-names></name><name name-style="western"><surname>Liles</surname><given-names>T</given-names></name><name name-style="western"><surname>Cucullo</surname><given-names>L</given-names></name></person-group>. <article-title>New experimental models of the blood-brain barrier for CNS drug discovery</article-title>. <source>Expert Opin Drug Discov</source>. (<year>2017</year>) <volume>12</volume>:<fpage>89</fpage>&#8211;<lpage>103</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/17460441.2017.1253676</pub-id><pub-id pub-id-type="pmid">27782770</pub-id><pub-id pub-id-type="pmcid">PMC5521006</pub-id></mixed-citation></ref><ref id="B362"><label>362</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Banks</surname><given-names>WA</given-names></name></person-group>. <article-title>
<italic toggle="yes">In vitro</italic> modeling of blood-brain barrier and interface functions in neuroimmune communication</article-title>. <source>Fluids Barriers CNS</source>. (<year>2020</year>) <volume>17</volume>:<fpage>26</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12987-020-00187-3</pub-id><pub-id pub-id-type="pmid">32228633</pub-id><pub-id pub-id-type="pmcid">PMC7106666</pub-id></mixed-citation></ref><ref id="B363"><label>363</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gastfriend</surname><given-names>BD</given-names></name><name name-style="western"><surname>Palecek</surname><given-names>SP</given-names></name><name name-style="western"><surname>Shusta</surname><given-names>EV</given-names></name></person-group>. <article-title>Modeling the blood-brain barrier: Beyond the endothelial cells</article-title>. <source>Curr Opin BioMed Eng</source>. (<year>2018</year>) <volume>5</volume>:<fpage>6</fpage>&#8211;<lpage>12</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cobme.2017.11.002</pub-id><pub-id pub-id-type="pmid">29915815</pub-id><pub-id pub-id-type="pmcid">PMC6003712</pub-id></mixed-citation></ref><ref id="B364"><label>364</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatherell</surname><given-names>K</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>PO</given-names></name><name name-style="western"><surname>Romero</surname><given-names>IA</given-names></name><name name-style="western"><surname>Weksler</surname><given-names>B</given-names></name><name name-style="western"><surname>Pilkington</surname><given-names>GJ</given-names></name></person-group>. <article-title>Development of a three-dimensional, all-human <italic toggle="yes">in vitro</italic> model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models</article-title>. <source>J Neurosci Methods</source>. (<year>2011</year>) <volume>199</volume>:<page-range>223&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jneumeth.2011.05.012</pub-id><pub-id pub-id-type="pmid">21609734</pub-id></mixed-citation></ref><ref id="B365"><label>365</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>PA</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>MJ</given-names></name></person-group>. <article-title>Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail&#8211;chick transplantation chimeras</article-title>. <source>Dev Biol</source>. (<year>1981</year>) <volume>84</volume>:<page-range>183&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0012-1606(81)90382-1</pub-id><pub-id pub-id-type="pmid">7250491</pub-id></mixed-citation></ref><ref id="B366"><label>366</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>J</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>M</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>J</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>AP</given-names></name></person-group>. <article-title>Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature</article-title>. <source>Science</source>. (<year>2008</year>) <volume>322</volume>:<page-range>1247&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.1164594</pub-id><pub-id pub-id-type="pmid">19023080</pub-id></mixed-citation></ref><ref id="B367"><label>367</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>CC</given-names></name><name name-style="western"><surname>Revest</surname><given-names>PA</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>J</given-names></name></person-group>. <article-title>Development and characterisation of a rat brain capillary endothelial culture: towards an <italic toggle="yes">in vitro</italic> blood-brain barrier</article-title>. <source>J Cell Sci</source>. (<year>1992</year>) <volume>103</volume>:<fpage>23</fpage>&#8211;<lpage>37</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1242/jcs.103.1.23</pub-id><pub-id pub-id-type="pmid">1429907</pub-id></mixed-citation></ref><ref id="B368"><label>368</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annunziata</surname><given-names>P</given-names></name><name name-style="western"><surname>Cioni</surname><given-names>C</given-names></name><name name-style="western"><surname>Toneatto</surname><given-names>S</given-names></name><name name-style="western"><surname>Paccagnini</surname><given-names>E</given-names></name></person-group>. <article-title>HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P</article-title>. <source>AIDS</source>. (<year>1998</year>) <volume>12</volume>:<page-range>2377&#8211;85</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/00002030-199818000-00006</pub-id><pub-id pub-id-type="pmid">9875575</pub-id></mixed-citation></ref><ref id="B369"><label>369</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franke</surname><given-names>H</given-names></name><name name-style="western"><surname>Galla</surname><given-names>H</given-names></name><name name-style="western"><surname>Beuckmann</surname><given-names>CT</given-names></name></person-group>. <article-title>Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier <italic toggle="yes">in vitro</italic>
</article-title>. <source>Brain Res Brain Res Protoc</source>. (<year>2000</year>) <volume>5</volume>:<page-range>248&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1385-299X(00)00020-9</pub-id><pub-id pub-id-type="pmid">10906490</pub-id></mixed-citation></ref><ref id="B370"><label>370</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helms</surname><given-names>HC</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Burek</surname><given-names>M</given-names></name><name name-style="western"><surname>Cecchelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>PO</given-names></name><name name-style="western"><surname>Deli</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">In vitro</italic> models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use</article-title>. <source>J Cereb Blood Flow Metab</source>. (<year>2016</year>) <volume>36</volume>:<page-range>862&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0271678X16630991</pub-id><pub-id pub-id-type="pmcid">PMC4853841</pub-id><pub-id pub-id-type="pmid">26868179</pub-id></mixed-citation></ref><ref id="B371"><label>371</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaillard</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Voorwinden</surname><given-names>LH</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>A</given-names></name><name name-style="western"><surname>Atsumi</surname><given-names>R</given-names></name><name name-style="western"><surname>Engman</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Establishment and functional characterization of an <italic toggle="yes">in vitro</italic> model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes</article-title>. <source>Eur J Pharm Sci</source>. (<year>2001</year>) <volume>12</volume>:<page-range>215&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0928-0987(00)00123-8</pub-id><pub-id pub-id-type="pmid">11113640</pub-id></mixed-citation></ref><ref id="B372"><label>372</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen-Kashi Malina</surname><given-names>K</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>I</given-names></name><name name-style="western"><surname>Teichberg</surname><given-names>VI</given-names></name></person-group>. <article-title>Closing the gap between the in-vivo and in-vitro blood-brain barrier tightness</article-title>. <source>Brain Res</source>. (<year>2009</year>) <volume>1284</volume>:<fpage>12</fpage>&#8211;<lpage>21</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.brainres.2009.05.072</pub-id><pub-id pub-id-type="pmid">19501061</pub-id></mixed-citation></ref><ref id="B373"><label>373</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Voorwinden</surname><given-names>LH</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>A</given-names></name><name name-style="western"><surname>Atsumi</surname><given-names>R</given-names></name><name name-style="western"><surname>Engman</surname><given-names>H</given-names></name></person-group>. <article-title>An improved <italic toggle="yes">in vitro</italic> blood-brain barrier model: rat brain endothelial cells co-cultured with astrocytes</article-title>. <source>Methods Mol Biol</source>. (<year>2012</year>) <volume>814</volume>:<page-range>415&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-61779-452-0_28</pub-id><pub-id pub-id-type="pmid">22144323</pub-id></mixed-citation></ref><ref id="B374"><label>374</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Culot</surname><given-names>M</given-names></name><name name-style="western"><surname>Dolman</surname><given-names>DE</given-names></name><name name-style="western"><surname>Drndarski</surname><given-names>S</given-names></name><name name-style="western"><surname>Fredriksson</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>An <italic toggle="yes">in vitro</italic> blood-brain barrier model for high throughput (HTS) toxicological screening</article-title>. <source>Toxicol In Vitro</source>. (<year>2008</year>) <volume>22</volume>:<fpage>799</fpage>&#8211;<lpage>811</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.tiv.2007.12.016</pub-id><pub-id pub-id-type="pmid">18280105</pub-id></mixed-citation></ref><ref id="B375"><label>375</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perriere</surname><given-names>N</given-names></name><name name-style="western"><surname>Lundquist</surname><given-names>S</given-names></name><name name-style="western"><surname>Vanuxeem</surname><given-names>D</given-names></name><name name-style="western"><surname>Nion</surname><given-names>S</given-names></name><name name-style="western"><surname>Landry</surname><given-names>C</given-names></name><name name-style="western"><surname>Delplace</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A functional <italic toggle="yes">in vitro</italic> model of rat blood-brain barrier for molecular analysis of efflux transporters</article-title>. <source>Brain Res</source>. (<year>2007</year>) <volume>1150</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.brainres.2007.02.091</pub-id><pub-id pub-id-type="pmid">17434463</pub-id></mixed-citation></ref><ref id="B376"><label>376</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilhelm</surname><given-names>I</given-names></name><name name-style="western"><surname>Fazakas</surname><given-names>C</given-names></name><name name-style="western"><surname>Krizbai</surname><given-names>IA</given-names></name></person-group>. <article-title>
<italic toggle="yes">In vitro</italic> models of the blood-brain barrier</article-title>. <source>Acta Neurobiol Exp (Wars)</source>. (<year>2011</year>) <volume>71</volume>:<page-range>113&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.55782/ane-2011-1828</pub-id><pub-id pub-id-type="pmid">21499332</pub-id></mixed-citation></ref><ref id="B377"><label>377</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patabendige</surname><given-names>A</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>RA</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>NJ</given-names></name></person-group>. <article-title>Establishment of a simplified <italic toggle="yes">in vitro</italic> porcine blood-brain barrier model with high transendothelial electrical resistance</article-title>. <source>Brain Res</source>. (<year>2013</year>) <volume>1521</volume>:<fpage>1</fpage>&#8211;<lpage>15</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.brainres.2012.06.057</pub-id><pub-id pub-id-type="pmid">22789905</pub-id><pub-id pub-id-type="pmcid">PMC3694297</pub-id></mixed-citation></ref><ref id="B378"><label>378</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helms</surname><given-names>HC</given-names></name><name name-style="western"><surname>Waagepetersen</surname><given-names>HS</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>CU</given-names></name><name name-style="western"><surname>Brodin</surname><given-names>B</given-names></name></person-group>. <article-title>Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood-brain barrier model by increasing media buffer capacity during growth</article-title>. <source>AAPS J</source>. (<year>2010</year>) <volume>12</volume>:<page-range>759&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1208/s12248-010-9237-6</pub-id><pub-id pub-id-type="pmcid">PMC2976989</pub-id><pub-id pub-id-type="pmid">20967520</pub-id></mixed-citation></ref><ref id="B379"><label>379</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banks</surname><given-names>WA</given-names></name><name name-style="western"><surname>Waagepetersen</surname><given-names>HS</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>CU</given-names></name><name name-style="western"><surname>Brodin</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit</article-title>. <source>J Neuroinflammation</source>. (<year>2015</year>) <volume>12</volume>:<fpage>223</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12974-015-0434-1</pub-id><pub-id pub-id-type="pmid">26608623</pub-id><pub-id pub-id-type="pmcid">PMC4660627</pub-id></mixed-citation></ref><ref id="B380"><label>380</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Descamps</surname><given-names>L</given-names></name><name name-style="western"><surname>Gray</surname><given-names>AM</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Salameh</surname><given-names>TS</given-names></name><name name-style="western"><surname>Damodarasamy</surname><given-names>M</given-names></name><name name-style="western"><surname>Sheibani</surname><given-names>N</given-names></name></person-group>. <article-title>Protective effect of glial cells against lipopolysaccharide-mediated blood-brain barrier injury</article-title>. <source>Glia</source>. (<year>2003</year>) <volume>42</volume>:<fpage>46</fpage>&#8211;<lpage>58</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/glia.10205</pub-id><pub-id pub-id-type="pmid">12594736</pub-id></mixed-citation></ref><ref id="B381"><label>381</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veszelka</surname><given-names>S</given-names></name><name name-style="western"><surname>Pasztoi</surname><given-names>M</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>AE</given-names></name><name name-style="western"><surname>Krizbai</surname><given-names>I</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>TK</given-names></name><name name-style="western"><surname>Niwa</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages</article-title>. <source>Neurochem Int</source>. (<year>2007</year>) <volume>50</volume>:<page-range>219&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neuint.2006.08.006</pub-id><pub-id pub-id-type="pmid">16997427</pub-id></mixed-citation></ref><ref id="B382"><label>382</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>D</given-names></name><name name-style="western"><surname>Dorovini-Zis</surname><given-names>K</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>SR</given-names></name></person-group>. <article-title>Cytokines, nitric oxide, and cGMP modulate the permeability of an <italic toggle="yes">in vitro</italic> model of the human blood-brain barrier</article-title>. <source>Exp Neurol</source>. (<year>2004</year>) <volume>190</volume>:<page-range>446&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.expneurol.2004.08.008</pub-id><pub-id pub-id-type="pmid">15530883</pub-id></mixed-citation></ref><ref id="B383"><label>383</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries</surname><given-names>HE</given-names></name><name name-style="western"><surname>Blom-Roosemalen</surname><given-names>MC</given-names></name><name name-style="western"><surname>van Oosten</surname><given-names>M</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>AG</given-names></name><name name-style="western"><surname>van Berkel</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>DD</given-names></name><etal/></person-group>. <article-title>The influence of cytokines on the integrity of the blood-brain barrier <italic toggle="yes">in vitro</italic>
</article-title>. <source>J Neuroimmunol</source>. (<year>1996</year>) <volume>64</volume>:<fpage>37</fpage>&#8211;<lpage>43</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0165-5728(95)00148-4</pub-id><pub-id pub-id-type="pmid">8598388</pub-id></mixed-citation></ref><ref id="B384"><label>384</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deli</surname><given-names>MA</given-names></name><name name-style="western"><surname>Descamps</surname><given-names>L</given-names></name><name name-style="western"><surname>Dehouck</surname><given-names>MP</given-names></name><name name-style="western"><surname>Cecchelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Joo</surname><given-names>F</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin</article-title>. <source>J Neurosci Res</source>. (<year>1995</year>) <volume>41</volume>:<page-range>717&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jnr.490410602</pub-id><pub-id pub-id-type="pmid">7500373</pub-id></mixed-citation></ref><ref id="B385"><label>385</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>J</given-names></name><name name-style="western"><surname>Heasman</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>JI</given-names></name><name name-style="western"><surname>Prat</surname><given-names>A</given-names></name><name name-style="western"><surname>Lyck</surname><given-names>R</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></name></person-group>. <article-title>Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain</article-title>. <source>Neuropathol Appl Neurobiol</source>. (<year>2011</year>) <volume>37</volume>:<fpage>24</fpage>&#8211;<lpage>39</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2990.2010.01140.x</pub-id><pub-id pub-id-type="pmid">20946472</pub-id></mixed-citation></ref><ref id="B386"><label>386</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biernacki</surname><given-names>K</given-names></name><name name-style="western"><surname>Prat</surname><given-names>A</given-names></name><name name-style="western"><surname>Blain</surname><given-names>M</given-names></name><name name-style="western"><surname>Antel</surname><given-names>JP</given-names></name></person-group>. <article-title>Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells</article-title>. <source>J Neuropathol Exp Neurol</source>. (<year>2001</year>) <volume>60</volume>:<page-range>1127&#8211;36</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/jnen/60.12.1127</pub-id><pub-id pub-id-type="pmid">11764086</pub-id></mixed-citation></ref><ref id="B387"><label>387</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Wedel-Parlow</surname><given-names>M</given-names></name><name name-style="western"><surname>Schrot</surname><given-names>S</given-names></name><name name-style="western"><surname>Lemmen</surname><given-names>J</given-names></name><name name-style="western"><surname>Treeratanapiboon</surname><given-names>L</given-names></name><name name-style="western"><surname>Wegener</surname><given-names>J</given-names></name><name name-style="western"><surname>Galla</surname><given-names>HJ</given-names></name></person-group>. <article-title>Neutrophils cross the BBB primarily on transcellular pathways: an <italic toggle="yes">in vitro</italic> study</article-title>. <source>Brain Res</source>. (<year>2011</year>) <volume>1367</volume>:<fpage>62</fpage>&#8211;<lpage>76</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.brainres.2010.09.076</pub-id><pub-id pub-id-type="pmid">20875807</pub-id></mixed-citation></ref><ref id="B388"><label>388</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coisne</surname><given-names>C</given-names></name><name name-style="western"><surname>Faveeuw</surname><given-names>C</given-names></name><name name-style="western"><surname>Delplace</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dehouck</surname><given-names>L</given-names></name><name name-style="western"><surname>Miller</surname><given-names>F</given-names></name><name name-style="western"><surname>Cecchelli</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Differential expression of selectins by mouse brain capillary endothelial cells <italic toggle="yes">in vitro</italic> in response to distinct inflammatory stimuli</article-title>. <source>Neurosci Lett</source>. (<year>2006</year>) <volume>392</volume>:<page-range>216&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.neulet.2005.09.028</pub-id><pub-id pub-id-type="pmid">16214291</pub-id></mixed-citation></ref><ref id="B389"><label>389</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coisne</surname><given-names>C</given-names></name><name name-style="western"><surname>Faveeuw</surname><given-names>C</given-names></name><name name-style="western"><surname>Delplace</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dehouck</surname><given-names>L</given-names></name><name name-style="western"><surname>Miller</surname><given-names>F</given-names></name><name name-style="western"><surname>Cecchelli</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Mouse syngenic <italic toggle="yes">in vitro</italic> blood-brain barrier model: a new tool to examine inflammatory events in cerebral endothelium</article-title>. <source>Lab Invest</source>. (<year>2005</year>) <volume>85</volume>:<page-range>734&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/labinvest.3700281</pub-id><pub-id pub-id-type="pmid">15908914</pub-id></mixed-citation></ref><ref id="B390"><label>390</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeStefano</surname><given-names>JG</given-names></name><name name-style="western"><surname>Xu</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Williams</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Yimam</surname><given-names>N</given-names></name><name name-style="western"><surname>Searson</surname><given-names>PC</given-names></name></person-group>. <article-title>Effect of shear stress on iPSC-derived human brain microvascular endothelial cells (dhBMECs)</article-title>. <source>Fluids Barriers CNS</source>. (<year>2017</year>) <volume>14</volume>:<fpage>20</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12987-017-0068-z</pub-id><pub-id pub-id-type="pmid">28774343</pub-id><pub-id pub-id-type="pmcid">PMC5543552</pub-id></mixed-citation></ref><ref id="B391"><label>391</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></name><name name-style="western"><surname>Coisne</surname><given-names>C</given-names></name></person-group>. <article-title>Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle</article-title>. <source>Fluids Barriers CNS</source>. (<year>2011</year>) <volume>8</volume>:<fpage>4</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/2045-8118-8-4</pub-id><pub-id pub-id-type="pmid">21349152</pub-id><pub-id pub-id-type="pmcid">PMC3039833</pub-id></mixed-citation></ref><ref id="B392"><label>392</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>EH</given-names></name><name name-style="western"><surname>Weninger</surname><given-names>W</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>CA</given-names></name></person-group>. <article-title>Trafficking of immune cells in the central nervous system</article-title>. <source>J Clin Invest</source>. (<year>2010</year>) <volume>120</volume>:<page-range>1368&#8211;79</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1172/JCI41911</pub-id><pub-id pub-id-type="pmcid">PMC2860945</pub-id><pub-id pub-id-type="pmid">20440079</pub-id></mixed-citation></ref><ref id="B393"><label>393</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheikh</surname><given-names>MH</given-names></name><name name-style="western"><surname>Henson</surname><given-names>SM</given-names></name><name name-style="western"><surname>Loiola</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mercurio</surname><given-names>S</given-names></name><name name-style="western"><surname>Colamatteo</surname><given-names>A</given-names></name><name name-style="western"><surname>Maniscalco</surname><given-names>GT</given-names></name><etal/></person-group>. <article-title>Immuno-metabolic impact of the multiple sclerosis patients&#8217; sera on endothelial cells of the blood-brain barrier</article-title>. <source>J Neuroinflammation</source>. (<year>2020</year>) <volume>17</volume>:<fpage>153</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12974-020-01810-8</pub-id><pub-id pub-id-type="pmid">32386505</pub-id><pub-id pub-id-type="pmcid">PMC7210692</pub-id></mixed-citation></ref><ref id="B394"><label>394</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prat</surname><given-names>A</given-names></name><name name-style="western"><surname>Henson</surname><given-names>SM</given-names></name><name name-style="western"><surname>Loiola</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mercurio</surname><given-names>S</given-names></name><name name-style="western"><surname>Colamatteo</surname><given-names>A</given-names></name><name name-style="western"><surname>Maniscalco</surname><given-names>GT</given-names></name></person-group>. <article-title>Migration of multiple sclerosis lymphocytes through brain endothelium</article-title>. <source>Arch Neurol</source>. (<year>2002</year>) <volume>59</volume>:<page-range>391&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/archneur.59.3.391</pub-id><pub-id pub-id-type="pmid">11890842</pub-id></mixed-citation></ref><ref id="B395"><label>395</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahbouhi</surname><given-names>B</given-names></name><name name-style="western"><surname>Berthelot</surname><given-names>L</given-names></name><name name-style="western"><surname>Pettre</surname><given-names>S</given-names></name><name name-style="western"><surname>Michel</surname><given-names>L</given-names></name><name name-style="western"><surname>Wiertlewski</surname><given-names>S</given-names></name><name name-style="western"><surname>Weksler</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line</article-title>. <source>J Leukoc Biol</source>. (<year>2009</year>) <volume>86</volume>:<page-range>1049&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1189/jlb.1008666</pub-id><pub-id pub-id-type="pmid">19696154</pub-id></mixed-citation></ref><ref id="B396"><label>396</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cucullo</surname><given-names>L</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M</given-names></name><name name-style="western"><surname>Puvenna</surname><given-names>V</given-names></name><name name-style="western"><surname>Marchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Janigro</surname><given-names>D</given-names></name></person-group>. <article-title>The role of shear stress in Blood-Brain Barrier endothelial physiology</article-title>. <source>BMC Neurosci</source>. (<year>2011</year>) <volume>12</volume>:<fpage>40</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1471-2202-12-40</pub-id><pub-id pub-id-type="pmid">21569296</pub-id><pub-id pub-id-type="pmcid">PMC3103473</pub-id></mixed-citation></ref><ref id="B397"><label>397</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>CF</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M</given-names></name><name name-style="western"><surname>Puvenna</surname><given-names>V</given-names></name><name name-style="western"><surname>Marchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Janigro</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Blood-brain-barrier spheroids as an <italic toggle="yes">in vitro</italic> screening platform for brain-penetrating agents</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>15623</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ncomms15623</pub-id><pub-id pub-id-type="pmid">28585535</pub-id><pub-id pub-id-type="pmcid">PMC5467173</pub-id></mixed-citation></ref><ref id="B398"><label>398</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urich</surname><given-names>E</given-names></name><name name-style="western"><surname>Patsch</surname><given-names>C</given-names></name><name name-style="western"><surname>Aigner</surname><given-names>S</given-names></name><name name-style="western"><surname>Graf</surname><given-names>M</given-names></name><name name-style="western"><surname>Iacone</surname><given-names>R</given-names></name><name name-style="western"><surname>Freskgard</surname><given-names>PO</given-names></name></person-group>. <article-title>Multicellular self-assembled spheroidal model of the blood brain barrier</article-title>. <source>Sci Rep</source>. (<year>2013</year>) <volume>3</volume>:<fpage>1500</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep01500</pub-id><pub-id pub-id-type="pmid">23511305</pub-id><pub-id pub-id-type="pmcid">PMC3603320</pub-id></mixed-citation></ref><ref id="B399"><label>399</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H</given-names></name><name name-style="western"><surname>Seo</surname><given-names>JH</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KHK</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Bong</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Three-dimensional blood-brain barrier model for <italic toggle="yes">in vitro</italic> studies of neurovascular pathology</article-title>. <source>Sci Rep</source>. (<year>2015</year>) <volume>5</volume>:<fpage>15222</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep15222</pub-id><pub-id pub-id-type="pmid">26503597</pub-id><pub-id pub-id-type="pmcid">PMC4622078</pub-id></mixed-citation></ref><ref id="B400"><label>400</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nzou</surname><given-names>G</given-names></name><name name-style="western"><surname>Wicks</surname><given-names>RT</given-names></name><name name-style="western"><surname>Wicks</surname><given-names>EE</given-names></name><name name-style="western"><surname>Seale</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sane</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Human cortex spheroid with a functional blood brain barrier for high-throughput neurotoxicity screening and disease modeling</article-title>. <source>Sci Rep</source>. (<year>2018</year>) <volume>8</volume>:<fpage>7413</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-018-25603-5</pub-id><pub-id pub-id-type="pmid">29743549</pub-id><pub-id pub-id-type="pmcid">PMC5943588</pub-id></mixed-citation></ref><ref id="B401"><label>401</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kostka</surname><given-names>K</given-names></name><name name-style="western"><surname>Sokolova</surname><given-names>V</given-names></name><name name-style="western"><surname>El-Taibany</surname><given-names>A</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>B</given-names></name><name name-style="western"><surname>Porada</surname><given-names>D</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>The application of ultrasmall gold nanoparticles (2 nm) functionalized with doxorubicin in three-dimensional normal and glioblastoma organoid models of the blood-brain barrier</article-title>. <source>Molecules</source>. (<year>2024</year>) <volume>29</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/molecules29112469</pub-id><pub-id pub-id-type="pmcid">PMC11173746</pub-id><pub-id pub-id-type="pmid">38893345</pub-id></mixed-citation></ref><ref id="B402"><label>402</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nzou</surname><given-names>G</given-names></name><name name-style="western"><surname>Wicks</surname><given-names>RT</given-names></name><name name-style="western"><surname>VanOstrand</surname><given-names>NR</given-names></name><name name-style="western"><surname>Mekky</surname><given-names>GA</given-names></name><name name-style="western"><surname>Seale</surname><given-names>SA</given-names></name><name name-style="western"><surname>El-Taibany</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Multicellular 3D neurovascular unit model for assessing hypoxia and neuroinflammation induced blood-brain barrier dysfunction</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>9766</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-66487-8</pub-id><pub-id pub-id-type="pmid">32555384</pub-id><pub-id pub-id-type="pmcid">PMC7299970</pub-id></mixed-citation></ref><ref id="B403"><label>403</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokolova</surname><given-names>V</given-names></name><name name-style="western"><surname>Mekky</surname><given-names>G</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>SB</given-names></name><name name-style="western"><surname>Seeds</surname><given-names>MC</given-names></name><name name-style="western"><surname>Atala</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Epple</surname><given-names>M</given-names></name></person-group>. <article-title>Transport of ultrasmall gold nanoparticles (2 nm) across the blood-brain barrier in a six-cell brain spheroid model</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>18033</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-75125-2</pub-id><pub-id pub-id-type="pmid">33093563</pub-id><pub-id pub-id-type="pmcid">PMC7581805</pub-id></mixed-citation></ref><ref id="B404"><label>404</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokolova</surname><given-names>V</given-names></name><name name-style="western"><surname>Nzou</surname><given-names>G</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>SB</given-names></name><name name-style="western"><surname>Ruks</surname><given-names>T</given-names></name><name name-style="western"><surname>Heggen</surname><given-names>M</given-names></name><name name-style="western"><surname>Loza</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Ultrasmall gold nanoparticles (2 nm) can penetrate and enter cell nuclei in an <italic toggle="yes">in vitro</italic> 3D brain spheroid model</article-title>. <source>Acta Biomater</source>. (<year>2020</year>) <volume>111</volume>:<page-range>349&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.actbio.2020.04.023</pub-id><pub-id pub-id-type="pmid">32413579</pub-id></mixed-citation></ref><ref id="B405"><label>405</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lippmann</surname><given-names>ES</given-names></name><name name-style="western"><surname>Al-Ahmad</surname><given-names>A</given-names></name><name name-style="western"><surname>Azarin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Palecek</surname><given-names>SP</given-names></name><name name-style="western"><surname>Shusta</surname><given-names>EV</given-names></name></person-group>. <article-title>A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources</article-title>. <source>Sci Rep</source>. (<year>2014</year>) <volume>4</volume>:<fpage>4160</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep04160</pub-id><pub-id pub-id-type="pmid">24561821</pub-id><pub-id pub-id-type="pmcid">PMC3932448</pub-id></mixed-citation></ref><ref id="B406"><label>406</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neal</surname><given-names>EH</given-names></name><name name-style="western"><surname>Marinelli</surname><given-names>NA</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>McClatchey</surname><given-names>PM</given-names></name><name name-style="western"><surname>Balotin</surname><given-names>KM</given-names></name><name name-style="western"><surname>Gullett</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>A simplified, fully defined differentiation scheme for producing blood-brain barrier endothelial cells from human iPSCs</article-title>. <source>Stem Cell Rep</source>. (<year>2019</year>) <volume>12</volume>:<page-range>1380&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.stemcr.2019.05.008</pub-id><pub-id pub-id-type="pmcid">PMC6565873</pub-id><pub-id pub-id-type="pmid">31189096</pub-id></mixed-citation></ref><ref id="B407"><label>407</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>RG</given-names></name><name name-style="western"><surname>Quan</surname><given-names>C</given-names></name><name name-style="western"><surname>Reyes-Ortiz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kedaigle</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gipson</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Huntington&#8217;s disease iPSC-derived brain microvascular endothelial cells reveal WNT-mediated angiogenic and blood-brain barrier deficits</article-title>. <source>Cell Rep</source>. (<year>2017</year>) <volume>19</volume>:<page-range>1365&#8211;77</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.021</pub-id><pub-id pub-id-type="pmcid">PMC5646270</pub-id><pub-id pub-id-type="pmid">28514657</pub-id></mixed-citation></ref><ref id="B408"><label>408</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R</given-names></name><name name-style="western"><surname>Page</surname><given-names>S</given-names></name><name name-style="western"><surname>Al-Ahmad</surname><given-names>AJ</given-names></name></person-group>. <article-title>Isogenic blood-brain barrier models based on patient-derived stem cells display inter-individual differences in cell maturation and functionality</article-title>. <source>J Neurochem</source>. (<year>2017</year>) <volume>142</volume>:<fpage>74</fpage>&#8211;<lpage>88</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/jnc.2017.142.issue-1</pub-id><pub-id pub-id-type="pmid">28397247</pub-id></mixed-citation></ref><ref id="B409"><label>409</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vatine</surname><given-names>GD</given-names></name><name name-style="western"><surname>Al-Ahmad</surname><given-names>A</given-names></name><name name-style="western"><surname>Barriga</surname><given-names>BK</given-names></name><name name-style="western"><surname>Svendsen</surname><given-names>S</given-names></name><name name-style="western"><surname>Salim</surname><given-names>A</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier</article-title>. <source>Cell Stem Cell</source>. (<year>2017</year>) <volume>20</volume>:<fpage>831</fpage>&#8211;<lpage>843.e5</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.stem.2017.04.002</pub-id><pub-id pub-id-type="pmid">28526555</pub-id><pub-id pub-id-type="pmcid">PMC6659720</pub-id></mixed-citation></ref><ref id="B410"><label>410</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantle</surname><given-names>JL</given-names></name><name name-style="western"><surname>Min</surname><given-names>L</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name></person-group>. <article-title>Minimum transendothelial electrical resistance thresholds for the study of small and large molecule drug transport in a human <italic toggle="yes">in vitro</italic> blood-brain barrier model</article-title>. <source>Mol Pharm</source>. (<year>2016</year>) <volume>13</volume>:<page-range>4191&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00818</pub-id><pub-id pub-id-type="pmid">27934481</pub-id></mixed-citation></ref><ref id="B411"><label>411</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>PA</given-names></name><name name-style="western"><surname>Al-Ahmad</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Qian</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>RR</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>HK</given-names></name><name name-style="western"><surname>Weichert</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Analysis of cancer-targeting alkylphosphocholine analogue permeability characteristics using a human induced pluripotent stem cell blood-brain barrier model</article-title>. <source>Mol Pharm</source>. (<year>2016</year>) <volume>13</volume>:<page-range>3341&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00441</pub-id><pub-id pub-id-type="pmcid">PMC5014630</pub-id><pub-id pub-id-type="pmid">27421304</pub-id></mixed-citation></ref><ref id="B412"><label>412</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schondorf</surname><given-names>DC</given-names></name><name name-style="western"><surname>Aureli</surname><given-names>M</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>FE</given-names></name><name name-style="western"><surname>Hindley</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>F</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>iPSC-derived neurons from GBA1-associated Parkinson&#8217;s disease patients show autophagic defects and impaired calcium homeostasis</article-title>. <source>Nat Commun</source>. (<year>2014</year>) <volume>5</volume>:<fpage>4028</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ncomms5028</pub-id><pub-id pub-id-type="pmid">24905578</pub-id></mixed-citation></ref><ref id="B413"><label>413</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondo</surname><given-names>T</given-names></name><name name-style="western"><surname>Asai</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsukita</surname><given-names>K</given-names></name><name name-style="western"><surname>Kutoku</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohsawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sunada</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Modeling Alzheimer&#8217;s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness</article-title>. <source>Cell Stem Cell</source>. (<year>2013</year>) <volume>12</volume>:<page-range>487&#8211;96</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.stem.2013.01.009</pub-id><pub-id pub-id-type="pmid">23434393</pub-id></mixed-citation></ref><ref id="B414"><label>414</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosworth</surname><given-names>AM</given-names></name><name name-style="western"><surname>Faley</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bellan</surname><given-names>LM</given-names></name><name name-style="western"><surname>Lippmann</surname><given-names>ES</given-names></name></person-group>. <article-title>Modeling neurovascular disorders and therapeutic outcomes with human-induced pluripotent stem cells</article-title>. <source>Front Bioeng Biotechnol</source>. (<year>2017</year>) <volume>5</volume>:<elocation-id>87</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fbioe.2017.00087</pub-id><pub-id pub-id-type="pmid">29441348</pub-id><pub-id pub-id-type="pmcid">PMC5797533</pub-id></mixed-citation></ref><ref id="B415"><label>415</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhavan</surname><given-names>M</given-names></name><name name-style="western"><surname>Nevin</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Shick</surname><given-names>HE</given-names></name><name name-style="western"><surname>Garrison</surname><given-names>E</given-names></name><name name-style="western"><surname>Clarkson-Paredes</surname><given-names>C</given-names></name><name name-style="western"><surname>Karl</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Induction of myelinating oligodendrocytes in human cortical spheroids</article-title>. <source>Nat Methods</source>. (<year>2018</year>) <volume>15</volume>:<page-range>700&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41592-018-0081-4</pub-id><pub-id pub-id-type="pmcid">PMC6508550</pub-id><pub-id pub-id-type="pmid">30046099</pub-id></mixed-citation></ref><ref id="B416"><label>416</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pensabene</surname><given-names>V</given-names></name><name name-style="western"><surname>Markov</surname><given-names>DA</given-names></name><name name-style="western"><surname>Allwardt</surname><given-names>V</given-names></name><name name-style="western"><surname>Neely</surname><given-names>MD</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Recreating blood-brain barrier physiology and structure on chip: A novel neurovascular microfluidic bioreactor</article-title>. <source>Biomicrofluidics</source>. (<year>2015</year>) <volume>9</volume>:<fpage>054124</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1063/1.4934713</pub-id><pub-id pub-id-type="pmid">26576206</pub-id><pub-id pub-id-type="pmcid">PMC4627929</pub-id></mixed-citation></ref><ref id="B417"><label>417</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Na</surname><given-names>D</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>SW</given-names></name><name name-style="western"><surname>Choi</surname><given-names>C</given-names></name><name name-style="western"><surname>Park</surname><given-names>JK</given-names></name></person-group>. <article-title>Reliable permeability assay system in a microfluidic device mimicking cerebral vasculatures</article-title>. <source>BioMed Microdevices</source>. (<year>2012</year>) <volume>14</volume>:<page-range>1141&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10544-012-9680-5</pub-id><pub-id pub-id-type="pmid">22821236</pub-id></mixed-citation></ref><ref id="B418"><label>418</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prabhakarpandian</surname><given-names>B</given-names></name><name name-style="western"><surname>Shen</surname><given-names>MC</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>JB</given-names></name><name name-style="western"><surname>Mills</surname><given-names>IR</given-names></name><name name-style="western"><surname>Sidoryk-Wegrzynowicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Aschner</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>SyM-BBB: a microfluidic Blood Brain Barrier model</article-title>. <source>Lab Chip</source>. (<year>2013</year>) <volume>13</volume>:<page-range>1093&#8211;101</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1039/c2lc41208j</pub-id><pub-id pub-id-type="pmcid">PMC3613157</pub-id><pub-id pub-id-type="pmid">23344641</pub-id></mixed-citation></ref><ref id="B419"><label>419</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katt</surname><given-names>ME</given-names></name><name name-style="western"><surname>Linville</surname><given-names>RM</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>LN</given-names></name><name name-style="western"><surname>Xu</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Searson</surname><given-names>PC</given-names></name></person-group>. <article-title>Functional brain-specific microvessels from iPSC-derived human brain microvascular endothelial cells: the role of matrix composition on monolayer formation</article-title>. <source>Fluids Barriers CNS</source>. (<year>2018</year>) <volume>15</volume>:<fpage>7</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12987-018-0092-7</pub-id><pub-id pub-id-type="pmid">29463314</pub-id><pub-id pub-id-type="pmcid">PMC5819713</pub-id></mixed-citation></ref><ref id="B420"><label>420</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linville</surname><given-names>RM</given-names></name><name name-style="western"><surname>DeStefano</surname><given-names>JG</given-names></name><name name-style="western"><surname>Sklar</surname><given-names>MB</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bogorad</surname><given-names>MI</given-names></name><etal/></person-group>. <article-title>Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior</article-title>. <source>Biomaterials</source>. (<year>2019</year>) <volume>190-191</volume>:<fpage>24</fpage>&#8211;<lpage>37</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.10.023</pub-id><pub-id pub-id-type="pmid">30391800</pub-id><pub-id pub-id-type="pmcid">PMC6289621</pub-id></mixed-citation></ref><ref id="B421"><label>421</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campisi</surname><given-names>M</given-names></name><name name-style="western"><surname>Shin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Osaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Hajal</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiono</surname><given-names>V</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>RD</given-names></name></person-group>. <article-title>3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes</article-title>. <source>Biomaterials</source>. (<year>2018</year>) <volume>180</volume>:<page-range>117&#8211;29</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.07.014</pub-id><pub-id pub-id-type="pmcid">PMC6201194</pub-id><pub-id pub-id-type="pmid">30032046</pub-id></mixed-citation></ref><ref id="B422"><label>422</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bang</surname><given-names>S</given-names></name><name name-style="western"><surname>Shin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Osaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Hajal</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiono</surname><given-names>V</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>RD</given-names></name><etal/></person-group>. <article-title>A low permeability microfluidic blood-brain barrier platform with direct contact between perfusable vascular network and astrocytes</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>8083</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-017-07416-0</pub-id><pub-id pub-id-type="pmid">28808270</pub-id><pub-id pub-id-type="pmcid">PMC5556097</pub-id></mixed-citation></ref><ref id="B423"><label>423</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skardal</surname><given-names>A</given-names></name><name name-style="western"><surname>Aleman</surname><given-names>J</given-names></name><name name-style="western"><surname>Forsythe</surname><given-names>S</given-names></name><name name-style="western"><surname>Rajan</surname><given-names>S</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S</given-names></name><name name-style="western"><surname>Devarasetty</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Drug compound screening in single and integrated multi-organoid body-on-a-chip systems</article-title>. <source>Biofabrication</source>. (<year>2020</year>) <volume>12</volume>:<fpage>025017</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1088/1758-5090/ab6d36</pub-id><pub-id pub-id-type="pmid">32101533</pub-id></mixed-citation></ref><ref id="B424"><label>424</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajan</surname><given-names>SAP</given-names></name><name name-style="western"><surname>Aleman</surname><given-names>J</given-names></name><name name-style="western"><surname>Wan</surname><given-names>M</given-names></name><name name-style="western"><surname>Pourhabibi Zarandi</surname><given-names>N</given-names></name><name name-style="western"><surname>Nzou</surname><given-names>G</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform</article-title>. <source>Acta Biomater</source>. (<year>2020</year>) <volume>106</volume>:<page-range>124&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.actbio.2020.02.015</pub-id><pub-id pub-id-type="pmcid">PMC11083435</pub-id><pub-id pub-id-type="pmid">32068138</pub-id></mixed-citation></ref><ref id="B425"><label>425</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivandzade</surname><given-names>F</given-names></name><name name-style="western"><surname>Cucullo</surname><given-names>L</given-names></name></person-group>. <article-title>In-vitro blood-brain barrier modeling: A review of modern and fast-advancing technologies</article-title>. <source>J Cereb Blood Flow Metab</source>. (<year>2018</year>) <volume>38</volume>:<page-range>1667&#8211;81</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0271678X18788769</pub-id><pub-id pub-id-type="pmcid">PMC6168917</pub-id><pub-id pub-id-type="pmid">30058456</pub-id></mixed-citation></ref><ref id="B426"><label>426</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meena</surname><given-names>M</given-names></name><name name-style="western"><surname>Vandormael</surname><given-names>R</given-names></name><name name-style="western"><surname>De Laere</surname><given-names>M</given-names></name><name name-style="western"><surname>Pintelon</surname><given-names>I</given-names></name><name name-style="western"><surname>Berneman</surname><given-names>Z</given-names></name><name name-style="western"><surname>Watts</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>A microfluidic <italic toggle="yes">in vitro</italic> three-dimensional dynamic model of the blood-brain barrier to study the transmigration of immune cells</article-title>. <source>Brain Sci</source>. (<year>2022</year>) <volume>12</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/brainsci12101293</pub-id><pub-id pub-id-type="pmcid">PMC9599663</pub-id><pub-id pub-id-type="pmid">36291227</pub-id></mixed-citation></ref><ref id="B427"><label>427</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>AL</given-names></name><name name-style="western"><surname>Groenendijk</surname><given-names>L</given-names></name><name name-style="western"><surname>Overdevest</surname><given-names>R</given-names></name><name name-style="western"><surname>Fowke</surname><given-names>TM</given-names></name><name name-style="western"><surname>Annida</surname><given-names>R</given-names></name><name name-style="western"><surname>Mocellin</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Human BBB-on-a-chip reveals barrier disruption, endothelial inflammation, and T cell migration under neuroinflammatory conditions</article-title>. <source>Front Mol Neurosci</source>. (<year>2023</year>) <volume>16</volume>:<elocation-id>1250123</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fnmol.2023.1250123</pub-id><pub-id pub-id-type="pmid">37818458</pub-id><pub-id pub-id-type="pmcid">PMC10561300</pub-id></mixed-citation></ref><ref id="B428"><label>428</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Selmaj</surname><given-names>KW</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial</article-title>. <source>Lancet Neurol</source>. (<year>2019</year>) <volume>18</volume>:<page-range>1021&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(19)30238-8</pub-id><pub-id pub-id-type="pmid">31492652</pub-id></mixed-citation></ref><ref id="B429"><label>429</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>KP</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>BR</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ford</surname><given-names>CC</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>J</given-names></name><name name-style="western"><surname>Lisak</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial</article-title>. <source>1995. Neurol</source>. (<year>2001</year>) <volume>57</volume>:<page-range>S16&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1114287</pub-id><pub-id pub-id-type="pmid">11902590</pub-id></mixed-citation></ref><ref id="B430"><label>430</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gold</surname><given-names>R</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Selmaj</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2012</year>) <volume>367</volume>:<page-range>1098&#8211;107</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1114287</pub-id><pub-id pub-id-type="pmid">22992073</pub-id></mixed-citation></ref><ref id="B431"><label>431</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naismith</surname><given-names>RT</given-names></name><name name-style="western"><surname>Wundes</surname><given-names>A</given-names></name><name name-style="western"><surname>Ziemssen</surname><given-names>T</given-names></name><name name-style="western"><surname>Jasinska</surname><given-names>E</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lembo</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study</article-title>. <source>CNS Drugs</source>. (<year>2020</year>) <volume>34</volume>:<page-range>185&#8211;96</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s40263-020-00700-0</pub-id><pub-id pub-id-type="pmcid">PMC7018784</pub-id><pub-id pub-id-type="pmid">31953790</pub-id></mixed-citation></ref><ref id="B432"><label>432</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Wundes</surname><given-names>A</given-names></name><name name-style="western"><surname>Ziemssen</surname><given-names>T</given-names></name><name name-style="western"><surname>Jasinska</surname><given-names>E</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lembo</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial</article-title>. <source>Lancet Neurol</source>. (<year>2019</year>) <volume>18</volume>:<page-range>1009&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(19)30239-X</pub-id><pub-id pub-id-type="pmid">31492651</pub-id></mixed-citation></ref><ref id="B433"><label>433</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Selmaj</surname><given-names>KW</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>. (<year>2010</year>) <volume>362</volume>:<page-range>416&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa0902533</pub-id><pub-id pub-id-type="pmid">20089960</pub-id></mixed-citation></ref><ref id="B434"><label>434</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oleszak</surname><given-names>EL</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><name name-style="western"><surname>Cook</surname><given-names>S</given-names></name><name name-style="western"><surname>Rammohan</surname><given-names>K</given-names></name><name name-style="western"><surname>Rieckmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Soelberg Sorensen</surname><given-names>P</given-names></name></person-group>. <article-title>Theiler&#8217;s virus infection: a model for multiple sclerosis</article-title>. <source>Clin Microbiol Rev</source>. (<year>2004</year>) <volume>17</volume>:<fpage>174</fpage>&#8211;<lpage>207</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CMR.17.1.174-207.2004</pub-id><pub-id pub-id-type="pmid">14726460</pub-id><pub-id pub-id-type="pmcid">PMC321460</pub-id></mixed-citation></ref><ref id="B435"><label>435</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bender</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>SR</given-names></name></person-group>. <article-title>Pathogenesis of murine coronavirus in the central nervous system</article-title>. <source>J Neuroimmune Pharmacol</source>. (<year>2010</year>) <volume>5</volume>:<page-range>336&#8211;54</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11481-010-9202-2</pub-id><pub-id pub-id-type="pmcid">PMC2914825</pub-id><pub-id pub-id-type="pmid">20369302</pub-id></mixed-citation></ref><ref id="B436"><label>436</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amor</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JR</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H</given-names></name><name name-style="western"><surname>Katsetos</surname><given-names>CD</given-names></name><name name-style="western"><surname>Platsoucas</surname><given-names>CD</given-names></name></person-group>. <article-title>Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis</article-title>. <source>J Gen Virol</source>. (<year>1996</year>) <volume>77</volume>:<page-range>281&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1099/0022-1317-77-2-281</pub-id><pub-id pub-id-type="pmid">8627232</pub-id></mixed-citation></ref><ref id="B437"><label>437</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plemel</surname><given-names>JR</given-names></name><name name-style="western"><surname>Michaels</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Weishaupt</surname><given-names>N</given-names></name><name name-style="western"><surname>Caprariello</surname><given-names>AV</given-names></name><name name-style="western"><surname>Keough</surname><given-names>MB</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy</article-title>. <source>Glia</source>. (<year>2018</year>) <volume>66</volume>:<page-range>327&#8211;47</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/glia.23245</pub-id><pub-id pub-id-type="pmid">29068088</pub-id></mixed-citation></ref><ref id="B438"><label>438</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felts</surname><given-names>PA</given-names></name><name name-style="western"><surname>Woolston</surname><given-names>AM</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>HB</given-names></name><name name-style="western"><surname>Asquith</surname><given-names>S</given-names></name><name name-style="western"><surname>Gregson</surname><given-names>NA</given-names></name><name name-style="western"><surname>Mizzi</surname><given-names>OJ</given-names></name><etal/></person-group>. <article-title>Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide</article-title>. <source>Brain</source>. (<year>2005</year>) <volume>128</volume>:<page-range>1649&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/brain/awh516</pub-id><pub-id pub-id-type="pmcid">PMC7109778</pub-id><pub-id pub-id-type="pmid">15872019</pub-id></mixed-citation></ref><ref id="B439"><label>439</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kipp</surname><given-names>M</given-names></name><name name-style="western"><surname>Clarner</surname><given-names>T</given-names></name><name name-style="western"><surname>Dang</surname><given-names>J</given-names></name><name name-style="western"><surname>Copray</surname><given-names>S</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>C</given-names></name></person-group>. <article-title>The cuprizone animal model: new insights into an old story</article-title>. <source>Acta Neuropathol</source>. (<year>2009</year>) <volume>118</volume>:<page-range>723&#8211;36</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00401-009-0591-3</pub-id><pub-id pub-id-type="pmid">19763593</pub-id></mixed-citation></ref><ref id="B440"><label>440</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franke</surname><given-names>H</given-names></name><name name-style="western"><surname>Galla</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Beuckmann</surname><given-names>CT</given-names></name></person-group>. <article-title>An improved low-permeability <italic toggle="yes">in vitro</italic>-model of the blood-brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol</article-title>. <source>Brain Res</source>. (<year>1999</year>) <volume>818</volume>:<fpage>65</fpage>&#8211;<lpage>71</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0006-8993(98)01282-7</pub-id><pub-id pub-id-type="pmid">9914438</pub-id></mixed-citation></ref><ref id="B441"><label>441</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dehouck</surname><given-names>MP</given-names></name><name name-style="western"><surname>Meresse</surname><given-names>S</given-names></name><name name-style="western"><surname>Delorme</surname><given-names>P</given-names></name><name name-style="western"><surname>Fruchart</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cecchelli</surname><given-names>R</given-names></name></person-group>. <article-title>An easier, reproducible, and mass-production method to study the blood-brain barrier <italic toggle="yes">in vitro</italic>
</article-title>. <source>J Neurochem</source>. (<year>1990</year>) <volume>54</volume>:<page-range>1798&#8211;801</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1471-4159.1990.tb01236.x</pub-id><pub-id pub-id-type="pmid">2182777</pub-id></mixed-citation></ref><ref id="B442"><label>442</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burek</surname><given-names>M</given-names></name><name name-style="western"><surname>Salvador</surname><given-names>E</given-names></name><name name-style="western"><surname>Forster</surname><given-names>CY</given-names></name></person-group>. <article-title>Generation of an immortalized murine brain microvascular endothelial cell line as an <italic toggle="yes">in vitro</italic> blood brain barrier model</article-title>. <source>J Vis Exp</source>. (<year>2012</year>):<elocation-id>e4022</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3791/4022</pub-id><pub-id pub-id-type="pmid">22951995</pub-id><pub-id pub-id-type="pmcid">PMC3486758</pub-id></mixed-citation></ref><ref id="B443"><label>443</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stone</surname><given-names>NL</given-names></name><name name-style="western"><surname>England</surname><given-names>TJ</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>SE</given-names></name></person-group>. <article-title>A novel transwell blood brain barrier model using primary human cells</article-title>. <source>Front Cell Neurosci</source>. (<year>2019</year>) <volume>13</volume>:<elocation-id>230</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fncel.2019.00230</pub-id><pub-id pub-id-type="pmid">31244605</pub-id><pub-id pub-id-type="pmcid">PMC6563620</pub-id></mixed-citation></ref><ref id="B444"><label>444</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barberio</surname><given-names>C</given-names></name><name name-style="western"><surname>Withers</surname><given-names>A</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>Y</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>PO</given-names></name><name name-style="western"><surname>Romero</surname><given-names>IA</given-names></name><name name-style="western"><surname>Weksler</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>A human-derived neurovascular unit <italic toggle="yes">in vitro</italic> model to study the effects of cellular cross-talk and soluble factors on barrier integrity</article-title>. <source>Front Cell Neurosci</source>. (<year>2022</year>) <volume>16</volume>:<elocation-id>1065193</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fncel.2022.1065193</pub-id><pub-id pub-id-type="pmid">36545654</pub-id><pub-id pub-id-type="pmcid">PMC9762047</pub-id></mixed-citation></ref><ref id="B445"><label>445</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Withers</surname><given-names>A</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>Y</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>PO</given-names></name><name name-style="western"><surname>Romero</surname><given-names>IA</given-names></name><name name-style="western"><surname>Weksler</surname><given-names>B</given-names></name></person-group>. <article-title>
<italic toggle="yes">In vitro</italic> model of the blood-brain barrier established by co-culture of primary cerebral microvascular endothelial and astrocyte cells</article-title>. <source>Neural Regener Res</source>. (<year>2015</year>) <volume>10</volume>:<page-range>2011&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4103/1673-5374.172320</pub-id><pub-id pub-id-type="pmcid">PMC4730827</pub-id><pub-id pub-id-type="pmid">26889191</pub-id></mixed-citation></ref><ref id="B446"><label>446</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernas</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>FL</given-names></name><name name-style="western"><surname>Daley</surname><given-names>SK</given-names></name><name name-style="western"><surname>Weinand</surname><given-names>ME</given-names></name><name name-style="western"><surname>Campos</surname><given-names>AR</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Establishment of primary cultures of human brain microvascular endothelial cells to provide an <italic toggle="yes">in vitro</italic> cellular model of the blood-brain barrier</article-title>. <source>Nat Protoc</source>. (<year>2010</year>) <volume>5</volume>:<page-range>1265&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nprot.2010.76</pub-id><pub-id pub-id-type="pmcid">PMC3109429</pub-id><pub-id pub-id-type="pmid">20595955</pub-id></mixed-citation></ref><ref id="B447"><label>447</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weksler</surname><given-names>BB</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>FL</given-names></name><name name-style="western"><surname>Daley</surname><given-names>SK</given-names></name><name name-style="western"><surname>Weinand</surname><given-names>ME</given-names></name><name name-style="western"><surname>Campos</surname><given-names>AR</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Blood-brain barrier-specific properties of a human adult brain endothelial cell line</article-title>. <source>FASEB J</source>. (<year>2005</year>) <volume>19</volume>:<page-range>1872&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1096/fj.04-3458fje</pub-id><pub-id pub-id-type="pmid">16141364</pub-id></mixed-citation></ref><ref id="B448"><label>448</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stins</surname><given-names>MF</given-names></name><name name-style="western"><surname>Badger</surname><given-names>J</given-names></name><name name-style="western"><surname>Sik Kim</surname><given-names>K</given-names></name></person-group>. <article-title>Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells</article-title>. <source>Microb Pathog</source>. (<year>2001</year>) <volume>30</volume>:<fpage>19</fpage>&#8211;<lpage>28</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1006/mpat.2000.0406</pub-id><pub-id pub-id-type="pmid">11162182</pub-id></mixed-citation></ref><ref id="B449"><label>449</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyer-Di Ponio</surname><given-names>J</given-names></name><name name-style="western"><surname>Subileau</surname><given-names>EA</given-names></name><name name-style="western"><surname>Perriere</surname><given-names>N</given-names></name><name name-style="western"><surname>Charneau</surname><given-names>P</given-names></name><name name-style="western"><surname>Holloway</surname><given-names>K</given-names></name><name name-style="western"><surname>Leveque</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Instruction of circulating endothelial progenitors <italic toggle="yes">in vitro</italic> towards specialized blood-brain barrier and arterial phenotypes</article-title>. <source>PLoS One</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>e84179</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0084179</pub-id><pub-id pub-id-type="pmid">24392113</pub-id><pub-id pub-id-type="pmcid">PMC3879296</pub-id></mixed-citation></ref><ref id="B450"><label>450</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cecchelli</surname><given-names>R</given-names></name><name name-style="western"><surname>El-Ayoubi</surname><given-names>F</given-names></name><name name-style="western"><surname>Glacial</surname><given-names>F</given-names></name><name name-style="western"><surname>Ganeshamoorthy</surname><given-names>K</given-names></name><name name-style="western"><surname>Driancourt</surname><given-names>C</given-names></name><name name-style="western"><surname>Godet</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells</article-title>. <source>PLoS One</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>e99733</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0099733</pub-id><pub-id pub-id-type="pmid">24936790</pub-id><pub-id pub-id-type="pmcid">PMC4061029</pub-id></mixed-citation></ref><ref id="B451"><label>451</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lippmann</surname><given-names>ES</given-names></name><name name-style="western"><surname>Azarin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kay</surname><given-names>JE</given-names></name><name name-style="western"><surname>Nessler</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>HK</given-names></name><name name-style="western"><surname>Al-Ahmad</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells</article-title>. <source>Nat Biotechnol</source>. (<year>2012</year>) <volume>30</volume>:<page-range>783&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nbt.2247</pub-id><pub-id pub-id-type="pmcid">PMC3467331</pub-id><pub-id pub-id-type="pmid">22729031</pub-id></mixed-citation></ref><ref id="B452"><label>452</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chung</surname><given-names>HJ</given-names></name></person-group>. <article-title>An improved <italic toggle="yes">in vitro</italic> blood-brain barrier model for the evaluation of drug permeability using transwell with shear stress</article-title>. <source>Pharmaceutics</source>. (<year>2023</year>) <volume>16</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/pharmaceutics16010048</pub-id><pub-id pub-id-type="pmcid">PMC10820479</pub-id><pub-id pub-id-type="pmid">38258059</pub-id></mixed-citation></ref><ref id="B453"><label>453</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>W</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HM</given-names></name><name name-style="western"><surname>Joo</surname><given-names>KM</given-names></name><name name-style="western"><surname>Nam</surname><given-names>DH</given-names></name></person-group>. <article-title>Simplified <italic toggle="yes">in vitro</italic> 3D co-culture-based blood-brain barrier model using transwell</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2022</year>) <volume>620</volume>:<page-range>63&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bbrc.2022.06.083</pub-id><pub-id pub-id-type="pmid">35780582</pub-id></mixed-citation></ref><ref id="B454"><label>454</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbakary</surname><given-names>B</given-names></name><name name-style="western"><surname>Badhan</surname><given-names>RKS</given-names></name></person-group>. <article-title>A dynamic perfusion based blood-brain barrier model for cytotoxicity testing and drug permeation</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>3788</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-60689-w</pub-id><pub-id pub-id-type="pmid">32123236</pub-id><pub-id pub-id-type="pmcid">PMC7052153</pub-id></mixed-citation></ref><ref id="B455"><label>455</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>SI</given-names></name><name name-style="western"><surname>Sei</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>175</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-019-13896-7</pub-id><pub-id pub-id-type="pmid">31924752</pub-id><pub-id pub-id-type="pmcid">PMC6954233</pub-id></mixed-citation></ref><ref id="B456"><label>456</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name><name name-style="western"><surname>Santhosh</surname><given-names>M</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JW</given-names></name></person-group>. <article-title>
<italic toggle="yes">In vitro</italic> blood-brain barrier-integrated neurological disorder models using a microfluidic device</article-title>. <source>Micromachines (Basel)</source>. (<year>2019</year>) <volume>11</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/mi11010021</pub-id><pub-id pub-id-type="pmcid">PMC7019695</pub-id><pub-id pub-id-type="pmid">31878184</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>